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Background: Glutathione-dependent catalysis is a metabolic adaptation to chemical challenges encountered
by all life forms. In the course of evolution, nature optimized numerous mechanisms to use glutathione as the
most versatile nucleophile for the conversion of a plethora of sulfur-, oxygen- or carbon-containing electrophilic
substances.
Scope of review: This comprehensive review summarizes fundamental principles of glutathione catalysis and
compares the structures and mechanisms of glutathione-dependent enzymes, including glutathione reductase,
glutaredoxins, glutathione peroxidases, peroxiredoxins, glyoxalases 1 and 2, glutathione transferases and
MAPEG. Moreover, open mechanistic questions, evolutionary aspects and the physiological relevance of gluta-
thione catalysis are discussed for each enzyme family.
Major conclusions: It is surprising how little is known about many glutathione-dependent enzymes, how often
reaction geometries and acid–base catalysts are neglected, and howmanymechanistic puzzles remain unsolved
despite almost a century of research. On the one hand, several enzyme families with non-related protein folds
recognize the glutathione moiety of their substrates. On the other hand, the thioredoxin fold is often used for
glutathione catalysis. Ancient as well as recent structural changes of this fold did not only signiﬁcantly alter
the reaction mechanism, but also resulted in completely different protein functions.
General signiﬁcance: Glutathione-dependent enzymes are excellent study objects for structure–function rela-
tionships and molecular evolution. Notably, in times of systems biology, the outcome of models on glutathione
metabolism and redox regulation is more than questionable as long as fundamental enzyme properties are
neither studied nor understood. Furthermore, several of the presented mechanisms could have implications
for drug development. This article is part of a Special Issue entitled Cellular functions of glutathione.© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Glutathione is the central redox agent of most aerobic organisms.
Its reduced form (GSH≡γ-L-glutamyl-L-cysteinylglycine) serves as a
ubiquitous nucleophile in order to convert a variety of electrophilic
substances under physiological conditions. Glutathione-dependent
enzymes signiﬁcantly accelerate most of these chemical reactions
in numerous metabolic pathways. Accordingly, tens of thousands
of articles on glutathione-dependent enzymes and pathways have
been published since the disputed discovery of glutathione by
Hopkins as well as Hunter and Eagles in the 1920s [1]. It is therefore
rather surprising that many fundamental mechanistic questions still
remain to be solved in order to precisely understand the role of gluta-
thione metabolism at the cellular and organismic level. This review
is a (doomed) attempt to summarize the knowledge on glutathione-
dependent catalysis and to outline the relevance of the currentr functions of glutathione.
-ND license.mechanistic models. I will approach the topic from two perspectives:
In Section 2, I will start with a focus on the substrates. I will present
theories on the origin and beneﬁts of glutathione-dependent pro-
cesses, summarize the properties of this extraordinary molecule and
provide an overview of the glutathione-dependent enzymes and
pathways. The mechanisms of glutathione-dependent enzymes and
their physiological relevancewill be subsequently discussed and com-
pared in Sections 3–8.
2. Theories on the beneﬁts, functions and evolution of
glutathione catalysis
2.1. Two chemical challenges for life
Why do we need a glutathione system? Life as we know it has en-
countered several chemical challenges in the course of evolution. In
fact, countless “natural” chemicals—including electrophilic substances—
are carcinogens, mutagens, teratogens and clastogens [2,3]. In addition
to xenobiotics, two of the presumably most important chemical chal-
lenges are (i) the formation of reactive oxygen species (ROS) due to an
3218 M. Deponte / Biochimica et Biophysica Acta 1830 (2013) 3217–3266aerobic atmosphere, and (ii) the formation of 2-oxoaldehydes (2-OA)
due to glycolysis and other fundamental metabolic pathways.
2.1.1. The formation of reactive oxygen species
Oxygenic photosynthesis most likely caused the ﬁrst global “envi-
ronmental pollution crisis”. As a consequence of anoxygenic and
oxygenic photosynthesis, the presumably reducing, hydrogen sulﬁde-
enriched oceans and atmosphere changed to oxidizing, oxygen-
enriched habitats with two signiﬁcant oxygenation boosts occurring
approx. 2.5–2.2 and 0.8-0.5 billion years ago (Fig. 1) [4,5]. Under the
present conditions, electrophilic ROS are expected to be easily formed
in all aerobic organisms with the help of light, ﬂavins, semiquinones
as well as iron, copper and other metal ions (Fig. 2A) [6–9]. H2O2
and O2•− can both react with selected proteins containing Fe/S-clusters,
liberating their iron ions. Free or complexed Fe2+ reduces H2O2, yield-
ing OH• which unspeciﬁcally modiﬁes all kinds of biomolecules at a
diffusion-limited rate. Hence, radicals, sulfenic acids, disulﬁdes and
(hydro)peroxides are directly or indirectly formed by ROS (Fig. 2B).
These ROS-dependent modiﬁcations result in inactivated proteins,
damaged membranes and mutations [8–10].
However, thiyl radicals, disulﬁdes, sulfenic acids and ROS can
also fulﬁll vital functions: (i) Some ROS are not only involved in the
defense against pathogens, but can also serve as signal mediators in
the redox regulation of metabolism and transcription. Accordingly,
there are several proteins and enzymes that either sense or even gen-
erate ROS [7,11,12]. Excellent examples for the latter enzymes are
myeloperoxidases, producing HOCl, and NADPH-oxidases, generating
O2•− [13]. (ii) Some cysteine-derived thiyl radicals, sulfenic acids and
disulﬁdes are pivotal intermediates during catalysis or could serve
as signal mediators [7,11,14,15]. Of note, the reduction of ribonucleo-
tides is a peculiar example for a fundamental thiyl radical-dependent
as well as disulﬁde-dependent physiological process in all domains of
life [16,17]. (iii) The importance of protein disulﬁde bonds is further-
more underlined by the fact that bacteria and eukaryotes established
non-related analogous machineries to stabilize secreted and intracel-
lular proteins in the periplasmic space, the endoplasmic reticulum
and the mitochondrial intermembrane space [18–20].
In summary, on the one hand, the ancestors of modern organ-
isms had to develop numerous mechanisms to maintain reducingFig. 1. The evolution of aerobic life and glutathione metabolism. Oxygenic photosyn-
thesis resulted in an oxidation of the environment followed by a delayed increase
of free oxygen in the atmosphere (during the so-called 1st and 2nd great oxidation
event highlighted in red). Several glutathione-dependent enzymatic activities are
found in contemporary eukaryotes as well as purple bacteria and cyanobacteria but
seem to be absent in many other bacteria and archaea. Ondarza as well as Fahey and
colleagues therefore suggested that glutathione metabolism evolved together with
oxygenic photosynthesis [86,549–551]. More recent in silico analyses revealed that
the domains of some glutathione-dependent enzymes such as Grx and GST are found
in all kingdoms of life, including some archaea and all kinds of bacteria [203,479]
(Deponte, unpublished). Thus, a putative earlier evolution of glutathione-dependent
enzymes and a subsequent loss or replacement in bacteria and archaea cannot be
fully excluded. Nevertheless, based on the current data, it seems more likely that the
few genes encoding glutathione-dependent enzymes in archaea and bacteria originate
from horizontal gene transfers.intracellular conditions, to avoid the formation of ROS, to detoxify
ROS, and to reverse or repair ROS-derived damage [8–10]. On the
other hand, partially oxidizing conditions as well as appropriate
redox steady states in different cellular compartments became essen-
tial for life. So-called oxidative stress occurs only when the balance
between the formation and the removal of ROS is disturbed, thereby
resulting in the accumulation of oxidized and damaged biomolecules
[10]. Please note that precise mechanistic deﬁnitions of oxidative
stress at the molecular level are just beginning to emerge and seem
to highly depend on the cell type or organism.
2.1.2. The formation of 2-oxoaldehydes
Glycolysis-dependent ATP-formation is an imperfect process. During
an “unwanted” side reaction of the Emden–Meyerhof–Parnas pathway,
phosphate is eliminated from the triosephosphates glyceraldehyde-
3-phosphate (GAP) and dihydroxyacetone-phosphate (DHAP) (Fig. 2C)
[21–23]. The molecular architecture of the glycolytic enzyme triose-
phosphate isomerase (TIM) stabilizes the enediolate intermediate
of the isomerization reaction and therefore signiﬁcantly reduces this
ubiquitous side reaction [24]. Nevertheless, the elimination product
methylglyoxal (MG) is continuously generated at a low level. For exam-
ple, in human red blood cells about 0.1% of GAP and DHAPwere estimat-
ed to end up as MG [25]. Even archaea—using the Entner–Doudoroff
instead of the Emden–Meyerhof–Parnas pathway—have a functional
TIM for gluconeogenesis [26] and were shown to produce MG [27].
MG and other structural analogs of glyoxal (OCHCHO≡ethanedial)
are 2-oxoaldehydes (2-OA). In addition to gylcolysis these compounds
are also formed during lipid peroxidation as well as acetone, glyc-
erol and threonine metabolism [21,23,28,29]. Owing to the adjacent
carbonyl groups, 2-OA are strong electrophiles that spontaneously
react with nucleophiles from proteins, lipids and nucleic acids,
thereby yielding so-called advanced glycation endproducts (AGEs)
(Fig. 2D). As a consequence, 2-OA are potentially cytotoxic and
mutagenic, and their removal by a detoxiﬁcation system is beneﬁ-
cial [30–32]. However, Escherichia coli and other bacteria sometimes
even generate MG with the help of methylglyoxal synthase to me-
tabolize DHAP under conditions of limited phosphate [21,28,33].
As outlined in Section 7.4, 2-OA can be also involved in signal trans-
duction and cellular differentiation. Hence, the structures, cellular
concentrations and effects of 2-OA highly depend on the often
neglected biological context. In summary, 2-OA are ubiquitous elec-
trophilic metabolites that are usually detoxiﬁed but that might also
exert regulatory functions in analogy to the janus-faced hydroper-
oxides [31].
2.2. One single solution: glutathione
2.2.1. Overview of glutathione metabolism and catalysis
How are the chemical challenges outlined in Section 2.1 mastered?
The glutathione system—together with the thioredoxin system—
probably evolved very early in aerobic organisms (Fig. 1). Owing to
the cysteine moiety of GSH, the whole system is based on common
sulfur biochemistry (Fig. 3A). It therefore requires, (i) an electron
relay, linking the universal reducing agent NADPH to thiol/disulﬁde-
metabolism, and (ii) a thiol-containing adapter molecule to transfer
electrons to a set of different acceptors. Flavoproteins are widely
used as electron relays [18]. Hence, it is not surprising that the reduc-
ing equivalents from NADPH enter the glutathione system either with
the help of the FAD-dependent enzyme glutathione reductase (GR)
[34–36] or the thioredoxin reductase/thioredoxin couple (TrxR/Trx)
[37–43]. The electrons are subsequently transferred to glutathione
disulﬁde (GSSG), yielding two molecules of GSH (Fig. 3B). GSH either
serves as a reducing agent for disulﬁdes (Fig. 3C) and hydroperoxides
(Fig. 3D), or is conjugated with 2-OA (Fig. 3E) and other electrophilic
substances (Fig. 3F). Alternatively, GSSG can also oxidize thiols under
Fig. 2. Formation of ubiquitous electrophiles and subsequent modiﬁcation of biomolecules. (A) Formation of ROS owing to ﬂavin- and Fenton-chemistry as well as other catalyzed
or spontaneous electron transfers. The chemical formula, the oxidation number and the Lewis structure of oxygen, superoxide anion, hydrogen peroxide and hydroxyl radical are
shown from the left to the right. (B) Representative modiﬁcations of molecules by ROS leading to the formation of low and high molecular weight peroxides, radicals, sulfenic acids,
nitrosothiols and disulﬁdes. (C) Formation of MG as a by-product of glycolysis due to the elimination of phosphate. (D) Exemplary modiﬁcations of arginine, lysine and guanine
residues (Arg, Lys and Gua, respectively) by glyoxal, MG and other 2-OA. The modiﬁed biomolecules are often summarized as AGEs.
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ticular, kinetic parameters as outlined in the next section.
In summary, disulﬁde-reducing GR and TrxR act as electron relays
to tap into the NADPH pool, GSH is a versatile adapter molecule, and
the glutathione system serves in most aerobic cells and organisms
as the central metabolic network to remove or modify endogenous
electrophilic compounds and numerous xenobiotics. Accordingly,
the effects that are summarized in Fig. 2B,D are mastered with the
help of GSH, demonstrating the versatility of glutathione-dependent
catalysis as an answer to different chemical challenges in the evolu-
tion of life.
2.2.2. The kinetics and thermodynamics of glutathione catalysis
As depicted in Fig. 3 and as outlined in the following sections,
several glutathione-dependent reactions are catalyzed by a variety
of enzymes with different physiological concentrations as well as
kcat and Km values. Some of these enzymes exert overlapping func-
tions and/or exist in a variety of isoforms.1 Thus, the relevance and
rates of the reactions in Fig. 3 highly depend on the overall enzyme rep-
ertoire (V=−d[S]/dt=V1+V2…=kcat1[E1][S]/(Km1+[S])+kcat2[E2]
[S]/(Km2+[S])…). The thermodynamic parameter expressing the
driving force of the redox reactions in Fig. 3 is the redox potential E′,
which can be easily derived from the Gibbs energy. In contrast to
many other physiological redox buffers, the redox potential of the glu-
tathione system not only depends on the GSH/GSSG ratio, the tempera-
ture and the pH, but also on the actual concentration of glutathione as
exempliﬁed by the Nernst equation in Fig. 4 [44,45]. The intracellular
concentration of GSH is quite high and ranges from approx. 0.1 to
15 mM. The concentration of GSSG is usually several orders of magni-
tude lower. Both concentrations depend on the subcellular compart-
ment (Fig. 4), the cell type and the organism. The cell cycle and the1 Please note that the term “isoform” is used for homologous proteins without im-
plying that such proteins have similar functions or are even isozymes.condition of the cell (stressed, apoptotic, etc.) were also reported to
inﬂuence the GSH/GSSG ratio [46,47]. As a consequence, GSH is
not only a potent nucleophile—despite a rather high thiol pKa value of
approx. 9 [44,48]—but also an extremely ﬂexible biological reducing
agent [44,49].
What is more important for glutathione catalysis: the kinetics or
the thermodynamics? As emphasized by Flohé in this BBA issue
[50], cells and organisms are open systems. Thus, metabolic ﬂuxes
are in transition or in regulated steady states, and isolated E′ values
at equilibrium do not necessarily explain whether a reaction is of
physiological signiﬁcance or not. It is the kinetics that determines
whether a potential is utilized in a physiological context. So what is
the relevance of measuring redox potentials and glutathione con-
centrations [50]? A controversy resulting from this valid question
might be solved by considering theoretical studies on the general reg-
ulation of metabolic ﬂuxes by Hofmeyr and Cornish-Bowden [51,52]:
According to their model, control of metabolism can be understood in
terms of elasticities of supply and demand. Each elasticity coefﬁcient
is the sum of a thermodynamic term (depending on the law of mass
action) and a kinetic term (determined by the enzymatic repertoire
and its status). The thermodynamic term in the supply elasticity be-
comes negligible at conditions far from equilibrium but “completely
swamps the kinetic term” near equilibrium [51,52]. In other words,
the relevance of the measured redox potentials and glutathione
concentrations depends on whether the analyzed ﬂux is close to or
far from equilibrium.
In summary, the GSH/GSSG couple is the redox buffer of the gluta-
thione system maintaining appropriate redox conditions from the
suborganellar to the organismic level. The glutathione-dependent
reactions summarized in Fig. 3 highly depend on kinetic parameters
and the enzymatic repertoire. The relevance of measured redox
potentials and glutathione concentrations for redox metabolism is
controversial and probably depends on the metabolic ﬂux and the
distance from equilibrium.
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The roles of GSH as the major reducing agent for disulﬁdes and of
GSSG as a major thiol-modifying agent are mediated either non-Fig. 3. Overview and current models of glutathione metabolism. (A) Composition and redox
by Trx and TrxR. Please note that the direct reaction of GSSG with Trx in vitro is rather slow
n.-e., non-enzymatic. (C) Reduction or oxidation of intra- or intermolecular disulﬁdes or thi
GSSG (right panel). The reactions can occur either non-enzymatically or enzymatically w
molecular weight compounds. (D) The GSH-dependent removal of H2O2 and other hydrop
a few Grx-isoforms. (E) The GSH-dependent conversion of 2-OA to 2-hydroxycarboxylic
other electrophiles are modiﬁed by GSH with the help of GST and MAPEG. The products arenzymatically or by glutaredoxins (Grx) (Fig. 3C) [14,53–55]. In addi-
tion, the reduction of non-native and the formation of native protein
disulﬁde bonds in the endoplasmic reticulum depend on GSH,conversion of GSH and GSSG. (B) NADPH-dependent regeneration of GSH by GR and/or
, and the Trx-dependent reduction in vivo might therefore be indirect (Section 2.2.3).
ols by 2 GSH/GSSG (left panel). Deglutathionylation/glutathionylation of thiols by GSH/
ith the help of Grx, PDI and some GST-isoforms. Reactants include proteins and low
eroxides is catalyzed by a variety of enzymes including specialized GPx, Prx, GST and
acids is catalyzed by the isomerase Glo1 and the thioesterase Glo2. (F) A variety of
e either removed from the cell or are precursors for metabolites such as eicosanoids.
Fig. 4. Correlation between the half cell reduction potential E′ and the percentage of oxidized glutathione. The equilibrium between GSSG and GSH can be calculated using the
Nernst equation [45], resulting in sigmoidal E′-GSSG diagrams. E′ not only depends on the [GSH]/[GSSG] ratio but also on the indicated total concentration of glutathione (as em-
phasized in the upper right version of the Nernst equation). An increase of glutathione—e.g. due to the de novo biosynthesis or uptake of GSH—shifts the curve to the left. The pro-
tonation of both sulfur atoms upon GSSG reduction depends on the pH value which therefore also affects E′. Please note that the pH at 25 °C is already considered in the presented
diagrams and versions of the Nernst equation (E°′=EpH7(25°C)=−0.24 V). At a more alkaline pH all curves are shifted to the left: EpH=−240–59.16×(pH—7.0) mV, resulting in
shifts of −24 and −59 mV at pH 7.4 and 8.0, respectively [45]. Please also note that the curves are based on calculated concentrations instead of the activities aGSH and aGSSG,
neglecting the fact that salts/H+/OH− as well as amino acid side chains all interact with the thiol, amino and carboxylate groups of glutathione and therefore inﬂuence E′. Calculated
redox potentials and glutathione ratios from different subcellular compartments in yeast [552–554] and mammals [46,555–557] at estimated pH values are indicated for compar-
ison. Most of the values should be interpreted with caution because the exact concentrations of GSH and GSSG in the compartments were often not determined (nd), and the
parameters depend on the metabolic and developmental conditions as well as the chosen methodology [45,46,555]. Obviously, much more work is necessary to obtain reliable
and comparable values for E′, pH, [GSH] and [GSSG] of all subcellular compartments.
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of PDI in vivo still remain to be clariﬁed [56,57] and are not discussed
in this review.) Once a disulﬁde bond has reacted with GSH (or a thiol
has reacted with GSSG), the stability of the resulting glutathionylated
molecule can vary over several orders of magnitude (Fig. 3C). The
stability depends on whether the mixed disulﬁde is an intermediate
during catalysis, a species required for redox-mediated signal trans-
duction, a protected cysteine residue under oxidizing conditions or
a biosynthetic product. These differences are highly important with
respect to the diversity of Grx-isoforms as described in Section 4.3.
The glutathionylated compound can subsequently react with another
GSH molecule yielding a second (regenerated) thiol product and
GSSG (Fig. 3C). Again, the thiol–disulﬁde exchange occurs either
non-enzymatically or enzymatically (with the help of the same or
another enzyme). GSSG is ﬁnally reduced by NADPH with the help
of GR or the TrxR/Trx couple (Fig. 3B) [14,53–55]. Please note that
the apparent second order rate constants for the direct reduction of
GSSG by Trx were found to be lower than 103 M−1 s−1 [37]. Thus, an
efﬁcient turnover at estimated nanomolar Trx and micromolar or even
nanomolar GSSG concentrations remains controversial (right side in
Fig. 3B). An alternative explanation for the Trx/TrxR-dependent reduc-
tion of GSSG in vivo [37–43] might be the GSSG-dependent formation
of glutathionylated/oxidized proteins (Fig. 3C) that are more efﬁcient
substrates of the system. In such a scenario the reduction of GSSG
by the thioredoxin system would be indirect. The latter hypothesis
is supported by a few in vitro studies, revealing for example that
glutathionylated human Grx2 and GSSG-treated Grx4 from E. coli can
be substrates of TrxR [58,59].
2.2.4. GSH as a reducing agent for peroxides
In analogy to the reduction of disulﬁdes, GSH also reduces a vari-
ety of hydroperoxides (Fig. 3D). These irreversible reactions are cata-
lyzed by a subgroup of glutathione peroxidases (GPx), yielding GSSG,
water and/or an alcohol [60–62] as outlined in Section 5. Alterna-
tively, selected peroxiredoxins (Prx)—which are usually highlyabundant Trx-dependent hydroperoxidases—can also utilize GSH as
an electron donor [63–67] and are therefore discussed in Section 6.
Noteworthy, in addition to specialized GPx- and Prx-isoforms, some
Grx- and many glutathione transferases (GST) can also act as hydro-
peroxidases on their own. However, the rate constants of these
enzymes, if determined, were usually found to be signiﬁcantly lower
than for catalase or the canonical thiol/selenol-dependent hydro-
peroxidases Prx and GPx [68–72]. In summary, there are numerous
proteins with a GSH-dependent hydroperoxidase activity. Their con-
tribution and relevance are often unknown but seem to highly depend
on the type of organism and/or subcellular compartment.
2.2.5. GSH as a nucleophile for other electrophiles
Disulﬁdes and peroxides are not the only compounds reacting
with GSH. Other electrophiles are converted in a GSH-dependent
manner by the glyoxalase pathway and by GST. In the glyoxalase
pathway, GSH spontaneously reacts with electrophilic 2-OA to form
a diastereomeric hemithioacetal (Fig. 3E). The latter substance is iso-
merized to a single thioester by glyoxalase 1 (Glo1) and subsequently
hydrolyzed by glyoxalase 2 (Glo2) as outlined in Section 7. The pathway
yields regenerated GSH and a non-toxic 2-hydroxycarboxylic acid such
as D-lactic acid fromMG. Thus, in contrast tomost GST-dependent path-
ways, GSH acts as a coenzyme and is not consumed in the over-
all reaction of the glyoxalase pathway (Fig. 3E). Moreover, since
the conversion of MG and other 2-OA is an intramolecular redox
reaction, GSH does not act as a reducing agent in the overall
reaction [21,23,31,73,74].
In addition to the reduction of peroxides and disulﬁdes, the predom-
inant function of the extremely heterogeneous families of GST-isoforms
and non-related MAPEG (membrane-associated proteins with diver-
gent functions in eicosanoid and glutathione metabolism) is the cata-
lytic conjugation of the sulfur atom of GSH to (carbon atoms of) a
large variety of electrophilic substances (Fig. 3F) [3,75–77]. These sub-
strates do not necessarily contain disulﬁde or peroxide bonds, and the
conjugation reactions often result in a reduced toxicity and an increased
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be subsequently metabolized and/or excreted. Alternatively, some
GST-isoforms also use GSH for isomerizations [3,76]. All these reactions
are summarized in Section 8.
2.3. Further evolutionary and chemical aspects of glutathione catalysis
2.3.1. The beneﬁts of a single thiol compound
The advantage of utilizing a single adapter molecule as a universal
nucleophile instead of different compounds for each electrophile
becomes obvious considering the numerous functions summarized
in Fig. 3: Instead of optimizing a large set of unrelated proteins for
(i) synthesizing different nucleophiles and for (ii) catalyzing the turn-
over of each nucleophile/electrophile couple, only one pathway for
glutathione synthesis was required and rather moderate structural
changes of ancient protein scaffolds such as the thioredoxin fold
were sufﬁcient to generate novel enzymatic activities in the course
of evolution (as outlined in Section 4.2 and as exempliﬁed in all sub-
sequent sections). Why has a thiol compound evolved as the univer-
sal adapter molecule? Taking into account Pearson's HSAB theory,
alcohols are quite hard bases and therefore far less versatile than
thiols [78]. In comparison with thiols, selenols are restricted due to
the limited bioavailability of the trace element selenium [79]. More-
over, although selenols have much lower pKa values and are usually
more reactive than thiols [79,80], the utilization of selenocysteine
for biocatalysis (e.g. in TrxR or GPx) remains enigmatic [80,81]. In
conclusion, owing to the bioavailability, size and electron conﬁg-
uration of sulfur, thiols instead of alcohols and selenols are pre-
destined to catalyze such a variety of reactions under physiological
conditions [79].
2.3.2. Comparison with alternative thiols as catalysts
Why is the major reducing agent a cysteine-containing tripeptide?
First of all, the availability of the proteinogenic amino acids cysteine,
glycine and glutamate during very early evolution is a prerequisite
for the success of GSH [82]. Second, in contrast to coenzyme A
(containing cysteamine due to a decarboxylation), all components/
amino acids of GSH can be directly salvaged [83], providing a poten-
tial advantage for the ancestors of modern organisms under limiting
growth conditions. Third, GSH provides signiﬁcant advantages over
unmodiﬁed cysteine: (i) Protein biosynthesis and other cysteine-
utilizing anabolic processes can be separated from detoxiﬁcation
and redox processes in the same cellular compartment. (ii) As I will
outline below, the charged functional groups of the glycine- and the
γ-glutamyl moiety are perfect electrostatic anchors for substrate rec-
ognition, resulting in substrate speciﬁcity. (iii) The modiﬁcation of
the amino group of cysteine was suggested to prevent the intramolec-
ular transfer of acyl groups (yielding amides from thioesters) [84].
However, whether the latter reaction could occur at a signiﬁcant
rate in vivo has, to my knowledge, not been systematically studied.
(iv) Protection of the amino and of the carboxy group of cysteine
can furthermore decrease the metal-, salt- and pH-dependent autoxi-
dation rate [48,84–87]. Obviously, this protection is highly important
since thiols are not only antioxidants but also sources for ROS
(Fig. 1A) [48]. A tripeptide with cysteine in the middle is the smallest
protected peptide and therefore a simple solution to this problem.
What could be the advantage of GSH in comparison to other
thiols? Some organisms employ glutathione precursors or derivates
instead of GSH, e.g. γ-glutamyl-cysteine in halophilic archaea [86]
and trypanothione (T(SH)2) in kinetoplastid parasites [44,88–90].
Even E. coli uses GSH and glutathionylspermidine which accumulates
under anaerobic conditions [91] and oxidative challenge [92]. Please
note that entropically favored monomeric T(SH)2 is a positively
charged dithiol with a pKa value of approx. 7.4 and therefore differs
signiﬁcantly from the negatively charged monothiol compound GSH
[44] (Fig. 3A). In addition, protective modiﬁcations of cysteine arenot restricted to amino acids as adjacent groups: In mycothiol—
which is the replacement for GSH in many actinobacteria (including
the important pathogen Mycobacterium tuberculosis)—the central
cysteine residue forms amide bonds with acetate and a neutral
amino sugar [85]. These modiﬁcations were also reported to slow
down copper-catalyzed autoxidation [84]. In bacillithiol—a similar
cysteine-containing compound from bacilli (including the model or-
ganism Bacillus subtilis)—only the carboxy group of cysteine is modi-
ﬁed by a negatively charged amino sugar [93,94]. Thus, it is not really
understood why GSH instead of other soluble cysteine derivates
became the central reducing agent in most organisms. In fact, even
non-cysteine thiol/disulﬁde couples are able to exert similar func-
tions: Coenzyme M (2-mercaptoethanesulfonate) and coenzyme B
(7-mercaptoheptanoylthreonine phosphate) both facilitate the re-
duction of methyl groups in CH4-producing archaea [85,95]. The
thiolhistidines ergothioneine and ovothiols also possess antioxidant
properties as scavengers, but differ signiﬁcantly from cysteine thiols
due to the instability of their disulﬁdes [44,95]. Although thiolhistidines
are found inmany organisms at high concentrations, their functions are
poorly understood and speciﬁc enzymes seem to be absent [85,88,95].
In summary, the utilization of cysteine-based thiols as universal
nucleophiles for the modiﬁcation or removal of diverse physiological
electrophiles is plausible. The chemical properties of GSH due to
its composition/structure provide a sufﬁcient condition for catalysis
and the complex metabolic network depicted in Fig. 3, even though
alternative thiols exert analogous functions in archaea and many
bacteria.
2.3.3. Mechanistic principles of glutathione catalysis
Before I discuss selected enzyme/substrate couples in detail, I
want to end Section 2 with an overview of chemical principles of glu-
tathione catalysis that seem to be often ignored. Most of the reactions
in Fig. 3 include one or multiple (predicted) nucleophilic substitu-
tions, regardless whether a disulﬁde, a hydroperoxide or a sulfenic
acid is the electrophile (reactions with electrophilic carbon atoms
are outlined in Sections 7.2 and 8.3). Mechanistically, bimolecular
nucleophilic substitutions (SN2 reactions) are likely for several of
these pathways (Fig. 5), even though atomistic data on enzyme catal-
ysis are so far rather limited to a few examples such as Trx [96,97].
Please note that glutathione—as well as cysteine residues at the active
site of a glutathione-dependent enzyme—can either play the role of
the nucleophile (GS−, Cys-S−) or the electrophile (GSSG, GSSR,
Cys-SSR, Cys-SOH) in SN2 reactions, depending on the elementary
reaction (Fig. 5).
Before or during the ﬁrst step of the SN2 reaction, the attacking
thiol (or selenol) group becomes deprotonated. As a consequence,
a negatively charged transition state is formed (Fig. 5). Thus, two
important aspects of glutathione catalysis are the generation of the
nucleophile by deprotonation and/or the stabilization of the negative
charge of the transition state (therefore lowering its Gibbs energy).
While GSH deprotonation is more often considered in glutathione
catalysis, sterical constraints are predominantly neglected [55]. A
SN2 reaction usually requires a trigonal bipyramidal transition state
with the entering and leaving groups in apical positions and substitu-
ents at the central atom in an angle of approx. 90°. As the cleavage of
a disulﬁde bond is thought to occur without essential participation of
3d orbitals, a linear orientation also seems to be valid for sulfur atoms
(Fig. 5) [98–100]. Thus, a central aspect of glutathione catalysis is to
align the electrophile and the nucleophile appropriately. Several en-
zymes seem to master this challenge with the help of positively
charged side chains that direct the glutathione substrate. Moreover,
before the nucleophilic attack, the substituent of the central atom
of the electrophile (e.g. the side chain of a cysteine residue RC-S)
could be stabilized in a position resembling the transition state (for ex-
ample, in a rather strained protein disulﬁde bond). As a result, the
reactivity of the electrophile could increase, and the activation energy
Fig. 5. Principles of thiol-dependent SN2 reactions. (A) Thiol–disulﬁde exchange reaction. (B) Thiol-dependent cleavage of electrophilic hydroperoxides. (C) Thiol-dependent cleav-
age of electrophilic sulfenic acids. In all reactions an initial deprotonation generates the nucleophilic thiolate. Upon attack, a linear, negatively charged transition state (highlighted
in brackets) is formed between the nucleophile and the electrophile. The properties of the leaving group can be altered owing to protonation. RN, residue of the nucleophile;
RC, residue of the central atom; RL, residue of the leaving group. Changes of the hybridization of the central atom and of the position of RC are indicated by red arrow heads. See
Section 2.3.3 for further details.
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reaction, the rather poor leaving group (RL-S−>RL-O−>OH−) can be
stabilized by protonation (Fig. 5). Whether this step occurs simulta-
neously or right after the bond is cleaved might depend on the enzyme
and the leaving group.
Are there alternatives to themechanism outlined in Fig. 5? (i) A SN1
reaction with an electrophilic, positively charged sulfur atom as an
intermediate is improbable [98,101], particularly under physiological
conditions. (ii) A direct nucleophilic attack of one of the two free
electron pairs of the thiol group without deprotonation also seems un-
likely. First, thiols are rather poor nucleophiles. Second, the resulting
uncharged transition state is acidic, and the simultaneous protonation
of the leaving group is therefore problematic. (iii) Under acidic condi-
tions, the leaving group could be protonated before the nucleophilic
attack of the thiolate. Accordingly, a better leaving group is generated,
and the orbital energy of the LUMO that accepts the incoming electrons
from the nucleophile is lowered [98,101]. However, even in a protein
environment, it is difﬁcult to envision disulﬁde protonation by a strong
acid on the one hand, and proximal thiol deprotonation on the other.
(iv) In a variation of the reaction in Fig. 5, the transition state might
be signiﬁcantly stabilized. Thus, the mechanism would be anaddition–elimination reaction with a rather stable intermediate instead
of a SN2 reaction [102].
In summary, the SN2 reaction presented in Fig. 5 is the most likely
mechanism for glutathione-dependent thiol–disulﬁde exchange reac-
tions. Principles including the deprotonation/activation of GSH as a
nucleophile, the correct substrate alignment via (positively charged)
binding sites, the stabilization of the (glutathionylated) transition
state, and the stabilization/activation of a leaving group are of course
also applicable to other glutathione-dependent enzymes that do not
catalyze thiol–disulﬁde exchange reactions (i.e. Fig. 5B,C).
3. Glutathione reductase
3.1. Pioneers of GR catalysis
Based on studies by Hopkins and several other groups between
the 1930–50s, Racker puriﬁed GR from yeast in 1955 and conﬁrmed
NADPH as the electron donor [103]. In 1963, Mapson and Isherwood
conﬁrmed that GR from pea seedlings requires FAD and a thiol-
group for activity. Their steady-state kinetics furthermore revealed
parallel lines in Lineweaver–Burk plots [104]. Two years later, Massey
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In 1977, the ﬁrst low resolution crystal structure of a GR-isoform
was solved for the human enzyme from erythrocytes, followed by a
key article on the structure at 3 Å resolution in 1978 by Schulz et al.
[36]. The exact amino acid sequence was obtained in the ensuing
years, and, in 1981, Thieme et al. assigned the sequence to an X-ray
data set with 2 Å resolution [106]. Owing to numerous additional
protein crystallographic studies, e.g. by Pai and Karplus, spectropho-
tometric analyses, e.g. by Williams, Arscott, Krauth-Siegel, Perham
and Scrutton, as well as genetic screens, e.g. by Grant, GR is nowadays
one of the best understood enzymes and a reference protein for redox
catalysis.
3.2. Structure and function of GR
GR (also termed GLR) is a ﬂavoenzyme of the pyridine nucleotide-
disulﬁde oxidoreductase family that also includes the related
enzymes trypanothione reductase, dihydrolipoamide dehydrogenase,
mercuric ion reductase and the so-called high Mr type TrxR-isoforms
[44,107,108]. GR-isoforms from pro- and eukaryotes form stable
homodimers of ~110 kDa with a large subunit interface of more
than 3000 Å2 (Fig. 6A) [36,108–112]. Each subunit contains an FAD-
binding site that is formed by a Rossmann-fold. The isoalloxazine
ring of FAD separates the distinguished substrate-binding sites for
NADPH and GSSG (Fig. 6B). The NADPH-binding site of each subunit
is also formed by a typical Rossmann-fold and presumably originated
from a gene duplication of the ancestor encoding most of the FAD-
binding site [113]. Each GSSG-binding site is formed by both subunitsFig. 6. Structure of GR. (A) Front view of homodimeric GR with one FAD molecule bound pe
side) are shown. Both subunits are not fully symmetrical owing to slight structural deviation
binds. (C) Zoom in at one active site of GR. An NADP+ molecule is bound at the re side in th
Conserved residues that are important for substrate binding and catalysis are highlighted. Th
tively) are located at the N-terminus of a long α-helix (presumably stabilizing thiolate anion
of both substrate-binding sites by the ﬂavin. Selected atoms of NADP+ and FAD are highligh
the structure of GR from E. coli (PDB ID: 1GET [109]).(Fig. 6C), and therefore the enzyme is only functional as a homodimer
[36]. The structure, both substrate-binding sites and even the overall
amino acid sequence of different GR-isoforms are extremely con-
served in the course of evolution. Biggest differences are found
at the subunit interface. For example, the subunits of crystallized
human GR are linked by a cysteine disulﬁde bond [106,108,114] in
contrast to the GR-isoforms from yeast [111], Plasmodium falciparum
[44,110] and E. coli [109]. Other poorly conserved cysteine residues—
e.g. residue Cys3 at the ﬂexible N-terminus of human GR or residue
Cys239 of yeast GR—are often solvent exposed and might play a regu-
latory role [34,106,111]. Another potential binding site for regulatory
molecules is a cavity at the dimer interface [44,110,114].
Functionally, GR is an NADPH:GSSG oxidoreductase (previously
EC 1.6.4.2, now 1.8.1.7). The enzyme has actually three substrates
(NADPH, H+ and GSSG) and two products (GSH and GSH), although
the proton is usually neglected as a substrate owing to the ofﬁcial
mechanistic nomenclature. The enzyme adopts a central role in gluta-
thione metabolism by linking the cellular NADPH-pool with the thiol/
disulﬁde-pool (Fig. 3B). Thus, GR helps to maintain a reducing intra-
cellular milieu owing to high GSH and low GSSG levels (Fig. 4). Note-
worthy, different GR-isoforms are found not only in the cytosol
but also in the mitochondrial matrix and in chloroplasts [115–120].
These proteins are often encoded by alternative in-frame start codons
of the same gene, resulting in the presence or absence of an
N-terminal targeting sequence [115,119–121]. The balance between
the isoforms—at least in yeast—seems to be regulated by the translation
initiation efﬁciency and therefore depends on the mRNA sequence
ﬂanking the start codon [115].r subunit. Based on the molecular 2-fold axis, the opposite sides of the ﬂavins (si and re
s. (B) Top view along the 2-fold axis revealing a cleft at the re side of FAD where NADPH
e back. The GSSG-binding site is composed of both subunits and is shown in the front.
e essential interchange and charge-transfer cysteine residues (Cysint and CysCTC, respec-
s due to its dipole). (D) Side view of one active site demonstrating the spatial separation
ted. See Section 3.2 for details. The images were generated using Swiss-Pdb viewer and
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The ping-pong mechanism of GR is coupled to the spatial separa-
tion of the NADPH- and the GSSG-binding site and comprises a reduc-
tive and an oxidative half-reaction (Fig. 7). First, the enzyme becomes
reduced by NADPH. Then, the electrons are transferred to GSSG,
regenerating the oxidized enzyme. Catalysis is facilitated by several
conserved key residues that are highlighted in Fig. 6C,D.
3.3.1. The reductive half-reaction of GR
OxidizedGR (GRox) contains two essential cysteine residues that form
a disulﬁde bridge at the si side of the isoalloxazine ring. The disulﬁde
bond is close to a histidine residue which is furthermore hydrogen-
bonded to a glutamate residue (His′ and Glu′, Fig. 6C,D). Please note
that His′ and Glu′ belong to the second subunit of the homodimer. A ty-
rosine residue (TyrNADPH) at the re side shields the FAD and acts as a gate-
keeper at the NADPH-binding site. Upon rapid NADPH binding, TyrNADPH
rotates away from the isoalloxazine ring and clamps the nicotinamide
moiety of the substrate [35,108,122,123]. A hydride transfer from
NADPH reduces the ﬂavin to FADH- (Fig. 7) which subsequently shuttles
an electron pair to the proximal cysteine residue (CysCTC). The thiolate
group of CysCTC forms a stable charge-transfer complexwith the isoallox-
azine ring, whereas the reduced distal cysteine residue (Cysint) could be
protonated by His′ [35,108,112,124–127]. At the end of the reductive
half-reaction, NADP+ dissociates from the two-electron reduced enzyme
species (GRH2) and is replaced by anothermolecule of NADPH [124,128].
3.3.2. The oxidative half-reaction of GR
Upon GSSG binding to GRH2, a tyrosine residue (TyrGSSG) is
repositioned in such a way that its hydroxyl group contacts the disul-
ﬁde bond of the substrate (Fig. 6C,D) [108]. In addition, GSSG is bound
by other conserved residues from both subunits, including four posi-
tively and two negatively charged side chains that compensate
the charges of the substrate (Fig. 3A) [35]. After substrate binding,
CysI of GSSG is attacked by the interchange residue Cysint of GRH2,
resulting in the formation of an intermolecular disulﬁde bond
(Fig. 7). The nucleophilic attack could be accelerated owing to the
deprotonation of the Cysint thiol group by His′. The interaction of
the latter residue with Glu′ could facilitate the deprotonation in ana-
logy to serine proteases [35,108,123]. His′was furthermore suggested
to protonate the thiolate leaving group of CysII which is liberatedFig. 7.Model of GR catalysis. Both subunits, FAD, the substrates NADPH, H+ and GSSG, aswell a
the GSSG-binding site is at the bottom. Please note that the glutathionemoieties GSI and GSII areupon GSSG reduction. This process might be assisted by TyrGSSG
[108,122,127,129–132]. Once the ﬁrst GSH molecule (GSHII) has left
the active site, the intermolecular disulﬁde bond is attacked at
the sulfur atom of Cysint by the thiolate of CysCTC yielding GRox. The
thiolate leaving group of the second GSH molecule (GSHI) could
again be protonated by His′ [35,108,123,127,132]. Considering the
kinetics of the numerous steps, one of the protonations (presumably
yielding GSHII) was suggested to be rate-limiting during the oxidative
half-reaction—which was furthermore reported to be slower than the
reductive half-reaction [122,130]. Accordingly, mutation of His′ was
shown to have drastic effects on catalysis [123,126,131].
3.3.3. Properties of GR reaction intermediates in vitro and in vivo
Reported macroscopic E°′ values for the reduction of the fully
oxidized enzyme GRox to the two-electron reduced form GRH2 are
between −227 and −243 mV for the isoforms from human, yeast
and E. coli [127]. Using (i) an estimated NADPH:NADP+ ratio of 4.2
for unbound pyridine dinucleotides in erythrocytes [133], (ii) an E°′
value of −317 mV, and (iii) the Nernst equation, the calculated E′
value for NADPH is −335 mV. Thus, under physiological conditions
(see also E′ values in Fig. 4), the concentration of GRox in the cytosol
or in the mitochondrial matrix is presumably low and the enzyme
gets permanently reduced owing to the rapid reaction with NADPH
[127,132,134].
Is the enzyme also constantly saturated with substrates? Apparent
and true Km values for NADPH in vitro were found to be usually
between 3 and 20 μM [104,122,135,136]. These values were predom-
inantly determined for GR from various species at a single ﬁxed
millimolar concentration of GSSG. Furthermore, different pH values
were used, although this might be rather unproblematic since the
pH optimum of most GR-isoforms is rather broad (with a maximum
around pH 7, except for some proteins from photosynthetic organ-
isms) [105,136,137]. Apparent and true Km values for GSSG were
often determined with 100 μM NADPH and usually ranged between
50 and 80 μM, though some isoforms with lower and higher values
were also reported [34,104,105,122,134,136,138]. Do the Km values
for NADPH and GSSG correspond to the physiological substrate con-
centrations? To my knowledge, there is surprisingly very limited in-
formation on the concentration of NADPH in vivo. In erythrocytes,
the concentrations of protein-bound and free NADPH were reported
to be 32 and 2 μM, respectively [133]. Considering the latter values residues Cysint, CysCTC andHis′ are highlighted. The NADPH-binding site is at the top, and
not identical. The charge-transfer complex is highlighted in red. See Section 3.3 for details.
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it is quite likely that the Kmapp values for NADPH and GSSG are signiﬁ-
cantly lower under physiological conditions (because decreasing the
concentration of one substrate also decreases the Kmapp value for the
second substrate of an enzyme with a ping-pong mechanism). For ex-
ample, reevaluation of ﬂuorimetric data on GR from peas at 0.3 μM
NADPH reveals a Kmapp value for GSSG of approx. 1 μM—a value far
below the true Km of 17 μM [104]. In summary, as long as we neither
know the exact concentrations of the substrates nor the corresponding
Km
app values under physiological conditions, it is difﬁcult to estimate or
to predict the degree of saturation of GR-isoforms in vivo.
3.3.4. Outlook on GR catalysis and mechanistic questions
There are still open questions concerning GR catalysis. (i) The fates
and sources of several protons remain to be determined: What hap-
pens for example to the proton Hs that was transferred as a hydride
ion from NADPH [108,131]? Is TyrGSSG really involved in acid–base
catalysis [108,122,127,131]? Which of the candidates Cysint, CysI
and CysII receives a proton from His′, and/or does His′ remain proton-
ated to stabilize the thiolate of CysCTC [108,112,125–127]? (ii) Does
the reductive half-reaction occur simultaneously or sequentially?
In contrast to previous kinetic studies on GR from E. coli and
P. falciparum [126,134], recent high resolution crystallographic stud-
ies on human GR suggested that the Hs hydride transfer of atom C4
from NADPH to atom N5 from the isoalloxazine on the one hand,
and the electron transfer from atom C4 of the isoalloxazine to CysCTC
on the other, are not separate steps, but occur in a simultaneous
1,2-addition reaction with respect to the ﬂavin [139]. (iii) Is Cysint of
someGR-isoforms predominantly glutathionylated in vivo as suggested
by Arscott and colleagues [132,134]? To my knowledge, an accumula-
tion of oxidized Cysint has so far not been detected (using for example
quantitative redox proteomics in E. coli, Caenorhabditis elegans and
yeast [140–142]). (iv) Is an NADH-dependent GR activity of any physi-
ological relevance? Some GR-isoforms were shown to utilize NADH
as an alternative electron donor in vitro. For example, the Vmax of GR
from spinach with NADH was found to be 18% of the activity with
NADPH [135]. In addition, at a rather acidic pH, the activities of mam-
malian GR with NADH and NADPH were reported to be similar [137].
(v) Kinetic studies indicate that the outlined mechanism might not be
that simple. For example, mutation of TyrNADPH in E. coli GR switched
the steady-state kinetics from ping-pong to sequential patterns
[123,143] in accordance with a hybrid ping-pong bi-bi/ordered bi-bi
mechanism [137,144,145]. Moreover, do both reaction centers of GR
function independently, or is there a synchronization of the catalytic
cycle including subunit cooperativity? Studies by the Perman lab
in the 1990s support both hypotheses. On the one hand, data on
heterodimeric GRmutants from E. coliwith one functional and onemu-
tated reaction center favor an independent catalysis [143]. On the other
hand, steady-state kinetics of an E. coli GR mutant with a single amino
acid replacement at the dimer interface revealed subunit cooperativity
at 0.1 mM NADPH that was lost with 0.4 mM NADPH [146,147]. The
crucial question is now, whether wild type GR also shows cooperativity
at physiological substrate concentrations (Section 3.3.3). Furthermore,
is a potential cooperativity of human GR coupled to the stability of
the cysteine disulﬁde bond at the dimer interface [106,108,114]?
In summary, GR works via a ping-pong mechanism. The enzyme
requires FAD, two essential cysteines, an activated histidine for acid–
base catalysis as well as several other conserved residues for substrate
binding. Although GR is one of the best understood enzymes, several
fundamental mechanistic aspects have not been unraveled yet.
3.4. Physiological and medical relevance of GR catalysis
3.4.1. Physiological relevance of GR catalysis
The physiological relevance of GR catalysis can be estimated from
a variety of GR mutants and knock-out organisms. Yeast GR knock-out strains are viable (as long as there is a functional TrxR/Trx
couple), but were suggested to be more sensitive to oxidants and to
have higher GSSG levels in the cytosol and in the mitochondrial
matrix [40,41,115,148]. Moreover, despite similar GR activities and
concentrations in both subcellular compartments [115], removal
of the mitochondrial but not of the cytosolic GR-isoform rendered
yeast cells more sensitive to hyperoxia [149]. In contrast to yeast,
E. coli GR knock-out strains lack a phenotype and do not have in-
creased GSSG levels as long as there is an alternative electron donor
system [150]. The GR from rodent malaria parasites was shown to
be essential for oocyst development in the mosquito midgut but not
for the blood stage parasites in the vertebrate host [39,42]. In con-
trast, blood stage cultures of the human malaria parasite P. falciparum
were suggested to require GR for survival [151]. The two GR-isoforms
from the plant Arabidopsis thaliana are encoded by alternative genes.
A deletion of the cytosolic isoform did not result in a signiﬁcant phe-
notype, even though the in vivo redox potential for the glutathione
system increased by 45 mV owing to higher GSSG levels [43]. In
contrast, a deletion of the dual targeted mitochondrial/chloroplast
GR-isoform was lethal during embryo development as revealed by a
genetic screen [152]. The human gene encoding the cytosolic and
the mitochondrial GR-isoform (locus p21.1 on the short arm of chro-
mosome 8) consists of 13 exons [120]. In addition to the full length
transcript, two splice variants lacking either exon 8 or 9 seem to be
present in various tissues. The physiological role of these variants is
rather cryptic, in particular, because the predicted translation prod-
ucts are expected to be inactive [153]. Up-regulation of mitochondrial
GR was shown to increase the resistance of lung cells to exogenous
hydroperoxides and hyperoxia in cell culture [154] but not in mice
[155]. Noteworthy, patients with low or even absent GR activity in
blood cells (that could not be compensated by FAD supplementation)
were already reported in the 1960s and 1970s [156–158]. More
recent genetic analyses revealed three rare underlying homo- and
heterozygous mutations resulting in either truncated/non-functional
or destabilized/short-lived GR [159].
In summary, functional GR is not a prerequisite for the survival of
several aerobic organisms including humans. Even though mitochon-
drial and chloroplast GR-isoforms seem to be more important with
respect to oxidative challenges than cytosolic GR, most prokaryotes
and eukaryotes have alternative back-up systems that provide elec-
trons at an adequate rate to maintain sufﬁcient amounts of GSH and
a physiologically acceptable GSH/GSSG ratio (Fig. 4).
3.4.2. Medical relevance of GR catalysis
Owing to the central role that GR exerts in glutathionemetabolism
(Fig. 3B), the absent or mild phenotypes of GR knock-outs from differ-
ent organisms are surprising at ﬁrst sight. Indeed, three patients
with homozygous GR deﬁciency in blood cells were reported to be
in good health at ages 48, 54 and 58. To date, the only documented
clinical symptoms related to a GR deﬁciency are restricted to a higher
susceptibility of erythrocytes to oxidative challenge (including hemo-
lytic crisis after eating fava beans) and cataract development during
early adulthood [157,159]. Nevertheless, the numerous studies on
the catalytic mechanism of GR provide excellent lessons on rational
drug development, and it is nowadays accepted that knowing as
much as possible about a target enzyme is highly advantageous. For
example, despite high overall sequence similarities, the GR-isoforms
from human and P. falciparum were shown to differ signiﬁcantly
with respect to their dimer interfaces as well as their kinetic and
redox properties [44,110,134,138,160]. Accordingly, alternative strate-
gies to exploit GR as a drug target have been developed: (i) Traditional
approaches included the inhibition of the enzyme at the GSSG-binding
site or at the dimer interface and its cavity [34,44,160,161].With respect
to irreversible inhibition of GR at the GSSG-binding site, highly reactive
electrophiles such as gold-compounds and ﬂuoronaphthoquinones
turned out to efﬁciently inactivate GR-isoforms in vitro, but to be of
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recent, alternative approach to kill malaria parasites aims to exploit
functional instead of inactive GR in order to regenerate drugs that sub-
sequently act as harmful redox cyclers. Based on in vitro experiments,
such drugs—including naphthoquinones and methylene blue—were
therefore classiﬁed as “turncoat inhibitors” or “subversive substrates”
[161,162]. Indeed, several synthetic naphthoquinones had a low toxici-
ty towards mammalian cells, a high activity with low nanomolar IC50
values against P. falciparum blood stage cultures, and a moderate acti-
vity in parasitizedmice [161]. Phase II trials in Burkina Faso furthermore
revealed that methylene blue can be useful in combination therapies
with fast acting antimalarials, even though the compound is not suited
for monotherapy [163,164]. Recent studies on rodent malaria parasites
suggested that the presence or absence of GR does not alter the activity
of methylene blue [39,42] in contrast to the GR-dependent drug-
activation hypothesis. Whether the latter results can be transferred to
the human system awaits clariﬁcation.
In summary, attempts to exploit GR as a traditional drug target have
failed to date, but the enzymemight be suited for the activation of sub-
versive substrates. Related ﬂavoenzymes of organismswith alternative,
non-redundant redox systems—such as thioredoxin–glutathione reduc-
tase in parasitic plathelminths [165] and trypanothione reductase in
kinetoplastid parasites [44]—could be better suited for drug develop-
ment. Future studies on such enzymes could beneﬁt from the experi-
ences with GR.
4. Glutaredoxins
4.1. Pioneers of Grx catalysis
A glutathione-dependent thiol:disulﬁde oxidoreductase activity
(Fig. 3C) was ﬁrst described in crude enzyme preparations from
beef liver by Racker in 1955. In this study GSH/homocystine and
homocysteine/GSSG were successfully used as redox couples, con-
ﬁrming the reversibility of the catalyzed thiol–disulﬁde exchange
reaction (Fig. 3C). The catalyst of the reaction was classiﬁed as a
“transhydrogenase” [166]. In the following years, several groups ana-
lyzed similar enzymatic activities in partially puriﬁed liver extracts
from mammals including human. Most of these studies focused on
the GSH-dependent reduction of insulin disulﬁde bonds [167–169].
In retrospective, as already pointed out by Freedman in 1979, it
is quite likely that canonical Grx were analyzed in these liver prepa-
rations, although other enzymes such as Trx, GST or PDI could also
have contributed to the detected activities [170,171].
In 1968, Nagai and Black published the ﬁrst characterization of an
isolated GSH:homocystine oxidoreductase. The 15 kDa protein was
puriﬁed from baker's yeast (Saccharomyces cerevisiae). Moreover,
the authors established a coupled spectrophotometric assay with GR
using different disulﬁde substrates including L- and D-cystine, several
cystine-derivates as well as bis(2-hydroxyethyl)disulﬁde (HEDS)
[172]. The latter substance became an important model substrate
for Grx research [53–55,173]. In 1974, Mannervik's group introduced
the name “thioltransferase” instead of transhydrogenase, based on
their mechanistic studies on partially puriﬁed rat liver extracts
[174]. Four years later, the group succeeded in purifying functional
rat liver thioltransferase [175] which was further analyzed in numer-
ous studies [176]. Alternative puriﬁcation procedures for mammalian
isozymes from calf thymus [177,178] and pig liver [179,180] were
established in the following years by Luthman and Holmgren as well
as Gan and Wells. The sequences of these model isozymes were deter-
mined [181], the according genes were cloned [182], and the crystal
and NMR structures of oxidized and mutant glutathionylated mam-
malian thioltransferase were solved in 1995 and 1998, respectively
[183,184].
In parallel to the studies on mammalian thioltransferases,
Holmgren discovered in 1976 a heat-stable GSH-dependent hydrogendonor for ribonucleotide reductase (RR) in crude extracts from an
E. coli strain lacking Trx [185] (which is the classic hydrogen donor
for RR [17]). He therefore introduced the term “glutaredoxin”. Three
years later, Holmgren reported the puriﬁcation of the enzyme and
the reconstitution of the RR-assay in vitro [186,187]. During the
following years, E. coli Grx1 (EcGrx1) became an excellent model
protein: The amino acid sequence was determined [188], the corre-
sponding gene was cloned, and two isoforms were successfully puri-
ﬁed [189,190]. Furthermore, between 1991 and 1994, Wüthrich
and colleagues determined the solution structure of EcGrx1 in the
oxidized, the reduced and the glutathionylated state by NMR-
spectroscopy [191,192].
Today, it is accepted that GSH-dependent transhydrogenases,
thioltransferases and Grx from yeast, mammals and E. coli are
isoforms of the same protein family. Since their discovery, numerous
studies on the structural diversity, the enzymatic mechanism and the
physiological functions of these ubiquitous proteins have been pub-
lished [14,53–55,173,193,194]. Nonetheless, as outlined in the follow-
ing sections, the more we know about Grx, the more questions seem
to arise.4.2. Structure of Grx and related glutathione-dependent proteins
4.2.1. Comparison of the catalytic core domains
All Grx-isoforms possess a thioredoxin fold and are therefore mem-
bers of the thioredoxin superfamily. This fold of approx. 11–13 kDa is
highly conserved in the course of evolution and is composed of four or
ﬁve central β-strands surrounded byα-helices (Fig. 8A,B) [195]. Similar
architectures are found in other (glutathione-dependent) enzymes
such as GST (Fig. 8C,D), GPx (Fig. 8E,F) and Prx (Fig. 8G,H), supporting
the theory of a common ancestor for all these proteins [195]. Please
note that the positions of the glutathione binding residues and of the
active site residues are often either interchanged, similar or even iden-
tical. Thus, selected mutations resulted in novel functions (see also
Section 2.3.1).
Biggest structural differences between Grx- and Trx-isoforms are
found at the active site and at the N-terminus because of an additional
β-strand in Trx (Fig. 8A). Furthermore, the N-terminus of many
eukaryotic Grx-isoforms is modiﬁed by a targeting sequence, a mem-
brane anchor or additional domains [53,196–199]. Grx can be distin-
guished from Trx owing to their speciﬁcity for glutathione. Accordingly,
Grx possess moderately conserved polar as well as charged amino acid
residues that interact with the carboxylate group(s) of glutathione as
highlighted in Figs. 8B and 9 [55,184,192,200–202]. However, despite
numerous alignment-based subgroup classiﬁcations [196,199], the
boundaries between Grx- and Trx-isoforms nowadays become more
andmore blurred [203], and it is difﬁcult to clearly separate both groups
because of structural hybrid forms and overlapping or absent activities
[55]. The same holds true for various Trx- or GSH/Grx-dependent GPx-
and Prx-isoforms [60,61,204] (Sections 5 and 6).
Was the ancestor of certain (sub)families of the thioredoxin su-
perfamily a glutathione-dependent protein? Considering the putative
onset of glutathione metabolism (Fig. 1), it seems far more likely that
glutathione-independent members of the thioredoxin superfamily
are more ancient. Nevertheless, recent in silico analyses suggest
that Grx evolved rather early from one initial gene in the last common
ancestor of all organisms [203]. The relatively low numbers of
glutathione-dependent GPx- and Prx-isoforms (Sections 5 and 6) fur-
thermore point to independent acquisitions of glutathione activities
for different (sub)families in the course of evolution. In addition, it
is also possible that various isoforms—including some Grx-like proteins
or GST-isoforms—have secondarily lost their speciﬁcity for glutathione
(see also Section 8.3.2). Obviously, the research ﬁeld could become
an eldorado for (bioinformatic) studies on the molecular evolution of
structure–function relationships.
Fig. 8. Structural comparison between members of the thioredoxin superfamily. Protein architectures are shown on the left side. Top and side views of the glutathione-binding site
of representative proteins are shown on the right side. More or less conserved residues that were demonstrated or suggested to bind the glycine moiety (1) or the γ-glutamyl moi-
ety (2) of glutathione are labeled. The ionic and hydrogen bonds with the substrate are predominantly formed by Lys/Arg and Asn/Gln residues. The structures were visualized
using Swiss-Pdb viewer. (A) Overall architecture of Grx and Trx. The canonical thioredoxin fold is highlighted in black. This fold is identical to the architecture of the most simple
Grx-isoforms such as Grx1 and Grx3 from E. coli. Helices α1 and α5 (blue) are found in many other Grx-isoforms. Trx have an additional N-terminal β-strand (green) but lack helix
α5. Additional targeting sequences or domains at the N-terminus of various Grx-isoforms are omitted for clarity. The N-terminal cysteine residue in the CxxC/S-motif at the active
site is highlighted by an asterisk. (B) NMR structure of glutathionylated human Grx1 with six glutathione conformations (PDB ID: 1B4Q [184]). (C) Common architecture of a single
GST subunit without the C-terminal helical domain. The tyrosine residue at the active site is highlighted by an asterisk. (D) Crystal structure of the N-terminal domain of a
P. falciparum GST subunit in complex with S-hexylglutathione (PDB ID: 2AAW [71]). (E) Common architecture of a single GPx subunit. Please note the insertion of additional struc-
tural elements (blue). The selenocysteine (or cysteine) residue at the active site is highlighted by an asterisk. (F) Crystal structure of a mammalian GPx1 subunit with the
selenocysteine residue at the active site in the ‘over’-oxidized seleninate state (PDB ID: 1GP1 [304]). The N-terminal part is omitted for clarity. (G) Common architecture of a single
Prx subunit. Please note the insertion of additional structural elements (blue). A C-terminal arm/domain interacting with a second subunit is present in many Prx classes. The cys-
teine residue at the active site is highlighted by an asterisk. (H) Crystal structure of a poplar D-Prx subunit with the peroxidatic residue (Cysp) at the active site (PDB ID: 1TP9 [558]).
The precise glutathione-binding site (if any) is unknown. The N-terminal part is omitted for clarity, and a C-terminal domain is absent.
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Several structures of Grx-isoforms in a variety of redox states are
shown in Fig. 9. Even though all Grx-isoforms share a solvent exposed
active site cysteine residue (Cysa) at the N-terminus of helix α2
(Fig. 8A,B, Fig. 9), they are an extremely heterogeneous proteinfamily. The numerous isoforms are traditionally subdivided into
monothiol and dithiol Grx, depending on the number of cysteine res-
idues in the CxxC/S-motif at the active site. For example, canonical
Grx are dithiol isoforms of the CPYC-type with the second cysteine
residue being rather buried (Fig. 9). The aromatic amino acid in this
Fig. 9. Structural comparison between the substrate/ligand-binding sites of Grx-isoforms. The orientation is identical to the left panel in Fig. 8B. The N-terminal cysteine residue at
the active site (Cysa) and the residues s1 and s2 in the s1-C-x-s2-C/S-motif at the N-terminus of helix α2 are highlighted. The predominantly positively charged glycine
moiety-binding site (1) is formed by residues r1, r2 and r3 (or r3* at an alternative position). The often negatively charged γ-glutamyl moiety-binding site (2) at the N-terminus
of helix α4 is formed by residues r4–r6. A conserved proline residue before strand β3 is shown in dark red at the center of each image. (A) Structures of S. cerevisiae Grx2 in the
oxidized, glutathionylated and reduced state (from left to right, PDB IDs: 3CTF, 3D5J and 3CTG, respectively [206,215]). Structural rearrangements—including single side chains
or the back bone of the active site motif—are indicated by black arrows. (B) Structures of S. cerevisiae Grx1 in the oxidized and glutathionylated state (PDB IDs: 3C1R and 3C1S,
respectively [205]). (C) Structure of S. cerevisiae Grx6 in the glutathionylated state (PDB ID: 3L4N [216]). (D–F) Structures of human Grx2, human Grx5 and E. coli Grx4 in complex
with an Fe/S-cluster (PDB IDs: 2HT9, 2WUL and 2WCI [201,209,210]). Only one subunit is displayed for clarity. An insertion between r1 and s1 is shown in pink and aWP-motif after
helix α3 is highlighted in purple. The structures were visualized using Swiss-Pdb viewer.
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since the γ-glutamylcysteinyl-moiety of glutathione is wrapped
around it. A second tyrosine residue preceding Cysa (residue s1 in
Fig. 9) has a surprisingly ﬂexible side chain (Fig. 9A,B) [205,206] but
is often replaced, i.e. by serine or threonine (Fig. 9C,D,F). Please note
that the type and the overall number of glutathione-binding residues
(r1–r7 in Fig. 9) differ signiﬁcantly among Grx-isoforms. The basic
residue r1 after strand β1 seems to be the most conserved one. Inter-
estingly, some mono- and dithiol Grx-isoforms have an additional
cysteine residue, replacing r4 after a GG-motif at the N-terminus of
helix α4 (C* in Fig. 9E). A CGFS-motif is common for the active site
of many monothiol Grx-isoforms, but other variations such as CSYS
[173,207] and CKYS are also found [208]. Additional structural alter-
ations in many monothiol Grx-isoforms include an inserted loop be-
tween residue r1 and the two residues preceding Cysa (Fig. 9E,F),
and the replacement of r3 in the loop connecting helix α3 and strand
β3 by a WP-motif (Fig. 9E,F) [173,196,208–211].
Although the general orientation of Grx-bound glutathione is quite
similar for a variety of isoforms (Fig. 9), the conformations—in particularof the γ-glutamyl moiety—seem to be rather variable (see also the
NMR-structures in Fig. 8B [184]).Moreover, the conformations of selected
Grx side chains and of the peptide backbone around the active site are
quite ﬂexible, indicating redox-dependent structural changes (Fig. 9)
[205,206,212–215]. As far as the quaternary structure is concerned, Grx
are usually thought to be monomeric proteins. However, non-covalently
linked dimers were detected for recombinant S. cerevisiae Grx6 and
Grx7 [173,216], Trypanosoma brucei 1-C-Grx1 [217], Populus tremula Grx
C4 [218] and EcGrx1 [219]. As outlined in Section 4.3.2, and as reviewed
by Berndt and Lillig, several Grx-isoforms are furthermore able to bind
Fe/S-clusters with glutathione as a ligand (Fig. 9D–F). The association
with Fe/S-clusters can lead to the formation of dimers and tetramers
with a variety of alternative protein–protein contact sites in mono- and
dithiol Grx [173,201,209,210].
4.3. Functions of Grx
As described in the previous section, Grx-isoforms can be structur-
ally categorized, i.e. as monomeric or dimeric monothiol or dithiol Grx
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(Fig. 9). Grx can be furthermore grouped based on alternative bio-
chemical properties such as enzymatic activities, subcellular localiza-
tions or (putative) physiological functions [53–55,173,194,196,199].
For many isoforms the functions and substrates of Grx seem to
overlap to a certain degree with Trx [220–222] (Section 6) or are
just beginning to emerge: Grx are ofﬁcially classiﬁed as electron
donor for arsenate reductases (EC 1.20.4.1) producing arsenite and
GSSG. Even though some isoforms have a high activity in the corre-
sponding in vitro assay [223], this rather specialized function does
not reﬂect the general importance of Grx. Central physiological sub-
strates of canonical dithiol Grx and Trx are the different isoforms of
oxidized RR. Hence, Grx and Trx are crucial for DNA synthesis
[171,185,186,222,224]. Human Grx and Trx furthermore differen-
tially regulate apoptosis signal-regulating kinase 1 upon oxidative
challenge in cell culture [221]. Moreover, a variety of Grx-isoforms
provide a biochemical platform for iron ion sensing and the delivery
of Fe/S-clusters (Fig. 9) and therefore play a central role in iron
homeostasis [173,193,196,198,201,209–211,225]. Further (potential)
functions are outlined in Section 4.5 and were previously reviewed,
for example, by Mieyal et al. [14]. In order to provide a summary of
the functions of a complete Grx system in an organism, I will continue
with a comparison of the eight different Grx-isoforms from S. cerevisiae
[55,193,196–198,220].
4.3.1. Enzymatic activities and functions of yeast dithiol Grx
Yeast has three dithiol Grx (ScGrx1/2/8) and ﬁve monothiol Grx
(ScGrx3–7) [53,173,196,197]. The two dithiol isozymes ScGrx1 and
ScGrx2 possess a canonical KxxCPYC-motif at the active site and
share 64% sequence identity [226] (Fig. 9A,B). The high similarity
presumably originates from a yeast genome duplication event in the
course of evolution [227]. The third dithiol Grx-isoform ScGrx8 has
an unusual Trp14-type SWCPDC-motif at the catalytic center [55]
and is a bona ﬁde candidate for a Grx/Trx hybrid (Section 4.2.1).
ScGrx1 and ScGrx8 both lack a targeting signal and are therefore
considered to be cytosolic proteins [55,196,228]. A GFP-fusion con-
struct of ScGrx8 was indeed detected in the cytosol [229]. In con-
trast, ScGrx2 is dual targeted to the cytosol and to the mitochondrial
matrix owing to alternative in-frame translation start codons. A sub-
population of the unprocessed mitochondrial precursor was further-
more suggested to localize to the outer mitochondrial membrane
[228,230,231] (or could be in the intermembrae space). According
to a global protein analysis [232], ScGrx2 is far more abundant than
ScGrx1 and ScGrx8 (approx. 3×104, 3×103 and 6×102 molecules
per cell, respectively). This estimation is in good agreement with
activity measurements in cell extracts from wild type and Grx-
mutant strains, suggesting that ScGrx2 accounts for the majority of
the detected activity in the HEDS assay [226]. The GSH:disulﬁde
oxidoreductase activity with HEDS was also conﬁrmed for recombi-
nant ScGrx1 and ScGrx2 [206,215] (with kcat and kcat/Km values
from secondary plots of 17 s−1 and 2.8×103 M−1 s−1 for ScGrx1,
and 129 s−1 and 1.4×105 M−1 s−1 for ScGrx2 [215]). Apparent kcat
and kcat/Km values for ScGrx8 were approx. thousand fold lower
[55]. Thus, the enzyme that was initially characterized by Nagai and
Black [172] (Section 4.1) was most likely ScGrx2.
The exact physiological substrates of ScGrx1/2/8 are (predomi-
nantly) unknown. As far as the reduction of RR is concerned, Trx-
isoforms seem to be more relevant electron donors than Grx [233].
Yeast strains carrying a single, double or triple deletion of the genes
encoding ScGrx1/2/8were not only viable, but also grewwith unaltered
rate on fermentable/non-fermentable carbon sources or on minimal
medium [55,226]. However, single and double mutant strains of
ScGrx1 and ScGrx2 were more susceptible to external hydroperoxides,
paraquat or iron chloride, and an overexpression of both genes in-
creased the tolerance towards oxidants [55,68,220,226,234]. The dele-
tion of ScGrx8 did not alter the growth phenotypes, suggesting aspecialized function of this protein [55]. Noteworthy, the thiol-
oxidizing agent diamide was less toxic in the absence of ScGrx1 and
ScGrx2 [55,226] (Section 4.4.3). Both proteins were furthermore
reported to possess signiﬁcant direct glutathione peroxidase and GST
activities in vitro and in vivo [68,234] (with apparent kcat and kcat/Km
values around 50 s−1 and 3–5×104 M−1 s−1 for H2O2 and 1–13 s−1
and 3–6×103 M−1 s−1 for the GST model substrate 1-chloro-2,4-
dinitrobenzene (CDNB) [234]). The latter results are quite surprising
and lead to the question whether such activities are either absent for
other Grx-isoforms [208] or are just often overlooked. The functions of
ScGrx1 and ScGrx2 are not fully overlapping (as revealed bymenadione
or paraquat treatment [55,226] and by expression analyses upon oxida-
tive challenge and heat-shock [226]). This is plausible considering the
different subcellular localizations and activities [215,228,230,231,234].
In summary, even though the exact substrates and metabolic networks
remain to be unraveled, ScGrx1 and ScGrx2 have partially overlapping
functions with Trx, GPx and GST and protect yeast cells from challenges
with oxidants and other electrophiles.
4.3.2. Enzymatic activities and functions of yeast monothiol Grx
Why do yeast cells have ﬁve monothiol Grx-isoforms (ScGrx3–7)?
On the one hand, ScGrx3 and ScGrx4 as well as ScGrx6 and ScGrx7
presumably originate from the aforementioned yeast genome dupli-
cation event [227]. On the other hand, the proteins localize in a vari-
ety of subcellular compartments. ScGrx3 and ScGrx4 are both found in
the cytosol and in the nucleus [193,196,235,236], and their additional
Trx-like domain at the N-terminus was suggested to be a prerequisite
for the nuclear localization [235]. In contrast, ScGrx5 is a mitochon-
drial protein with an N-terminal matrix-targeting sequence [211].
ScGrx6 and ScGrx7 are the ﬁrst Grx-isoforms that were identiﬁed in
the secretory pathway of eukaryotes. Both proteins are N-terminally
membrane-anchored facing the lumen of the cis-Golgi [197,198].
In addition, tagged ScGrx6 was also detected in the endoplasmic retic-
ulum [198]. Estimated concentrations [232] of ScGrx3 and ScGrx4
are approx. 1.1×104 and 7.8×103 molecules per cell, respectively.
Based on these numbers and on an estimated compartment volume
of 25 ﬂ the concentrations of ScGrx3 and ScGrx4 are roughly 0.4
and 0.3 μM, respectively. The organellar concentrations of ScGrx5
and ScGrx6 (6.3×103 and 1.6×103 molecules per cell, respectively)
are presumably higher owing to the smaller volume of the cellular
compartments.
First functional insights on monothiol Grx were gained during
the last decade by the Herrero lab: Loss of ScGrx5 resulted in growth
defects in minimal medium, hypersensitivity to external oxidants
and protein hypercarbonylation indicative for oxidative damage
[237]. Like most other monothiol Grx, ScGrx5 was found to be
inactive in the HEDS assay (although the protein was shown to
deglutathionylate rat carbonic anhydrase III in vitro) [238]. Notably,
the absence of ScGrx5 resulted in the accumulation of iron ions and
in a reduced activity of Fe/S-cluster-containing enzymes [196,211].
Moreover, the growth phenotype was reversed by the overexpression
of the genes SSQ1 and ISA2 [211] which are both involved in the
mitochondrial biosynthesis and assembly of Fe/S-clusters [239].
Thus, mitochondrial ScGrx5 was the ﬁrst Grx-isoform shown to par-
ticipate in iron metabolism. The auxotrophy in the absence of
ScGrx5 was presumably based on the requirement of Fe/S-cluster-
containing enzymes for the biosynthesis of selected amino acids,
whereas the increased susceptibility to oxidants could have been
caused by the oxidizing basal conditions [196,211] owing to Fenton
chemistry (Fig. 2A). The increased glutathionylation of proteins such
as GAP-dehydrogenase [240] in a ScGrx5 mutant strain supports the
latter theory. Most important, the function of ScGrx5 in the assembly
or synthesis of Fe/S-clusters seems to be conserved in the course
of evolution [196] as indicated by studies on zebraﬁsh [241] and
A. thaliana [242]. Further studies are now required to decipher the
exact mode of action of ScGrx5. Recent analyses on ScGrx5 and its
3231M. Deponte / Biochimica et Biophysica Acta 1830 (2013) 3217–3266homologues suggest a direct interaction between the complexed
Grx-isoform and Fe/S-cluster-binding proteins in mitochondria and
chloroplasts [196,210,242,243].
ScGrx3 and ScGrx4 are also involved in iron metabolism [193,196].
Both proteins interact with the iron-sensing transcription factor
Aft1 in the nucleus. Under conditions of limited iron ion availability,
Aft1 activates the transcription of genes in an iron regulon. The
Grx-isoforms negatively regulate Aft1 as reﬂected by a constitutive
transcription in the absence of ScGrx3 and ScGrx4. In the presence
of ScGrx3 and ScGrx4 the localization of Aft1 is shifted towards
the cytosol. The redistribution is mediated by the Grx- and not
by the Trx-domain of ScGrx3 and ScGrx4 in an iron-independent
manner [244,245]. Analogously, the homologue of ScGrx4 from
Schizosaccharomyces pombe triggers the nuclear export of Php4, a
component of an iron-dependent transcription repressor complex
[246]. ScGrx4 was furthermore shown to be a substrate of the nuclear
kinase Bud32 in vitro and in vivo, but the physiological relevance
of the phosphorylation remains to be deciphered [236,247]. Apart
from the interaction with Aft1, Fe/S-cluster-containing ScGrx3 and
ScGrx4 were shown to play an important role in iron ion sensing
and delivery in the cytosol [193]. The latter function probably
explains the (redox-sensitive) phenotype in the absence of both
proteins owing to free iron ions (Fig. 2A) [193,245,246]. Noteworthy,
regulatory roles of monothiol Grx-isoforms containing a Trx-domain
are not restricted to yeast [53,196]. For example, the human PICOT
protein also localizes to the cytosol and the nucleus of T lymphocytes
where it was reported to negatively regulate the activity of protein
kinase Cθ and, therefore, to inﬂuence the transcription factors AP-1
and NFκB [248]. In summary, the monothiol Grx-isoforms ScGrx3 and
ScGrx4 signiﬁcantly differ from mitochondrial ScGrx5. They exert
overlapping regulatory functions with respect to iron-dependent gene
expression in the nucleus and inﬂuence the availability of intracellular
iron ions for biosynthetic processes.
In contrast to ScGrx3-5 and most other monothiol Grx-isoforms,
ScGrx6 and ScGrx7 have a signiﬁcant oxidoreductase activity in the
HEDS assay in vitro [173,197,198,216]. Genetic experiments further-
more suggest a contribution of both proteins to redox homeostasis
in the secretory pathway in vivo [197,198]. Metabolic challenges
lead to a differential up-regulation of the encoding genes depending
on the Crz1-calcineurin pathway (ScGrx6) or the transcription factor
Msn2/4 (ScGrx7) [198]. Notably, ScGrx6—but not ScGrx7—binds a
glutathione-stabilized Fe/S-cluster in vitro, resulting in a loss of
the oxidoreductase activity [173]. Since ScGrx6 also binds iron ions
in vivo [198], it is tempting to speculate that ScGrx6 plays a role in
iron metabolism (i.e. as a sensor regulating a transporter-dependent
uptake or the storage of iron ions). In summary, ScGrx6 and ScGrx7
are enzymatically active monothiol Grx-isoforms with partially over-
lapping functions in the secretory pathway. Their physiological sub-
strates or interaction partners are unknown. ScGrx6 might play
a role in iron metabolism in analogy to the monothiol Grx-isoforms
ScGrx3–5.
4.4. The enzymatic mechanism of Grx
Many, but by far not all, Grx-isoforms catalyze the GSH-dependent
reduction of the model substrate HEDS in a standard GR-coupled
enzymatic assay [53–55,172,173]. A signiﬁcant activity in the HEDS
assay (yielding GSSG and two molecules of 2-mercaptoethanol) was
detected for dithiol Grx-isoforms from E. coli [178,186,249,250], mam-
mals [59,178,249,251–255], P. falciparum [256], yeast [172,206,226] as
well as plants and algae [257–259]. In contrast, with very few excep-
tions [173,198,216], all monothiol Grx-isoforms analyzed so far were
found to be inactive in this assay [58,208,238,257,259,260]. Alternative
Grx-dependent assays include the reduction of L-cysteine-glutathione
disulﬁde (Cys-SSG), dehydroascorbate, RR, 3′-phosphoadenylylsulfate
reductase, insulin and glutathionylated model proteins [53,55,173,178,186,187,238,252,259,261,262]. To my knowledge, there are no
standardized kinetic assays for the Grx-dependent transfer or incorpo-
ration of Fe/S-clusters, and it remains to be shown that such processes
obey typical enzyme kinetics with kcat and Km values. In fact, the in
vitro transfer of an Fe/S-cluster from poplar GrxS14 to ferredoxin was
best ﬁt by (non-enzymatic) second order kinetics yielding an apparent
rate constant of 3×102 M−1 s−1 [242]. Thus, I will focus in the follow-
ing sections on the thiol:disulﬁde oxidoreductase activities of Grx
and outline only structural aspects as far as Fe/S-cluster binding is
concerned.
4.4.1. The traditional model of Grx catalysis
The traditional model of the catalytic mechanism of dithiol Grx
is summarized in Fig. 10 [14,53,55]. It is based on studies on E. coli
Grx by Holmgren and co-workers [54,187,200] as well as on kinetic
analyses on mammalian Grx (thioltransferase) by Yang and Wells
[263,264] and, in particular, by Mieyal and colleagues [184,252,
256,262,265]. According to the traditional model, dithiol Grx reduce
disulﬁde bonds of (i) glutathionylated substrates or (ii) protein disul-
ﬁde substrates:
(i) Deglutathionylation of substrates occurs via a monothiol
ping-pong (double displacement) mechanism. During the oxi-
dative half-reaction of Grx, the reduction of a glutathionylated
substrate starts with the nucleophilic attack of the thiolate
group of Cysa (Fig. 10). The deglutathionylated ﬁrst product is
released, and a mixed disulﬁde between glutathione and Cysa
of Grx is formed (Grx-SSG). During the reductive half-reaction,
one molecule GSH regenerates Grx, yielding dithiol Grx(SH)2
and GSSG as the second product. Please note that the more
C-terminal cysteine residue of the CxxC-motif at the active site
of dithiol Grx-isoforms is not required for glutathionylated sub-
strates in this model. The formation of Grx disulﬁde (Grx(S2))
is in fact considered an unnecessary side reaction detracting
from catalysis.
Steady-state kinetics with the substrates GSH and Cys-SSG (as
well as mass spectrometric analyses) support a ping-pong
mechanism for dithiol Grx1 from human erythrocytes and rat
liver [262], for recombinant human dithiol Grx2 [252] and
for monothiol ScGrx7 [55,173]. Ping-pong patterns were also
found for human dithiol Grx1 and Grx2 as well as poplar
monothiol GrxS12 using GSH and glutathionylated BSA (or he-
moglobin) as substrates [252,262,265,266]. Of note, replacing
the second cysteine residue in the CxxC-motif with serine did
not abolish the general activity of several dithiol Grx-isoforms
with these substrates or with HEDS [184,200,252,257,263].
Thus, the monothiol mechanism was validated for small
glutathionylated molecules and proteins and is utilized by
mono- and dithiol Grx-isoforms.
(ii) In contrast to the monothiol mechanism, the enzyme species
Grx(S2) is a central intermediate during the reduction of select-
ed protein disulﬁde substrates via the dithiol mechanism
(Fig. 10). In this model, the dithiol Grx-isoform and the pro-
tein disulﬁde substrate exchange the disulﬁde bond. Thus, an
intermolecular protein–protein disulﬁde bond between the sub-
strate and Grx is transiently formed before the C-terminal cyste-
ine residue in the CxxC-motif attacks the sulfur atom of Cysa.
Grx(S2) is subsequently reduced in two steps with the help of
two molecules of GSH yielding GSSG. The species Grx-SSG is an
intermediate of the latter regeneration.
RR from E. coli is the traditional model substrate for the disulﬁde
mechanism. A mutant of EcGrx1 with a serine residue replacing
the second cysteine residue in the CPYC-motif was still function-
al in the HEDS assay but lost its activity with RR [200]. The NMR
structure of a mixed disulﬁde between mutant EcGrx1 and a
peptide of subunit B1 of RR furthermore suggested the
Fig. 10. Traditionalmodel of Grx catalysis. Themonothiolmechanism for glutathionylated
substrates and the dithiol mechanism for protein disulﬁde substrates are shown on the
left and right sides, respectively. Since Cysa is sufﬁcient for the monothiol mechanism,
the second cysteine residue in the CxxC-motif can be replaced with serine (X). A side
reaction of the monothiol mechanism for dithiol Grx is shown in the middle. See
Section 4.4.1 for further details.
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easily attacked by an external nucleophile [212]. Sterical hin-
drance might therefore explain the general relevance of dithiol
Grx for the reduction of non-glutathione disulﬁdes. However,
the dithiol mechanism for RR itself is not conserved throughout
evolution. Studies on a mammalian Grx/RR couple indeed re-
vealed an efﬁcient GSH-dependent reduction of oxidized RR re-
gardless whether the second cysteine residue in the CxxC-motif
of Grx was replaced by serine or not. Thus, RR was probably
glutathionylated and subsequently reduced by Grx via the
monothiol mechanism [224]. Since the dithiol mechanism does
not seem to be a prerequisite for the reduction of protein disul-
ﬁde bonds, why are dithiol Grx-isoforms found in so many bac-
teria and all kinds of eukaryotes? To address this and other
questions in more detail, we will have to extent and reﬁne the
traditional model of Grx catalysis.
4.4.2. Reﬁned models of Grx catalysis
A central aspect of Grx catalysis is not addressed by the traditional
model: The glutathionyl moieties of protein-bound RSSG and GSH are
not equal owing to the geometry of the transition state of SN2 reac-
tions (Fig. 5). In fact, both moieties must adopt alternative positions
during catalysis unless signiﬁcant conformational changes occur
(Fig. 11) [55]. As a consequence, two non-exclusive mechanisms can
be theoretically distinguished: (i) The “glutathione scaffold model”
and (ii) the “glutathione activator model”. (iii) Furthermore, a combi-
nation of the latter model with a concept named “cysteine resolving
model” might explain the relevance of dithiol Grx-isoforms [55].
(i) For the glutathione scaffold model, the glutathionyl moiety of
the disulﬁde substrate occupies the glutathione-binding site
during the entire catalytic cycle (Fig. 11). Grx working with
this mechanism would therefore provide an optimal geometry
for the ﬁrst SN2 reaction (the oxidative half-reaction). The
scaffold model could explain why even monothiol Grx-
isoforms that lack an activity in the HEDS assay can be easilyglutathionylated [58,208,259]. Moreover, in this model, the
second cysteine residue in the CxxC-motif is dispensable for
catalysis and can be replaced with another amino acid without
(complete) loss of function (Fig. 11) in accordance with previ-
ous ﬁndings on monothiol [173] and mutant dithiol Grx-
isoforms [184,200,252,257,263]. The scaffold model could also
explain the rather low afﬁnity of some Grx-isoforms for GSH
as a reducing agent, or why GSH can be replaced by other thiols
during the reductive half-reaction in vitro [265]. Based on this
model, the structures of glutathionylated Grx-isoforms in Fig. 9
would reveal the permanent binding site for the glutathione
moiety of the ﬁrst substrate (Fig. 11). Nevertheless, the gluta-
thione scaffold model also has several limitations. Why are
most monothiol Grx-isoforms inactive in the HEDS assay
[58,208,238,257,259,260]? Why do mutations of the second
cysteine residue in the CxxC-motif (or of residues that are
equivalent to C* in Fig. 9) sometimes signiﬁcantly reduce or
even abolish the enzymatic activity [55,200,238,257]? These
phenomena might be explained by the glutathione activator
model and the cysteine resolving model.
(ii) For the glutathione activator model, the interaction of Grx with
GSH during the reductive half-reaction is most important for
catalysis (Fig. 11) [55]. Kinetic studies, in particular by
Srinivasan et al., indeed suggest that the reductive
half-reaction is critical and often rate-limiting for two reasons:
First, GS- nucleophile formation and, second, the stability of the
leaving group [55,238,265,266]. The thiol group of Cysa in
Figs. 9–11 is quite acidic with an (apparent) pKa value that usu-
ally ranges from 3.2 to 5.5 [208,215,238,252,255,266]. Hence,
Cysa is deprotonated and highly reactive in vitro and in vivo.
According to the glutathione activator model, a strong/perma-
nent interactionwith the disulﬁde substrate is not necessarily re-
quired as long as a correct orientation of the substrate is achieved
for a short moment during the oxidative half-reaction (Fig. 11).
(The model in principle also allows the turnover of non-
glutathionylated lowmolecularweight andprotein disulﬁde sub-
strates.) Binding and activation of the nucleophile GSH, however,
presumably require a deﬁned interaction (Fig. 11), for example,
with a potential base or a thiolate-stabilizing residue such as
the positively charged r1 in Fig. 9. Distinct, yet unassigned,
GSH-activating interactions could therefore be responsible for
the variable enzymatic activities of Grx-isoforms [55]. Some stud-
ies indeed indicate a speciﬁc recognition of GSH via the
γ-glutamyl moiety, resulting in a signiﬁcantly increased activity
as compared to other thiols [252,265,267]. Moreover, the (appar-
ent) Km value for GSH ranges from 0.3 to 4 mM for different
Grx-isoforms [55,173,207,253,266], pointing to a highly variable
afﬁnity for the reducing agent. Regarding the glutathione moie-
ties in the Grx and GST structures in Fig. 8B and D, respectively,
similar molecule orientations but different positions of the gluta-
thione sulfur atoms become obvious. The position of the glutathi-
onemoiety in the GST structure in Fig. 8D could indeed resemble
the position of the nucleophile GS− in Grx. In the same line of
thought, the thiolate of GS− could become activated/stabilized
by the basic side chain of r1 (explaining its conservation in Grx)
which is equivalent to Tyra in GST. Of note, a basic residue at
the same position is also important for serine- and
cysteine-dependent GST-isoforms (Section 8.3).
As demonstrated for mammalian Grx1 and Grx2, the reductive
half-reaction also depends on the Cysa thiolate leaving group
[252,265]: The lower the pKa value of Cysa, the higher the reac-
tivity of the Grx-isoform because of the stabilized leaving group
of the second SN2 reaction. This might explain the absent enzy-
matic activity of some Grx-isoforms with less acidic (predicted)
pKa values around 5–6 [55,208,238]. A comparison of ScGrx1
and ScGrx2, however, revealed that such a strict correlation
Fig. 11. Reﬁned models of Grx catalysis. The glutathione scaffold and the glutathione activator model discriminate between the non-identical glutathione moieties of both Grx sub-
strates (see also Fig. 5). The cysteine resolving model provides an alternative mechanistic explanation for the conservation of a proximal cysteine residue in Grx. The models are not
exclusive. See Section 4.4.2 for further details.
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mary, the contribution of both factors—GS− nucleophile forma-
tion and leaving group stability—could be weighted differently
depending on the enzyme.
Please note that the scaffold and activator models are not exclu-
sive. For example, there could be two glutathione-binding sites,
one for the disulﬁde substrate and one for GSH. Sequential
kinetic patterns with HEDS [173,255,262] might indeed be inter-
preted this way as discussed in Section 4.4.4. In another scenario,
Grx-SSG could be formed according to the scaffold model
and subsequently undergo a conformational change (Fig. 9 and
Section 4.2.2). As a result, the glutathione-binding site becomes
available for GSH and the reaction could proceed according to
the activator model (Fig. 11) [55].
(iii) The cysteine resolving model extends the activator model and
provides an alternative explanation as to why so many Grx-
isoforms retained a second cysteine residue in the course of evo-
lution. After release of the ﬁrst product, the reaction could either
continue without any difﬁculties, or the covalently bound gluta-
thione moiety could undergo a conformational change and
occupy the GSH activator-site (Fig. 11) in agreement with kinetic
studies on ScGrx7 and ScGrx8 [55]. For inactive (artiﬁcial)
monothiol Grx-isoforms the described side reaction could result
in a dead-end complex unless the conformational change isreversed (Fig. 11). Based on these mechanistic assumptions,
some structures of glutathionylated Grx-isoforms (Fig. 9) might
resemble such a protein conformation. If the enzyme has a
CxxC-motif or a C* residue (Fig. 9), the trapped protein species
could be reintroduced in the catalytic cycle (Fig. 11). The role
of the second cysteine would therefore be to maintain or to re-
generate the functional Grx-isoform. The cost for this resolving
function could be that some dithiol Grx have a reduced activity
owing to the additional reaction loop depicted in the resolving
model [55]. In conclusion, by considering the reaction geometry
and potential conformational changes, the reﬁned mechanistic
models could be useful to unravel Grx catalysis and the molecu-
lar evolution of this highly versatile protein family.
4.4.3. Properties of Grx reaction intermediates in vitro and in vivo
As mentioned in Section 4.4.2, Cysa of reduced Grx is deprotonated
under physiological conditions; but how stable are the reduced and
the oxidized protein species? In vitro, many monothiol isoforms
are efﬁciently glutathionylated at the active site (and at additional
residues), and the resulting Grx-SSG species are often stable
[55,205,208,216,238]. Interestingly, the proposed dead-end species
with respect to monothiol Grx-SSG in Fig. 11 (Section 4.4.2) fulﬁlls
the recently proposed central criteria for redox sensors in vivo [11]:
First, Grx can have a high speciﬁcity and high reactivity with respect
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the oxidative half-reaction in Fig. 11, speciﬁc signal transduction can
take place because of a signiﬁcant structural change of the trapped
sensor [55]. Thus, the low or absent activity of some Grx-isoforms
during the reductive half-reaction might be a desirable property in
vivo. In contrast, the Grx-SSG species of dithiol isoforms is usually
instable owing to the rapid formation of Grx(S2) [55,262,266].
The reactivity/stability might be reﬂected by the redox potentials
which vary drastically among Grx-isoforms. However, the (macro-
scopic) E°′ values are seldom comparable because of multiple thiol
groups and alternative redox states (including the formation of
intra- and intermolecular disulﬁde bonds). For example, ScGrx5 has
a quite high E°′ value of −175 mV [238] as compared to −198 mV
and −233 mV for EcGrx3C66Y and EcGrx1, respectively [268]. The
pH-adjusted E°′ value of a chloroplast monothiol Grx-isoform is
even as low as −270 mV and therefore more similar to canonical
Trx [259]. The redox potentials of EcGrx3C66Y and EcGrx1 were
assigned to the couple Grx(S2)/Grx(SH)2with the typical CxxC disulﬁde
bond at the active site [268]. In contrast, E°′ of ScGrx5 reﬂects the redox
potential of the couple Grx(S2)/Grx(SH)2 with an atypical disulﬁde
bond between residue Cysa and residue C* (Section 4.2.2). Residue C*
is also found in some other “monothiol” Grx-isoforms—including
EcGrx3, EcGrx4 (Fig. 9F) [202] and the mentioned chloroplast protein
[259]—as well as canonical dithiol Grx-isoforms such as mammalian
Grx1 [183]. Of note, in the solution structure of reduced EcGrx4 and in
the crystal structures of oxidized and glutathionylated mammalian
Grx1, the thiol groups of Cysa and residue C* are separated by 9 to
14 Å [183,184,202]. Thus, disulﬁde bond formation between these res-
idues would require signiﬁcant structural rearrangements in accor-
dance with the resolving cysteine model (Fig. 11). In summary,
macroscopic and, in particular, microscopic redox potentials probably
differ considerably among alternative oxidized or glutathionylated
Grx species and conformations. It is therefore extremely diffult to corre-
late E°′ values with the reactivity/stability of Grx.
How much Grx is reduced, glutathionylated or associated with
Fe/S-clusters in vivo? Even though there is no quantiﬁcation of
Fe/S-cluster binding, redox proteomics revealed that approx. 30% of
residue C* of EcGrx3 are oxidized under aerobic steady-state condi-
tions in vivo. This value increased to roughly 65% upon oxidative
challenge [140]. Cysa in ScGrx1 was even 80% oxidized under
steady-state conditions [142]. Although Grx-SSG and Grx(S2) were
not discriminated in these quantitative studies, the results are quite
surprising considering the low redox potential of the cytosol (Fig. 4)
and the range of E°′ values mentioned above. It is therefore possible
that Grx-SSG or Grx(S2) accumulate in vivo owing to the rather
slow reduction by GSH (see also Section 2.2.2). This interpretation
has important implications with respect to the physiological function:
Are Grx predominantly deglutathionylating enzymes [14], sensors,
or can they sometimes also glutathionylate selected proteins [252]
by catalyzing the reverse reaction in Fig. 11? The latter possibility
might, for example, explain why artiﬁcial diamide treatment of yeast
cells (resulting in an increase of GSSG) is less toxic for Grx knock-out
strains [55], because the accumulation of (inactivated) glutathionylated
enzymes could be slowed down. However, this hypothesis obviously
requires experimental validation. In summary, the physiological redox
states of several Grx-isoforms seem to lack an obvious correlation
with E°′ values, and our understanding of Grx catalysis in vivo remains
incomplete.
4.4.4. Outlook on Grx catalysis and mechanistic questions
To the best of my knowledge, it is neither knownwhich structure–
function relationships exactly determine whether a Grx-isoform has a
hydroperoxidase or GST activity, nor how such Grx-catalyzed reac-
tions exactly proceed. Furthermore, the potential proton acceptor(s)
or stabilizing residues with respect to Cysa and GSH activation—as
well as the proton donor for the thiolate leaving group—are unknown.The sequential kinetic patterns with the model substrate HEDS are
another enigma of Grx-catalysis [173,255]: Experimental data sup-
port the theory that HEDS itself is not the substrate of Grx. It ﬁrst
has to non-enzymatically react with GSH yielding a mixed disulﬁde
between GSH and 2-mercaptoethanol (EtOH-SSG) that is subse-
quently attacked by Cysa [55,173,255,262]. Nevertheless, the non-
enzymatic formation of the substrate does not necessarily explain
the sequential patterns [55,173], and other factors such as (i) de-
creased net concentrations of GSH in the assay (owing to EtOH-SSG
formation), (ii) product inhibition (owing to 2-mercaptoethanol
formation during the non-enzymatic reaction), or (iii) a sequential
mechanism reﬂecting simultaneous binding of small EtOH-SSG and
GSH cannot be excluded. Notably, in contrast to Grx, ping-pong
patterns at low HEDS concentrations were reported for bacterial
cysteine-containing GST B1-1 [269]. Thus, assay-dependent aspects
(i) and (ii) seem less likely, and the sequential patterns might indeed
indicate simultaneous binding of two small substrates to Grx. A more
detailed analysis of the HEDS assay could therefore reveal whether
there are two different glutathione-binding sites (with signiﬁcant
implications for the models in Fig. 11). In summary, much more
work is required to unravel the enzymatic mechanism(s) of Grx and
to deﬁne which structure–function relationships precisely determine
the enzymatic properties in vitro and in vivo.
4.5. Physiological and medical relevance of Grx catalysis
The physiological relevance of Grx catalysis depends on the iso-
form and on the presence or absence of redundant redox systems.
For example, whether monothiol Grx that are involved in iron meta-
bolism really have an enzymatic function in vivo awaits clariﬁcation.
Furthermore, knock-outs of Grx-isoforms in yeast result in inconspi-
cuous up to lethal phenotypes (Section 4.3), and Grx1 knock-out
mice are not only viable, but also do not even have an increased sus-
ceptibility to hyperoxia-mediated injury [270]. Of note, the distribu-
tion of the human isoforms Grx1/2/3/5 has been recently reported
in an impressive redox atlas, revealing tissue-speciﬁc localization
and expression patterns [271]. Such patterns might explain why
some tissues are more susceptible to genetic manipulation than
others. For example, knock-down of dithiol Grx2 in zebraﬁsh was
shown to impair neuron development, presumably owing to redox
regulation of collapsin response mediator protein 2 [225].
Other reversibly glutathionylated components that were suggested
or sometimes even shown to be physiological Grx substrates include
glycolytic enzymes [272,273], creatine kinase [274], carbonic anhydrase
III [275], components of the respiratory chain [276,277], actin [278,279],
membrane receptors, transporters and ion channels [280–284], several
protein kinases and phosphatases [285–290] as well as other pro-
teins involved in signal transduction such as nuclear factor I [291], Ras
[292] and NFκB [293,294]. Glutathionylation of these proteins (poten-
tially) alters enzymatic activity [273–275,285–290], ion and metabolite
transport [280,282–284], the formation of ROS [276,277], the cytoskel-
eton [279], signal transduction [285,289,291,292] and cell death
[281,283,294]. Thus, as reviewed by Mieyal et al., perturbations in Grx
content and activity could have consequences on the organellar, cellular
and organismic level with implications for pathophysiological condi-
tions including diabetes, cardiovascular diseases, lung diseases and
cancer [14]. A compromised glutathione system was also suggested
to be detrimental to the human brain [295], and alterations of Grx
contents and/or the accumulation of glutathionylated proteins due to
oxidative challenge might therefore inﬂuence the onset or the progres-
sion of Alzheimer's disease, Parkinson's disease, Huntington's disease,
amyothrophic lateral sclerosis and Friedreich's ataxia [14].
Importantly, the number and variety of proteins that are (de)
glutathionylated in vertebrates point to regulatory networks far
beyond so-called oxidative stress (Section 2.1.1). The involvement
of Grx in such physiological redox networks is not restricted to
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example, Grx-dependent redox networks are also found in plants
[194,296] and begin to emerge for malaria parasites [297]. Neverthe-
less, we are still far from understanding the precise physiological
functions of Grx catalysis and their implications for health and
disease.
5. Glutathione peroxidases
5.1. Pioneers of GPx catalysis
The term glutathione peroxidase was introduced by Mills who dis-
covered the activity with H2O2 in enzyme preparations frommamma-
lian erythrocytes in 1957 [298]. In 1962, Neubert et al. described GPx
as “contraction factor I” for swollen mitochondria [299]. (The authors
presumably observed the inﬂuence of GPx4 on the mitochondrial
transition pore owing to the removal of mitochondria-derived hydro-
peroxides.) The ping-pong mechanism of GPx1 [300] and the sig-
niﬁcant reactivity with a variety of hydroperoxides [301] were
characterized in 1972 by Flohé and co-workers. One year later,
based on studies with crystalline bovine GPx1, the tetrameric enzyme
became the ﬁrst mammalian selenoprotein to be discovered [302],
pointing to an explanation as to why some GPx have such a high
activity in the absence of heme (see also Sections 2.3.1 and 5.3). In
1979 and 1983, Ladenstein and Epp et al. solved and reﬁned the crys-
tal structure of bovine GPx1 (even though the full sequence was still
unknown resulting in some reassignments) [303,304]. The analysis of
rat liver GPx by Forstrom et al. revealed that selenium is incorporated
as selenocysteine [305]. This conclusion was later conﬁrmed by
Günzler et al. who determined the amino acid sequence of bovine
GPx1 [306], and by Chambers et al. who showed that the seleno-
cysteine residue in mouse GPx is encoded by a stop codon [307].
During that time GPx4—having a high peroxidase activity with
phospholipid substrates—was discovered as a second mammalian
selenoprotein by Ursini and colleagues [308,309]. In 1992, Rocher
et al. experimentally conﬁrmed that a selenocysteine to cysteine sub-
stitution signiﬁcantly reduces the GPx activity and that a serine
mutant is completely inactive [310] (see also Section 2.3.1). Interest-
ingly, of the seven or eight mammalian GPx-isoforms only four or ﬁve
have a selenocysteine at the active site, and two or three were shown
to possess a cysteine residue [60]. Furthermore, among the numerous
GPx-isoforms that have been identiﬁed in all domains of life, non-
mammalian GPx usually have a cysteine residue at the active site
[311]. During the last decade, several of these cysteine-containing
GPx-isoforms from a variety of organisms turned out to be Trx-
dependent enzymes as demonstrated by Sztajer et al., Jung et al., Tanaka
et al., Maiorino et al. and Schlecker et al. [204,312–315]. Thus, GSH-
dependent (mammalian) GPx-isoforms are the exception and seem to
be a rather recent evolutionary acquisition (Section 4.2.1).
5.2. Structure and function of GPx
GPx have a signiﬁcantly altered thioredoxin fold containing several
additional structural elements as highlighted in Fig. 8E,F. For example,
helix α2—which seems to be speciﬁc for GPx and Prx (Fig. 8E–H)—
contributes to the monomer–monomer contact site in crystallized
homotetrameric GPx1 (Fig. 12A) [304]. This area is highly variable
among the different GPx classes [204,316,317]. Moreover, helix α2
often contains a cysteine residue that is mechanistically relevant for
Trx-dependent GPx-isoforms such as yeast Gpx2 [313], poplar GPX5
[316], and isoforms from Drosophila melanogaster [204] and T. brucei
[314,318]. This structural element was therefore termed “Cys block”
(Fig. 12A) [204]. The active site (seleno)cysteine residue is found at
the N-terminal end of helix α1 (Fig. 8E,F). In the crystallized structure
of oxidized poplar GPX5, partial unfolding of the N-terminus of helix
α1 and complete unwinding of helix α2 allowed the formation of anintramolecular disulﬁde bond between the active site and the Cys
block [316] in analogy to atypical Prx-isoforms (Section 6.2). Even
though the structural rearrangements upon disulﬁde formation were
less drastic for a GPx-isoform from T. brucei [318], such conformational
changes are presumably a prerequisite for the transfer of electrons
from bulky protein substrates. In agreement with this theory, a (puta-
tive) resolving cysteine in helix α2 is found in the Trx-dependent
GPx-isoforms [204,312,314,316,318], whereas the GSH-dependent
isoforms either do not have such a residue or (were suggested to)
adopt alternative quaternary structures with a trapped conformation
preventing disulﬁde bond formation (Fig. 12A,B) [60,204]. Of note, a
second/third cysteine residue in a FPCN-motif at the end of strand β2
is extremely conserved among all GPx classes (Fig. 12A,B). However,
this residue seems to be dispensable for GPx catalysis and its role
remains unclear (Section 5.4) [314,315].
Another structural variation among the different GPx classes is a
so-called oligomerization loop after helix α3 at the top of the active
site (Fig. 8E,F). This loop mediates the contact between two dimers
in crystallized homotetrameric bovine GPx1 and covers a part of
the active site (Fig. 12A) [304]. Accordingly, GPx-isoforms cannot
only be grouped based on their electron donor, active site residue
and sequence similarity, but also on the their quaternary structure:
Mammalian GPx4 (Fig. 12B) as well as GPx-isoforms from P. falciparum,
T. brucei and D. melanogaster were reported to be monomeric enzymes
[204,312,318], whereas poplar GPX5 forms unusual dimers that are
similar to Prx [316]. All of these ﬁve examples have no oligomeriza-
tion loop in contrast to homotetrameric mammalian GPx1/2/3
[304,319,320] and related GPx5/6 [204]. This demonstrates that
the quaternary structure is indeed correlated with the oligomeriza-
tion loop, whereas the GSH-dependency (e.g. of monomeric GPx4
and tetrameric GPx1) is not. To my knowledge, it is unclear whether
tetrameric mammalian GPx-isoforms evolved as a specialized subclass
of the already specialized class of GSH-dependent GPx, or whether con-
vergent evolution is the cause for the GSH-dependency of monomeric
GPx4 and tetrameric GPx1.
Functionally, GSH-dependent GPx are GSH:hydroperoxide and/or
GSH:lipid-hydroperoxide oxidoreductases (EC 1.11.1.9 and/or EC
1.11.1.12) with a more or less pronounced speciﬁcity for the peroxide
substrate [61,62,301,309]. Since GPx3 is a secreted plasma protein
[320]—and therefore cannot efﬁciently work at low GSH concentra-
tions (Fig. 4)—the protein has been suggested to be a good candidate
as a redox sensor [60]. Mammalian GPx4 was furthermore shown to
have an additional moonlighting function as a structural protein of
the mitochondrial capsule that is formed during spermatogenesis:
Redox-dependent capsule formation requires the covalent oligomeri-
zation of the protein via the active site and surface-exposed cysteine
residues (Fig. 12B) [60,317,321]. GPx4 therefore provides an excellent
example for a rather recent event in the molecular evolution of
glutathione-dependent enzymes outlined in Sections 2.3 and 4.2.1.
In contrast to GPx1 and intestinal GPx2 in the cytosol, and secreted
GPx3 in the plasma, GPx4 has an extremely variable subcellular locali-
zation in the cytosol, in the nucleus and in mitochondria (Section 5.4).
Furthermore, the protein exists in a free and a membrane-associated
form [309] in accordance with its preference for lipid hydroperoxides.
Some Trx- or tryparedoxin-dependent GPx are also found in chloro-
plasts or mitochondria [322,323].
5.3. The enzymatic mechanism of glutathione-dependent GPx
Numerous kinetic measurements clearly revealed that diverse
GPx-isoforms act via a ping-pong mechanism [60,300,301]. Thus,
there is no ternary complex between the enzyme, the hydroperoxide
and GSH, and the reaction can be subdivided into an oxidative half-
reaction and a reductive half-reaction. Even though the GSH-
dependent overall reaction somehow resembles the Grx-catalyzed
reduction of disulﬁde substrates (Fig. 3C,D), the mechanism for the
Fig. 12. Structures of GSH-dependent GPx. Helices and strands are labeled according to Fig. 8E,F. (A) View along the 2-fold axis of two subunits of homotetrameric GPx1. Two sub-
units interacting with the so-called oligomerization loops are omitted. The selenocysteine residue in the ‘over’-oxidized seleninate state is highlighted and further structural ele-
ments are labeled. (B) Similar view on monomeric GPx4 with the catalytic tetrad highlighted (the selenocysteine at the N-terminus of helix α1 is mutated to cysteine). GPx4
lacks the oligomerization loop. Moreover, helix α2 adopts an alternative position and lacks a cysteine residue. Three additional surface-exposed cysteines are shown on the left
side. (C) Zoom in at the active site of GPx4 with the catalytic tetrad and a highly conserved cysteine residue. (D) Zoom in at the predicted substrate-binding site of GPx1. Residues
that were suggested to bind GSHI and/or GSHII are highlighted. The orientation is identical to the left panel in Fig. 8F. The oligomerization loop is shown in dark red. The tryptophane
and asparagine residue of the tetrad are highlighted in purple and green, respectively. (E) Zoom in at the predicted substrate-binding site of GPx4. The images were generated using
Swiss-Pdb viewer and the structures of bovine GPx1 and human GPx4U47C (PDB IDs: 1GP1 and 2OBI, respectively [304,317]). See Sections 5.2 and 5.3 for details.
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(i) The hydroperoxide is not glutathionylated before it is attacked
by GPx. (ii) A highly reactive selelenic/sulfenic acid is formed as an in-
termediate. (iii) The regeneration of the modiﬁed enzyme requires
two steps during the reductive half-reaction.5.3.1. The oxidative half-reaction of glutathione-dependent GPx
The position of the selenocysteine/cysteine residue in GPx is
identical to Grx (Fig. 8A,E), however, apart from the helix dipole,
the activation seems to differ signiﬁcantly. In principle, the deproton-
ation and orientation of the active site selenol/thiol group could be
identical for all GPx classes (regardless of the reducing agent) because
of the separation of the oxidative and reductive half-reaction. Activa-
tion of the nucleophile was suggested to depend on the side chains of
three proximal residues: a glutamine residue in a QE-motif in the loop
after strand β2, and a tryptophane and asparagine residue in a WNF-
motif after the oligomerization loop preceding strand β4 (Fig. 8F,
Fig. 12C) [60]. Even though mutational analyses indicate that the
glutamine and asparagine residues are more important than the tryp-
tophane [60,314], the precise role of these residues is all but clear.
First, not only the nucleophile in this potential catalytic tetrad [60]
but also the glutamine residue is sometimes variable [316]. Second,
the conformation of the crystallized mammalian GPx-isoforms might
not be representative/universally valid for the activated enzyme. In
fact, NMR and mutational analyses of a T. brucei GPx-isoform pointed
to an alternative conformation, and a conserved lysine residue at the
end of strand β3 was suggested to play an important role for peroxide
reduction [318].After the highly reactive anionic nucleophile is formed (Fig. 13),
the ROOH substrate is irreversibly turned over as soon as it adopts
the required SN2 geometry (Fig. 5B). Thus, based on the high reacti-
vity of the active site residue, there is probably not a real binding
site for the hydroperoxide substrate, explaining the rather low
substrate-speciﬁcity [60,301]. Nevertheless, there are signiﬁcant dif-
ferences among the GPx-isoforms regarding the accessibility of the
active site, for example, owing to the presence or absence of the olig-
omerization loop (Fig. 12D,E). These differences could explain why
monomeric GPx4 has such a high activity with lipid hydroperoxides
[60,309,317]. The oxidative half-reaction ends with the release of a
molecule of water or alcohol, depending on whether R in ROOH is a
hydrogen atom or not (Fig. 13).
5.3.2. The reductive half-reaction of glutathione-dependent GPx
After formation of the instable selenenic/sulfenic acid, the ﬁrst
GSH molecule (GSHI) enters the active site and is turned over during
the ﬁrst reductive SN2 reaction, yielding a water molecule as the
second product (Fig. 13). (Alternatively, the selenenic acid was
suggested to initially react within the catalytic tetrad yielding a
selenylamide which subsequently reacts with GSH. This postulated
“parked” enzyme species could decrease the probability of further
‘over’-oxidation in analogy to 2-Cys Prx [60,61] described in
Section 6.2.). Since GPx1 is highly speciﬁc for GSH [60,61], there has
to be a deﬁned substrate-binding site. However, a structure of a
glutathionylated GPx intermediate has not been solved to date,
which is not surprising considering that the second reductive SN2
reaction directly follows in the presence of GSHII, yielding GSSG as
the third product (Fig. 13). It is therefore all but understood which
Fig. 13. Model of GPx catalysis. The active site either contains a deprotonated selenocysteine or cysteine residue. A conformational change could occur at the end of the oxidative
half-reaction. The reductive half-reaction comprises two parts. The existence and composition of a glutathione-binding site highly depend on the GPx-isoform and therefore both
predicted sites are labeled with a question mark (alternatively, GSHI and GSHII might also compete for some binding residues). See Section 5.3 for further details.
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sis, even though crystal structures and molecular models support the
theory that different basic residues (residues r1–r4 in Fig. 12D) bind
GSHI and GSHII via their glycine and γ-glutamyl carboxylate groups
[60,61,304,317]:
For bovine GPx1, Epp et al. suggested that the glycine carboxylate
group interacts with r1, and the γ-glutamyl carboxylate group binds
to r2 (without clear discrimination between GSHI and GSHII) [304].
Notably, this pattern results in a signiﬁcant bending of the glutathi-
one backbone, and the binding mode is therefore very different
from the one seen in Fig. 9. According to a model in ref. [60], it is
the glycine carboxylate group of GSHI that interacts with r1, whereas
the γ-glutamyl carboxylate group was suggested to bind to r4 instead
of r2. In this model, r2 binds the glycine carboxylate group of GSHII,
and the two γ-glutamyl carboxylate groups of both glutathione
molecules compete for r4 and a lysine residue from a second sub-
unit. To increase the number of permutations—and the confusing
possibilities—a recent model for human GPx1 suggested that the
glycine moiety of GSHI interacts with r3 (instead of r1) while the
γ-glutamyl moiety interacts with r1 (instead of r2 or r4) [61]. With
respect to GPx4, residue r1* is located at an alternative position
whereas residue r5 is found instead of r2–r4 (Fig. 12E). Thus, one
of the two predicted GSH binding sites could be absent (Fig. 13),
and these structural alterations were suggested to be responsible
for the lower speciﬁcity of GPx4 for GSH as a reducing agent [60,61].
Interestingly, the area corresponding to the glycine moiety-binding
site in the structures of Grx and GST is blocked by additional loops in
mammalian GPx1 but not in GPx4 (please compare the panels in the
middle of Fig. 8 as well as Fig. 9 and Fig. 12) [304]. Thus, if this surface
area is utilized by either GSHI or GSHII, GPx1 has to undergo signiﬁcant
conformational changes.
Of note, the positions of the two glutathione sulfur atoms and
the selenium atom in ref. [60] are not in agreement with the SN2
geometry described in Fig. 5A, and an efﬁcient reaction between
GSHII and glutathionylated GPx without structural rearrangements
is therefore questionable: As the catalytic cycle comprises three con-
secutive SN2 reactions, either (i) the reaction geometry is not in
accordance with the chemical principle (for example, owing to the
usage of other selenium orbitals), (ii) the positions of the ﬁve
involved atoms (SII–SI–Se/Sa–O–O) adopt a linear orientation; an
unlikely scenario owing to the limited space at the active site—or
(iii) there is a conformational change as suggested in Fig. 13. As
outlined in the next section, a conformational change (with or with-
out selenylamide formation) at the end of the oxidative half-reaction
is in agreement with the kinetic data and could indeed explain
why productive GSH binding is rate-limiting [60,300]. Finally, the
suggested competition of the two γ-glutamyl carboxylate groups of
both glutathione molecules for r4 [60] might explain the efﬁcient
release of GSSG at the end of the reaction.5.3.3. Properties of GPx reaction intermediates in vitro and in vivo
The oxidative half-reaction of GPx1 and other selenocysteine-
containing GPx-isoforms is very efﬁcient with second order rate
constants around 1–5×107 M−1 s−1. For these enzymes there is vir-
tually no enzyme–hydroperoxide complex, and, accordingly, the kcat
and Km values for several GPx-isoforms obtained from secondary
plots are inﬁnite [60,300]. The ping-pong patterns and an apparently
absent inhibition by GSSG furthermore indicate that the enzyme–
substrate complexes with GSHI and GSHII cannot be saturated. GSH
binding and the adoption of a correct conformation were therefore
suggested to be rate-limiting for GPx1 catalysis [60]. In vivo, GPx-
isoforms are expected to be more or less fully reduced. As a conse-
quence, irreversible hydroperoxide removal was suggested to only
depend on (i) the concentrations of GPx and hydroperoxide, (ii) the
encounter of both molecules, and (iii) the second order rate constant
of the oxidative half-reaction. Thus, under physiological conditions,
the exact concentration of GSH or the redox potential (see also
Section 2.2.2) could be irrelevant for GPx catalysis [60,300].
5.3.4. Outlook on GPx catalysis and mechanistic questions
The high catalytic efﬁciency of GPx-isoforms usually results in a
focus on the activation of the nucleophile. However, the poor leaving
group of the ﬁrst SN2 reaction (RO− or OH−) also requires signiﬁcant
activation, e.g. by simultaneous protonation. A network of hydrogen
bonds between the conserved glutamine and asparagine residues
might fulﬁll this task [60]. Nevertheless, as partially outlined above,
how the thiol/selenol is really deprotonated and the leaving group
is protonated still remains to be clariﬁed. The situation gets even
more confusing regarding the end of the oxidative half-reaction and
the whole reductive half-reaction: (i) The existence of conformation-
al changes and/or the formation of a selenylamide obviously require
experimental validation. (ii) Analogous to the situation described
for Grx (Fig. 11), we still do not know which of both glutathione
moieties exactly binds to which protein area. (iii) How are both
GSH molecules activated as a nucleophile and what is the fate of the
protons (Fig. 13)? Owing to the position (Fig. 12D,E), and based on
mutational studies [60,314], the conserved glutamine residue might
also play a role in deprotonation during the reductive half-reaction
(regardless of the nature of the electron donor that is utilized by the
various GPx-isoforms). (iv) Another important aspect that could be
addressed in far more detail is the relevance of the active site residue
as a leaving group. The advantage of selenocysteine-dependent
GPx-isoforms could be that the selenolate is a better leaving group
than the thiolate group (see also Section 4.4.2 on Grx activity).
Thus, the relevance of this residue could be the second part of
the reductive half-reaction instead of the oxidative half-reaction.
(v) What is the role of the highly conserved cysteine residue in the
FPCN-motif (Fig. 12)? It appears rather unlikely that the residue has
been maintained in almost all GPx-isoforms without being somehow
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inconspicuous [314], initial studies on a GPx-isoform from Chinese
cabbage suggested the formation of alternative disulﬁde bonds
[315]. Whether these bonds and the residue have a regulatory, pro-
tective or structural function—i.e. for protein trapping in the mito-
chondrial intermembrane space (Section 5.4)—remains to be studied.
5.4. Physiological and medical relevance of GPx catalysis
Homozygous GPX1 and GPX2 single and double knock-out mice
are all viable [324,325], presumably due to overlapping functions
with cytosolic Prx-isoforms (Section 6). GPX1 knock-out mice lack a
phenotype under normal growth conditions, but are more susceptible
to oxidative challenges in accordance with a function for peroxide
removal [325]. The GPX1/GPX2 double knock-out mice were shown
to have inﬂammatory bowel disease with a high incidence of mucosal
inﬂammation in the ileum and colon but not in the jejunum
[324]. The phenotypes become explainable considering the similar/
complementary activity levels of both enzymes in the mucosal
epithelium [326]. Whether mucosal inﬂammations in the human
digestive tract are also correlated with decreased GPx activities
needs clariﬁcation. In contrast to GPX1 and GPX2, GPX4 is essential,
and knock-out mice were reported to die in utero [327]. Which of
the different GPx4 forms and functions (Section 5.2) are required
for survival?
In rodents, all different GPx4 forms are encoded by one single
gene with eight exons. The N-termini of the short form, sGPx4, and
of the long form, lGPx4, are encoded by the same exon 1A. The
expression of both variants probably not only depends on the transla-
tion initiation efﬁciency at alternative in-frame start codons, but also
on alternative transcription initiation sites in exon 1A [328,329]. As a
result lGPx4 has an additional N-terminal bipartite presequence
consisting of a positively charged amphipathic helix and a hydro-
phobic sorting signal [329]. Proteins with such signals are usually
inserted into the inner mitochondrial membrane facing the inter-
membrane space, and the mature protein is often released into the
latter compartment after proteolysis of the transmembrane segment
[330]. This import pathway and a localization of GPx4 in the inter-
membrane space are in accordance with subfractionation and
in organello import assays using rat mitochondria [331,332]. Of note,
speciﬁc deletion of lGPx4 in mice allowed normal embryogenesis
and postnatal development, but caused male infertility owing to
impaired mitochondrial capsule formation during spermatogenesis
(Section 5.2) [333]. The same phenotype was observed for condi-
tional GPX4 knock-out mice [334]. Hence, the structural function of
GPx4 provides an explanation for the crucial role of the trace element
selenium for male fertility in mammals [321,333]. In addition to its
structural role, a peroxidase activity-based anti-apoptotic function
of lGPx4 has been reported for cell cultures [335] in agreement with
the initial observations by Neubert et al. [299] (Section 5.1). However,
deregulation of apoptosis was not observed in the lGPx4 knock-out
mice under normal growth conditions [333].
The nuclear form, nGPx4, from rat testis was reported to be
chromatin-associated [336]. Accordingly, nGPx4 has an alternative,
arginine-rich N-terminus which is encoded by exon 1B (located after
exon 1A). This form is generated by transcription initiation at an exon
1B-speciﬁc promoter and not by alternative splicing [328,337]. Selective
deletion of nGPx4 in mice neither affected viability nor fertility, but the
peroxidase activity was suggested to contribute to chromatin stability
[338]. The lethal effect of the GPX4 deletion in mice therefore has to
be attributed to the short form sGPx4 [333]. In fact, up-regulation of
human sGPx4 in the GPX4 knock-out background rescued the mice—
even though male mice were infertile—whereas up-regulation of
lGPx4 did not reverse the lethal phenotype [339]. Interestingly,
a major fraction of sGPx4 was reported to associate with the inner
mitochondrial membrane [339], in contrast to in organello importstudies revealing no time-dependent import of sGPx4 [332]. Neverthe-
less, a trapping mechanism in the intermembrane space [330] could
theoretically result in the mitochondrial import of sGPx4. The highly
conserved cysteine residue in the FPCN-motif and residue Cys108 of
human GPx4 (in a well conserved IxVNG-motif) are indeed quite
close to each other, and I hypothesize that they could form a trapped
disulﬁde bond in the oxidizing intermembrane space. Notably, of the
three yeast GPx-isoforms, only one protein has a cysteine residue
in the IxVNG-motif, and only this protein (GPx1) is annotated to
interact with the outer mitochondrial membrane in accordance with
the hypothesis. Importantly, a (somatic) mitochondrial sGPx4 species
might also explain why the selective knock-out of (testicular) lGPx4
had no effect on apoptosis [333], because the ﬁnal protein in the
intermembrane space should be identical regardless of the import
pathway. Thus, the reported lipid hydroperoxidase-dependent anti-
apoptotic effects of mitochondrial GPx4 in vitro and in vivo
[335,339–341] could be achieved by (up-regulation) of sGPx4 and/or
lGPx4.
6. Peroxiredoxins
6.1. Pioneers of Prx catalysis
As reviewed previously, the ﬁrst Prxwas described in 1968 byHarris
owing to the peculiar ring-shaped quaternary structure of a decamer-
forming isoform [61]. Much later, in 1994, Rhee and colleagues showed
for the ﬁrst time that a yeast Prx-isoform—which was previously
discovered in the Stadtman lab as thiol-speciﬁc antioxidant protein
(Tsa1)—is a Trx-dependent hydroperoxidase [342,343]. Since then,
Prx have been identiﬁed in all domains of life. Their reduction by ﬂavo-
proteins in bacteria and by Trx or closely related thiol-containing
proteins in eukaryotes and other bacteria has been studied in much
detail by the groups of Rhee, Poole, Flohé, Karplus and many others
[61,67,343–347]. In contrast, only little is known about the GSH-
dependent reduction of Prx.
6.2. Structure and function of glutathione-dependent Prx
Based on their primary structure Prx-isoforms can be grouped into
ﬁve major classes [67,343,346,347]. However, such Prx classiﬁcations
are often complicated by the fact that a few amino acid substitutions
can completely change the enzymatic mechanism and/or the quater-
nary structure [61,63,345,348] which often ranges from monomeric
to dimeric and (do)decameric protein species (Fig. 14A,B) [67,346].
Thus, a mechanistic classiﬁcation seems to be more appropriate
[61,67,343–345]: All Prx-isoforms have the peroxidatic cysteine resi-
due Cysp in common (Fig. 8H, Fig. 14). This residue is found in a con-
served Px3Tx2C-motif and reacts with the hydroperoxide substrate,
resulting in an instable (easily ‘over’-oxidizable) sulfenic acid in ana-
logy to GPx (Section 5.3). The mechanistic classiﬁcation of Prx-
isoforms into 2-Cys and 1-Cys Prx now depends on the fate of the
sulfenic acid: For 1-Cys Prx only one subunit is mechanistically
required, and the sulfenic acid is expected to directly react with the
often unknown reducing substrate. For typical 2-Cys Prx a resolving
cysteine residue (CysR) from a second subunit attacks the sulfenic
acid, and an intermolecular disulﬁde bond is formed. The disulﬁde-
bridged homodimer subsequently reacts with the reducing agent
yielding the regenerated enzyme. In contrast, CysR from atypical
2-Cys Prx forms an intramolecular disulﬁde bond within the same
subunit before the reaction with the reducing agent [61,67,343–345].
Functionally, Prx are thiol-containing-reductant:hydroperoxide
oxidoreductases (EC 1.11.1.15). In vitro hydroperoxidase assays
revealed that some Prx-isoforms do not only accept electrons from a
coupled Trx/TrxR donor system, but also work with a coupled Grx/
GSH/GR system. Such activities were detected for various Prx-
isoforms from plants, algae, cyanobacteria [67,349], Gram-negative
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non-related eukaryotes including yeast [64,66] and P. falciparum
[63,352]. Most of these GSH-dependent enzymes seem to belong to
the mechanistically heterogeneous classes of Prx5-type and Prx6-
type isoforms [346] and are found in the cytosol, in mitochondria
[66,67], in plastids [67,119] or in the nucleus [352]. A physiological
relevance of GSH/Grx-dependent hydroperoxide removal by Prx is
supported by the natural H. inﬂuenzae Prx–Grx hybrid protein
(Fig. 14B) which cannot be reduced by the Trx/TrxR system in vitro
[350]. Nevertheless, considering the redundancy and high abundance
of different peroxidase systems in subcellular compartments, the
exact roles of the GSH-dependent pathways remain predominantly
unclear, in particular, for the Prx-isoforms accepting electrons from
both Grx/GSH and Trx. Interestingly, one of the six mammalian
Prx-isoforms, the 1-Cys isoform PrxVI, was shown to reduce phos-
pholipid hydroperoxides with the help of GSH and the pi class GST
P1-1 [65,353–355]. The enzyme was also reported to have a moon-
lighting function as a phospholipase A2 [353]. So far, the combination
of these properties is unique, suggesting that they have evolved rath-
er recently during the speciation in mammals (see also Sections 2.3
and 4.2.1).
6.3. The enzymatic mechanism of glutathione-dependent Prx
To the best of my knowledge, a comprehensive kinetic analysis
supporting a precise mechanistic model for Grx/GSH-dependent Prx
has not been published to date. Nonetheless, in the models depicted
in Fig. 15, the reactions of all GSH-dependent Prx-isoforms are assumedFig. 14. Structures of Prx. Helices and strands are labeled according to Fig. 8G,H. (A) Structu
formed between helices α4 and α4′. (B) Structure of H. inﬂuenzae Prx–Grx hybrid protein w
tation of the subunit on the right side is similar to the subunit on the left side in panel A. Th
side. The two other subunits of the tetramer are missing in the PDB ﬁle. (C) Zoom in at the
histidine residue proximal to the thiol group of Cysp is predominantly found in Prx6-type iso
active site of PrxVI is poorly accessible in the “closed” conformation. The sulfur atom (which
enter. The second subunit is labeled in blue. (E) Comparison of two active sites of crystalli
using Swiss-Pdb viewer and the structures of human PrxVI and H. inﬂuenzae hyPrx5 (PDB Ito follow a ping-pong mechanism analogous to Trx-dependent Prx
catalysis. Ping-pong patterns were indeed reported for recombinant
GST/GSH-dependent PrxVI using variable phospholipid hydroperoxide
concentrations, however, the essential (?) GST P1-1 was absent in these
measurements [355].
The oxidative half-reaction of Prx (Fig. 15A) is similar to cysteine-
containing GPx (Fig. 13), although other amino acids are involved
[61,345]. Formation or stabilization of the thiolate of Cysp was sug-
gested to depend on two residues that are highly conserved in most
Prx-isoforms regardless of the mechanistic class [61,345,346]: a thre-
onine (or sometimes serine) residue in the Px3Tx2C-motif at the
N-terminus of helix α1 and an arginine residue at the N-terminus of
strand β6 (Fig. 14C). Please note the similar positions of several active
site residues in GPx (Fig. 12C) and Prx (Fig. 14C), pointing to a con-
vergent evolution (Section 4.2.1). Replacement of the cysteine resi-
due or of the threonine hydroxyl group was demonstrated to
inactivate a variety of Prx-isoforms, whereas replacement of the
arginine residue did not always result in a completely inactive en-
zyme [61]. Notably, a histidine residue before the proline in the
Px3Tx2C-motif is relatively conserved in (1-Cys and 2-Cys) Prx6-type
isoforms and could also interact with the Cysp thiolate (Fig. 14C)
and/or protonate the ﬁrst leaving group [348,356].
After formation of the Cysp sulfenic acid and the release of the ﬁrst
product, an alternative conformation was demonstrated for several
Prx-isoforms (Fig. 15A) [346], including the GSH-dependent Prx–
Grx hybrid protein from H. inﬂuenzae [357]. Analogous to some
GPx-isoforms (Section 5.2), helix α1 is partially unwound and the
sulfenic acid is exposed in a loop (left subunit in Fig. 14B). However,re of human PrxVI with an extended β-sheet along the so-called B-type dimer interface
ith a so-called A-type dimer interface formed between helices α2 and α2′. The orien-
e positions of both subunits are switched owing to the dimer interface on the opposite
active site of PrxVI in its “closed” conformation with the catalytic triad highlighted. A
forms. The orientation is analogous to GPx in Fig. 12C to facilitate comparison. (D) The
is oxidized to a sulfenic acid) points to a small window where the peroxide group can
zed H. inﬂuenzae Prx–Grx adopting alternative conformations. Images were generated
Ds: 1PRX and 1NM3, respectively [356,357]). See Sections 6.2 and 6.3 for details.
Fig. 15.Models of Prx catalysis. Please note that Prx exist in a monomer–dimer equilibrium or can also form higher oligomers even if only one subunit is shown. (A) Universal ox-
idative half-reaction resulting in three different Prxox species depending on the mechanistic class. (B) Potential mechanisms for the reductive half-reaction of GSH/Grx-dependent
Prx-isoforms with 1-Cys Prx on top, atypical 2-Cys Prx in the middle, and typical 2-Cys Prx at the bottom. Potential ﬁrst and second reducing agents are shown below (a–c). A con-
formational change of reduced Prx at the end of the reaction and the reduction of the R'SSR disulﬁdes by GSH are omitted. (C) Suggested mechanism for the reductive half-reaction
of GSH/GST-dependent PrxVI. A potential shortcut is labeled with a question mark. See Section 6.3 for further details.
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widely accepted to be a general prerequisite for Prx catalysis. This
theory is plausible considering that the active sites of crystallized
Prx-isoforms with a “closed” conformation are not accessible for large
physiological reducing agents (Fig. 14D,E) [346]. Whether the sulfenic
acid forms a Prx disulﬁdebondbefore reduction by the second substrate
depends on the mechanistic class as outlined in Section 6.2 (Fig. 15A).
The reduction of the oxidized enzyme (Prxox) seems to differ signiﬁ-
cantly among various GSH-dependent Prx-isoforms, and I will thereforedescribe the reductive half-reaction for Grx- and GST-dependent
isoforms separately.
6.3.1. The mechanism of Grx-dependent Prx
During the reductive half-reaction, the electron donor could
either directly attack the sulfenic acid, or reduce the disulﬁde bond
of a typical or atypical 2-Cys Prx (or of a 1-Cys Prx dimer that is
disulﬁde-bridged by two Cysp residues). These theoretical possi-
bilities, illustrated in Fig. 15B, are furthermore complicated
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Prx-isoforms: a) A dithiol Grx might simply replace Trx as the elec-
tron donor for Prxox. In this mechanistic scenario, GSH is not a Prx
substrate but just reduces Grx(S2) after Prx catalysis. b) Alternatively,
the sulfenic acid/disulﬁde of Prxox might be attacked by a monothiol
Grx as a ﬁrst reductant. The resulting Grx–SS–Prx intermediate could
subsequently react with GSH as the second reductant, yielding
glutathionylated Grx which is regenerated by another GSH molecule.
c) Vice versa, the sulfenic acid/disulﬁde of Prxox might be initially
attacked by GSH as a ﬁrst reductant, and the (monothiol) Grx could
subsequently deglutathionylate Prx-SSG. Of note, in the latter sce-
nario, Grx can either act as a true third substrate or as an enzyme.
Which of these alternative mechanisms are supported by experimen-
tal data?
Rouhier et al. determined the in vitro activity of a Prx5-type
isoform from poplar at variable Grx-concentrations using a set of
cysteine mutants. Saturation kinetics and SDS-PAGE analyses sup-
ported a role of Grx as a true substrate with a Kmapp of approx.
2.5 μM. The authors therefore suggested that the enzyme is directly
reduced by Grx either via a monothiol or a dithiol mechanism with
respect to Grx [349]. This mechanism is in accordance with path-
ways a) and b) in Fig. 15B. Glutathionylation of Cysp of the same
Prx-isoform was, however, later shown to lead to a dissociation of
the homodimeric enzyme, and an alternative mechanism was there-
fore suggested [358] in accordance with pathway c) in Fig. 15B. More-
over, although a second cysteine residue of this enzyme was not
essential for catalysis (therefore leading to a mechanistic classiﬁca-
tion as a 1-Cys Prx), mutation of this residue signiﬁcantly reduced
the activity [349]. Thus, the true Grx/GSH-dependent mechanism of
the poplar enzyme remains to be unraveled.
Steady-state kinetics of the (α2)2 tetrameric H. inﬂuenzae Prx–Grx
hybrid protein [357]—which is also a Prx5-type isoform [346]—
revealed a hyperbolic activity plot with respect to the peroxide sub-
strate concentration and a sigmoidal dependency regarding the
GSH concentration [350]. In addition, glutathionylation of Cysp was
detected after protein puriﬁcation from E. coli [350]. Pauwels et al.
therefore suggested a mechanism in accordance with pathway c) in
Fig. 15B with pathway b) distracting from catalysis at lower GSH con-
centrations. Based on glutathionylation studies, pathway c) was also
favored for the mitochondrial Prx6-type isoform from yeast (Prx1)
with either Grx or TrxR as the second reducing agent [64,66].
A deﬁned binding site for Grx or GSH, if there is any, awaits iden-
tiﬁcation for most Prx-isoforms. In the crystal structure of the
H. inﬂuenzae hybrid protein, the Prx domain has a negatively charged
surface that is complementary to the positively charged surface on
the Grx domain of another (α2) dimer (Fig. 14B) [357]. Kim et al.
therefore proposed that such complementary areas could be absent
or partially replaced by hydrophobic patches in Trx-speciﬁc enzymes.
Furthermore, a molecular model suggested that GSH is bound in a
cleft between the Grx- and Prx-domain where GSH is predominantly
associated with the Grx-domain [357]. Of note, the positively charged
residues on the complementary surface of the dithiol Grx-domain
(Fig. 14B) correspond to residues r1 and r2 in Fig. 9. In summary, the
mechanistic data on Grx/GSH-dependent Prx-isoforms are neither
sufﬁcient nor consistent. The suggested catalytic mechanisms in
Fig. 15 remain to be tested experimentally and presumably have to
be determined individually for each enzyme.
6.3.2. The mechanism of GST-dependent Prx
The physiological reducing agent of homodimeric PrxVI was ques-
tionable for a long time (and this is still the case for other Prx6-type
enzymes [63,344,348]). However, in 2004, Manevich et al. discovered
a GST P1-1-dependent activity for heterodimeric PrxVI using impure
enzyme preparation from bovine lung [65]. Based on co-puriﬁcation,
reconstitution, oligomerization and glutathione-labeling studies, the
authors proposed an unusual catalytic mechanism for the reductivehalf-reaction that was later reﬁned (Fig. 15C) [65,353,354]: First,
a complex of GST P1-1 and GSH replaces a subunit of dimeric
PrxVI-SOH, resulting in the formation of a GST/Prx heterodimer.
Heterodimerization was reported to also occur in the presence of
S-methylglutathione and therefore seems to be independent of the
thiol group of GSH. In contrast, in the general absence of glutathione,
heterodimerization was less efﬁcient [354]. During the second step
of the reductive half-reaction, GST-bound GSH becomes activated
(Section 8.3.1) and reduces the exposed sulfenic acid of PrxVI
(Fig. 15C). Thus, GST acts as glutathionylating enzyme with its active
site facing the sulfenic acid at the heterodimerization interface [354].
Notably, residue Cys47 of GST P1-1 was found to be essential for dimer
stabilization, and a disulﬁde-bridged heterodimer was detected by
non-reducing SDS-PAGE. Based on these results, Cys47 was suggested
to attack Cysp of PrxVI-SSG yielding GSH and a GST–SS–Prx interme-
diate (Fig. 15C). GST P1-1 therefore also provides a resolving residue
and was suggested to act as an unusual deglutathionylating enzyme.
In accordance with this theory, other GST-isoforms that lack the
resolving cysteine cannot activate PrxVI [65,354]. In the last part of
the reaction, the GST–SS–Prx intermediate was suggested to react
with two GSH molecules yielding GSSG, and PrxVI adopts its original
closed conformation (Fig. 15C) [65,353,354].
Please note that the reduction of PrxVI–SSG could be signiﬁcantly
simpliﬁed/accelerated (Fig. 15): Residue Cys47 of GST P1-1 could direct-
ly react with the glutathionylmoiety of PrxVI–SSG via a Grx-like “usual”
deglutathionylation yielding reduced PrxVI. Glutathionylated GST could
subsequently reactwith the secondGSHmolecule. Thus, the release and
binding steps for the ﬁrst GSH molecule become obsolete (Fig. 15C).
This variation of the original model by Fisher and colleagues is based
on the assumption that the proposed GST–SS–Prx intermediate accu-
mulates as a thermodynamically stabilized product under oxidative
conditions in vitro. The activity of a serine mutant of GST P1-1 has not
been analyzed in the enzymatic assay because a stable heterodimer
could not be puriﬁed [354], however, this does not exclude that a tran-
sient dimer could be active.
6.3.3. Properties of Prx reaction intermediates in vitro and in vivo
Prx generally seem to have an activated Cysp, and a thiol pKa value
around 6 has been reported for different isoforms [61,345,351]. Thus,
the reduced enzyme is also deprotonated in vivo. Whether the
enzyme stays fully reduced under physiological conditions (as
suggested for the highly efﬁcient GPx-isoforms, Section 5.3.3) could
not only depend on the mechanistic class, but—for those Prx that
are less efﬁciently reduced—also on the cellular redox state. For ex-
ample, quantitative mass spectrometry indicated that approx. 15%
of the active sites of the cytosolic Prx-isoform Ahp1 from yeast are
oxidized under steady-state conditions in vivo. This value increased
to 50% upon peroxide treatment [142]. Tpx from E. coli was even
found to be 35% oxidized under steady-state conditions and more
than 60% oxidized upon oxidative challenge [140]. On the one hand,
these values suggest that the reductive half-reaction becomes rate-
limiting and/or that a trapped oxidized species accumulates in vivo.
On the other hand, the accumulation of oxidized enzyme species is
in accordance with a function of Prx as redox sensors [11].
In order to draw further conclusions on reaction intermediates
and catalytic properties of GSH-dependent Prx in vivo, a comprehen-
sive analysis of the kinetics in vitro would be extremely helpful. This
includes the determination of the (apparent) kcat and Km values for all
potential substrates. So far, the characterization of most of the
GSH-dependent Prx-isoforms is rather preliminary. The best studied
examples are the H. inﬂuenzae Prx–Grx hybrid protein and human
PrxVI: (i) The H. inﬂuenzae Prx–Grx hybrid protein has the advantage
of an immanent ﬁxed Grx concentration, and apparent kcat and kcat/Km
values for H2O2 at a single GSH concentration were determined to
be 11 s−1 and 5×106 M−1 s−1, respectively. The apparent kcat and
Km values for GSH at a single tert-butyl hydroperoxide (tBOOH)
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value for GSH in vivo could be much lower because of a lower phys-
iological concentration of the ﬁrst substrate (see also Section 3.3.3).
In accordance with the rather high apparent catalytic efﬁciency, the
enzyme was reported to be of physiological relevance for growth
under aerobic conditions (Section 6.4). (ii) Km and k1 values of re-
combinant PrxVI around 120 μMand 5×106 M−1 s−1 were estimat-
ed from secondary plots for phospholipid hydroperoxides [355].
However, because catalysis was analyzed in the absence of GST
P1-1, the high activity of the recombinant enzyme in this study re-
mains enigmatic. Nevertheless, similar values were later reported
in the presence of GST P1-1 [65,354].
The apparent kcat and kcat/Km values of mitochondrial PrxIIF from
poplar for tBOOH were much lower (0.5 s−1 and 3×104 M−1 s−1,
respectively) [67]. This was also the case for chloroplast PrxIIE
(0.9 s−1 and 1×105 M−1 s−1) [67] and the versatile BCP/PrxQ-type
enzyme from E. coli (0.1 s−1 and 7×103 M−1 s−1 for H2O2) [351].
Since the apparent values were only determined for the peroxide
substrate—at just one GSH and Grx concentration—the true kcat and
the catalytic efﬁciency could be much higher. Alternatively, a high
enzyme concentration could compensate the lower activity. Several
Prx are in fact among the most abundant proteins (explaining why
they often show up in proteomic studies) [67,343,347]. In this scenar-
io, oxidized Prx might accumulate owing to a rate-limiting reductive
half-reaction in accordance with the in vivo results. However, the
physiological relevance of a GSH-dependent peroxidase activity will
remain a matter of debate for most Prx-isoforms as long as the kinetic
parameters (and the cellular concentrations) have not been analyzed
in more detail. Some Prx-isoforms could, for example, predominantly
act as redox sensors [11] or could have a moonlighting function as
chaperones [359,360].
6.3.4. Outlook on Prx catalysis and mechanistic questions
As outlined in the previous sections, there are far more open ques-
tions than answers regarding GSH-dependent Prx catalysis. (i) Similar
to GPx catalysis, the exact fate of the proton of the Cysp thiol group as
well as the proton donor for the leaving group of the hydroperoxide
substrate require further consideration. (ii) Regarding the reductive
half-reaction, the activation of the GSH thiol group has not been
addressed for the Grx-dependent Prx-isoforms. Maybe some Grx
also serve as activators that deprotonate GSH for the subsequent reac-
tion with Prx-SOH in analogy to GST P1-1. (iii) In that context, do GSH
and Grx bind simultaneously or one after the other? Is Grx the ﬁrst or
second reductant, or is it just a (de)glutathionylating enzyme that has
to be present in catalytic amounts? Maybe the alternative mechanisms
depicted in Fig. 15B are all valid and are used by different subclasses
with so far unknown mechanistic principles and structure–function
relationships. (iv) The question why many Prx6-type isoforms are
neither efﬁciently reduced by the Trx/TrxR electron donor system
nor the GST or Grx/GSH/GR system in vitro also awaits further clariﬁca-
tion [63,344,348]. (v) Moreover, how does GST P1-1 exactly work? The
rate-limiting step and the reaction between the postulated GST–SS–Prx
intermediate and GSH have not been characterized to date. (vi) Last but
not least, what is the role of the reported monomer formation of
glutathionylated Prx-isoforms [358]? Even though the homodimer
dissociation might be a prerequisite for the interaction with Grx, an
interaction of the dimer cannot be excluded to date. In summary,
GSH-dependent Prx catalysis is a rather young research ﬁeld with a
great potential for multiple future discoveries.
6.4. Physiological and medical relevance of Prx catalysis
The physiological relevance of Trx-dependent Prx-isoforms for
(potential) antioxidant defense and redox regulation has been
reviewed before [11,67,220,343,344,347]. The distribution of the six
mammalian Prx-isoforms has been recently reported, revealingtissue-speciﬁc localization and expression patterns [271]. GSH-
dependent PrxVI was usually among the highly abundant proteins
and had a (peri-)nuclear localization (i.e. in astroglia cells in the hip-
pocampus and in all kinds of epithelial cells) [271,361]. Human PrxVI
is considered to play a protective role against oxidative membrane
damage in vivo. In fact, although the encoding gene was non-
essential, the lungs of knock-out mice were more susceptible to
hyperoxia-mediated injury, and the enzyme was suggested to be
more important for this organ than the lipid hydroperoxidase GPx4
[353,361].
Gram-negative H. inﬂuenzae—a major cause of pneumonia and
non-epidemic meningitis in children—is a glutathione auxotroph
pathogen that lacks the canonical bacterial Prx1-type alkyl hydroper-
oxide reductase AhpC. Thus, the peroxidase activities of the Prx–Grx
hybrid protein and catalase are expected to play an important role
upon infection of the human respiratory tract. In accordance with this
theory, a knock-out of Prx–Grx was reported to be lethal for stationary
H. inﬂuenzae cell cultures under aerobic (but not under anaerobic) con-
ditions [362]. Almost nothing is known about GSH-dependent isoforms
form other organisms and pathogens, and therefore—also considering
the aspects summarized in Section 6.3.3—it currently does not make
sense to further speculate on the physiological relevance of GSH-
dependent Prx catalysis.
7. Glyoxalase 1 and glyoxalase 2
7.1. Pioneers of Glo catalysis
Exactly 100 years ago, in 1913, Neuberg as well as Dakin and
Dudley independently discovered the conversion of MG to lactic
acid in a variety of tissue and cell extracts and introduced the name
“glyoxalase” for the unknown catalyst [363,364]. Two decades
later, Lohmann as well as Jowett and Quastel discovered that GSH is
a coenzyme of the reaction [365,366]. During that period the Emb-
den–Meyerhof–Parnas pathwaywas unraveled (1927–1942). Many sci-
entists therefore lost their interest in MG and questioned the
physiological relevance of Glo catalysis, and, as a consequence,
glyoxalases are still neglected in most textbooks. Based on previous ob-
servations by Yamazoye as well as Hopkins and Morgan, Racker sepa-
rated two yeast proteins in 1951, and showed that Glo1 and Glo2 are
both necessary for the conversion of MG to lactic acid [367]. He correct-
ly predicted the activity of Glo2 as a thioesterase and demonstrated the
irreversibility of the overall reaction. Racker furthermore assigned a
condensation reaction to the activity of Glo1, but it took the following
decades and two key publications by Vander Jagt [368,369] to
adequately address the one- vs. two-substrate hypotheses and to
show that Glo1 is actually an isomerase converting a variety of gluta-
thione hemithioacetals [73]. Notably, some of the observed discrepan-
cies from these decades might become explainable considering
that different classes of Glo1-isoforms from yeast and mammals
(Section 7.2.1) were studied, yielding alternative kinetic patterns [370].
In 1973, Ekwall and Mannervik conﬁrmed that Glo1 speciﬁcally forms
S-D-lactoylglutathione fromMG [371], and Uotila reported the ﬁrst thor-
ough characterization of puriﬁed Glo2 [372]. Ten years later, studies
from the Creighton lab indicated that Glo1 is not stereospeciﬁc for
its substrate [373]. This theory was later conﬁrmed by Landro, Rae
and co-workers [374,375]. The ﬁrst crystal structures of Glo1
and Glo2 were reported by Cameron et al. in 1997 and 1999, respec-
tively [376,377]. Since the initial studies, numerous Glo1- and
Glo2-isozymes have been studied from prokaryotes [378] and
eukaryotes including human [23,73,372,376,377,379,380], S. cerevisiae
[379,381–384], A. thaliana [385–388], P. falciparum [31],Onchocerca vol-
vulus [389] and kinetoplastid parasites [390–394]. Nevertheless, as Iwill
outline separately for Glo1 and Glo2 in the following sections, the enzy-
matic mechanisms and catalytic functions of glyoxalases still have sev-
eral surprises in store.
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7.2.1. Structure and function of Glo1
Glo1 (also termed GloI or GlxI) belongs to the superfamily of vicinal
oxygen chelate enzymes, containing an ancient βαβββ-motif required
for metal ion binding (Fig. 16) [395,396]. Different Glo1-isoforms can
be roughly subdivided into two major classes: (i) small homodimeric
and (ii) large monomeric enzymes (Fig. 16A–C). (i) The small isoforms
(~20 kDa) are more common and have been structurally characterized
e.g. from human [376], E. coli [397] and the kinetoplastid parasite Leish-
maniamajor [390]. Due to an early gene duplication event these isoforms
contain two βαβββ domains per subunit (Fig. 16B) [395,396]. The func-
tional dimeric proteins consist of four βαβββ-domains with the
N-terminal domain of one subunit interacting with the C-terminal do-
main of the other subunit [376,390,397]. Thus, the two structurally iden-
tical active sites A and A′ are formed between the swapped domains of
the homodimer (Fig. 16A–C). (ii) Although a crystal structure of a large
monomeric Glo1 (~35 kDa) has not been solved yet, the overall architec-
ture is probably similar to the homodimeric isoforms (except for a link-
er area between the two inner domains) [370,383,398]. Monomeric
Glo1 arose from a second gene duplication event [398] that might
have occurred independently in non-related organisms such as fungi,
plants and apicomplexan parasites [370]. As consequence, the two ac-
tive sites A and B in monomeric Glo1-isoforms are structurally (and
functionally) non-identical (Fig. 16C) [370,399,400]. An alternative
classiﬁcation of Glo1-isoforms is based on the metal ion-dependency:
Some Glo1, including homodimeric human Glo1 as well as the mono-
meric enzymes from yeast and P. falciparum, prefer one Zn2+ (or
Fe2+) at each active site [379,383,398,401]. In contrast, Glo1 from sev-
eral bacteria such as E. coli [402] and the important pathogens Yersinia
pestis, Pseudomonas aeruginosa and Neisseria meningitidis [403]—but
also the protist L. major [390,394]—are optimally activated in the pres-
ence of Ni2+ (or Co2+).
Regarding the enzymatic function, Glo1 is ofﬁcially classiﬁed
as a lactoylglutathione lyase (EC 4.4.1.5). However, based on mecha-
nistic studies [368,369], Glo1 is a metal ion-dependent isomerase
(EC 5) converting various glutathione hemithioacetals to glutathione
thioesters [23,73,74]. The diastereomeric hemithioacetals are formed
during a non-enzymatic reaction between GSH and the unhydrated
2-OA (Fig. 3E) [23,73,74,368]. Both diastereoisomers are then con-
verted by Glo1 to a single thioester [373–375]. With respect to the
subcellular localization, Glo1 is regarded to be a cytosolic protein; a
plausible scenario considering the major source of MG (glycolysis),
and the absence of targeting sequences in the Glo1-isoforms analyzed
so far [400]. Moreover, traditional Glo1 puriﬁcation protocols were
performed with erythrocytes which lack membrane-bound organ-
elles [404–406]. However, there are probably exceptions to this rule.
For example, Glo1-isoforms from L. major and T. cruziwere suggested
to be dual targeted to the cytosol and to mitochondria [391], and
several uncharacterized monomeric isoforms from fungi such as
Ashbya gossypii (gi|45188159), Kluyveromyces lactis (gi|50310681)
and Verticillium dahliae (gi|83267732) [370] carry N-terminal mito-
chondrial targeting sequences with high bioinformatic prediction
scores (Deponte, unpublished). Furthermore, the N-terminus of a
so far non-functional Glo1-like protein from P. falciparum guided a
GFP-fusion construct to the apicoplast [119], and the uncharacterized
monomeric Glo1-isoform from A. thaliana (gi|21537360) [370] con-
tains a predicted chloroplast transit peptide (Deponte, unpublished).
In some of these cases additional non-cytosolic MG-detoxiﬁcation
processes cannot be excluded, however, considering the lack of ex-
perimental data, the functions of these (insular?) targeted proteins
are completely unknown [31].
7.2.2. The enzymatic mechanism of Glo1
The two active sites of homodimeric and monomeric Glo1-isoforms
contain highly conserved metal-binding residues (Fig. 16D) as well asglutathione-binding residues (Fig. 16E). Two essential glutamate resi-
dues per active site exert the acid–base catalyzed isomerization of
both diastereoisomers to a single thioester (residues GluI and GluII′ in
Fig. 16D) [370,383,401,407–409]. The substrate seems to be pre-
dominantly bound by basic/polar residues via the γ-glutamyl and gly-
cine moiety (Fig. 16E) [370,376,378,380], explaining the broad range
of 2-OA that are efﬁciently isomerized [73,368,369]. Two additional
residues, usually a histidine and a glutamine, are associated with the
metal ion (residues HisM and GlnM′ in Fig. 16D). In bacterial Glo1-
isoforms and the trypanothione-dependent L. major enzyme, GlnM′ is
replaced by a second histidine residue, and the overall geometry is al-
tered owing to the different metal ion [378,390,397]. The following
two catalytic models—which are predominantly based on structural
analyses on human Glo1 [376,380,401]—have been proposed for the
proton transfer between atoms C1 and C2 in both diastereomeric sub-
strates (Fig. 17).
(i) According to a model that is supported by computations by
Himo and Siegbahn [408], a ﬁrst and a second proton transfer
can be distinguished (Fig. 17A). After substrate binding, atom
C1 becomes deprotonated, resulting in a ﬁrst cis-enediolate.
This step requires either GluI (Glu172 in the human enzyme)
for the (S)-diastereomer or GluII′ (Glu99′ in human Glo1) for
the (R)-diastereomer. Reprotonation of the enediolate yields
the same cis-enediol intermediate for both diastereomers.
Atom O1 is then deprotonated by GluI which subsequently
transfers the proton to atom C2 of the second cis-enediolate,
giving the ﬁnal product (Fig. 17A) [408]. As a result, a single
(R)-diastereomer is obtained (e.g. S-D-lactoylglutathione from
MG). Please note that residue GluI is required for the turnover
of both diastereomeric substrates. In contrast, residue GluII′ is re-
quired only for deprotonation of C1 of the (R)-diastereomer
(Fig. 17A) [408].
(ii) An alternative model for the turnover of the (S)-diastereomer
was proposed by Creighton and Hamilton [407] and computed
by Richter and Krauss [409] (Fig. 17B). One difference is that
residue GluI (partially) dissociates from the metal ion upon the
initial protonation. In the second step, GluI directly protonates
atomC2 (instead ofO2). This step is coupled to a simultaneous pro-
ton transfer from atom O1 to residue GluII′ that subsequently pro-
tonates atomO2, yielding the same product. Noteworthy, atomO2
is permanently associated with GlnM′ in this model [407,409]. In
summary, the biggest differences to the model depicted in
Fig. 17A are the early protonation of C2 by GluI, the interchanged
ﬁnal positions of the protons, and the participation of residue
GluII′ in the turnover of the (S)-diastereomer (Fig. 17B).
Both models are in good agreement with base- and metal-catalyzed
chemical studies supporting an cis-enediol(ate) mechanism [73,407]
and with site-directed mutagenesis studies [370,383,401,407]. Proton
abstraction from atom C1 was suggested to be a rate-limiting step—
in contrast to biochemical isotope exchange analyses [73]. These dis-
crepancies could be explained by conformational changes upon cataly-
sis. In fact, the absent isotope effects, biphasic kinetic patterns, the
inactivation of Glo1-mutants in phosphate buffer as well as proteolytic
susceptibility analyses suggest that Glo1 adopts a protected, closed
conformation in the absence of substrate and during catalysis, whereas
a kind of lid opens during substrate binding and product release
[73,370,407,410]. Conformational changes and catalysis at the two
active sites of monomeric Glo1 from P. falciparum were furthermore
shown to be allosterically coupled [31,370,399,400].
7.2.3. Outlook on Glo1 catalysis and mechanistic questions
The capacity of Glo1 to convert both diastereomers as substrates
was estimated to result in a 3- to 6-fold advantage in the steady-
state rate in vivo [411]. Nevertheless, none of the mechanistic models
sufﬁciently explains the formation of a single (R)-diastereomeric
Fig. 16. Structure of Glo1. (A) Top view of homodimeric Glo1 along the 2-fold axis. Each quadrant contains one of the four βαββ(α)β domains. The metal ion complex and a glu-
tathione transition state analog (GTSA) are highlighted at both active sites. (B) Same view with one subunit omitted. Domains I and II are highlighted and contribute to one half of
each active site. (C) Schematic illustration of the protein architectures of small homodimeric and large monomeric Glo1-isoforms. (D) Zoom in at one active site of Glo1. Conserved
residues that are important for metal ion coordination and acid–base catalysis are highlighted. (E) Illustration of conserved residues that were demonstrated or suggested to bind
the glycine moiety (1) or the γ-glutamyl moiety (2) of glutathione. Residues r1′ (Arg37′), r2′ (Thr101′) and r3′ (Asn103′) are highly conserved, whereas r4 (Arg122) is often replaced by
Gln. Positively charged residues at position r5 (Lys150) and r6 (Lys156) are also found in most homologues. The images were generated using Swiss-Pdb viewer and the structure of
human Glo1 (PDB ID: 1QIN [380]). See Section 7.2.1 for details.
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be controlled by the asymmetric protein environment at the active
site [407–409], but how this is exactly driven remains to be shown.
This central enigma is of course related to the question which of
both models in Fig. 17 is correct. Speciﬁc isotope labels and NMR-
analyses might reveal the fate of the transferred protons for both
substrates. Another puzzling aspect in Glo1-catalysis is the structural
variability of the enzyme. Why are there monomeric and homo-
dimeric Glo1-isoforms (Fig. 16C) as well as Zn2+- and Ni2+-dependent
enzymes? Are both active sites in homodimeric Glo1 really identical
and do they work independently? Several studies indeed suggest that
metal binding to Ni2+-dependent homodimeric Glo1-isoforms is not
identical [378,394,412]. Furthermore, the structure–function relation-
ships that determine allosteric effects in monomeric P. falciparum
Glo1 are unclear and several hypotheses with respect to alternative
substrates/regulators andmetabolic adaptations remain to be addressed
[31,370].
7.3. Glo2 catalysis
7.3.1. Structure and function of Glo2
Glo2 (also termed GloII or GlxII) is composed of an N-terminal
β-lactamase domain with a conserved zinc/metal-binding motif at
the active site and a C-terminal domain with ﬁve α-helices
(Fig. 18A) [377,387,393,413]. Owing to the β-lactamase fold the pro-
tein is a member of the structurally diverse group of binuclearmetallohydrolases [414,415]. Glo2-isoforms are highly variable with
respect to metal ion binding: A variety of isoforms were shown to
contain either two zinc ions or one zinc/iron ion pair per protein
molecule [377,385,392,416–418]. Other promiscuous recombinant
isoforms were reported to either contain a Zn2+/Zn2+ center, a
Fe3+/Zn2+ center, a Fe3+/Fe2+ center or even a Mn2+/Mn2+ center
[265,387,413,419]. The composition of the center seems to depend on
the medium and growth conditions [413,419]. With respect to the
quaternary structure, human Glo2 [377] and mitochondrial Glx2-5
from A. thaliana [387] were reported to be monomeric, even though
alternative monomer–monomer contact sites were detected in their
crystal structures (Fig. 18A–D). A recent study on cytosolic Glo2
from P. falciparum furthermore revealed a monomer–dimer equilibri-
um in solution [400], and Glo2 from human erythrocytes indeed ran
in one and two bands after denaturing and non-denaturing PAGE,
respectively [420]. Notably, the monomer–monomer contact site of
crystallized human Glo2 is formed by the C-terminal helix α8 which
carries two important glutathione-binding residues (Fig. 18B). In con-
trast, the active sites of crystallized A. thaliana Glx2–5 are completely
blocked (Fig. 18D) [31,377,387].
Regarding the enzymatic function, Glo2 is a thioesterase that cat-
alyzes the hydrolysis of S-(2-hydroxyacyl)glutathione (EC 3.1.2.6). A
variety of other thioesters including S-acylglutathione substrates—
but usually no non-glutathione thioesters—are also hydrolyzed in
vitro [23,73,74,372,386,420,421]. On the one hand, Glo2 catalyzes
the last step of the glyoxalase pathway, regenerating GSH and
Fig. 17. Two models of Glo1 catalysis. Depending on the stereochemistry of the substrate, alternative acid–base catalyzed isomerization mechanisms have been suggested. (A) Sym-
metrical reaction pathway with a ﬁrst and second proton transfer for both diastereomeric hemithioacetal substrates. (B) Alternative shortened, non-symmetrical mechanism for the
(S)-diastereomer. See Section 7.2.2 for further details.
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hand, Glo2-isoforms are not only found in the cytosol. In fact, mito-
chondrial and even plastid Glo2 are either encoded by the same
gene like the cytosolic enzyme (due to an alternative exon usage)
[422] or by separate nuclear-encoded genes [381,382,386,387,400,423].
Some of these isoforms seem to act independently from Glo1. This
theory is not only supported by the turnover of alternative substrates
[23,73,74,372,386,420,421], but also by the existence of insular Glo2
in mitochondria from rat [424], human [422], yeast [381,382] and
A. thaliana [386,387]. Another apparently insular Glo2-isoform was
found in the apicoplast from P. falciparum [400] (the unusual Glo1-like
protein in this organelle is a non-functional partner for standard sub-
strates [31,423]). The parasite T. brucei even lacks Glo1 activity [421]
and has just one (trypanothione-dependent [392]) glyoxalase (GLXII).
This enzymewas furthermore shown not to contribute to the detoxiﬁca-
tion ofMG [421]; a plausible result considering that these parasites could
be protected from MG owing to membranous organelles (glycosomes)
where a major part of glycolysis takes place [425]. In summary, Glo2
are not only a part of the glyoxalase system, but can also exist as insular
isoforms with individual, yet unknown, physiological functions.7.3.2. The enzymatic mechanism of Glo2
The active site of Glo2 canbe subdivided into (i) themetal binding site
(Fig. 18E) forming the catalytic center, and (ii) the substrate-binding site
(Fig. 18F). (i) As their name implies, binuclear metallohydrolases
bind two metal ions that generate a nucleophile (e.g. an activated water
molecule or hydroxide ion) and/or coordinate an oxygen atom of the
hydrolyzable substrate [415,417]. Metal ion 1 is bound by three highly
conserved histidine residues (HisM1A,B,C in Fig. 18E), whereas metal ion
2 is bound by one aspartate (AspM2) and two histidines (HisM2A,B).
Both ions are bridged by an aspartate residue (AspBri) opposite to the
substrate-binding site (Fig. 18E) [377]. (ii) The substrate-binding
site contains ﬁve well conserved residues among diverse eukaryotic
and prokaryotic Glo2-isoforms (r1–r5 in Fig. 18F), indicating that the
enzyme predominantly interacts with the glutathione-moiety of the
substrate [377,378,387,413,417] (which explains the efﬁcient turnover
of a variety of glutathione substrates [23,73,74,372,386,420,421]).
Residues r2 and r3 are aromatic, with the hydroxyl group of residue r3
pointing at the sulfur atom of the substrate (Fig. 18F). Accordingly,
mutation of r3 was shown to increases the Kmapp value [423,426]. Resi-
dues r1, r4 and r5 are basic and interact with the carboxylate groups of
Fig. 18. Structures of Glo2. (A) Top view of two subunits of human Glo2 in the asymmetric crystal unit. The metal ion complex and GSH or a glutathione transition state analog
(GTSA) are highlighted at both active sites. The N-terminal β-lactamase domain and the C-terminal α-helical domain are circled. (B) Front view of human Glo2 along helix α8
with subunit interactions highlighted in the middle. Residues Arg249 and Lys252 bind the glycine-moiety of glutathione on the other side of the helix. (C) Structure of dimeric
Glo2–5 from A. thaliana with the left subunit in the same orientation as in panel A and the second subunit in front. (D) Top view on Glo2–5 revealing the proximity of the metal
ion complex to the dimer interface (left side). Accordingly, both active sites are hidden and blocked in the crystallized dimer by the subunit interface (highlighted on the right
side). (E) Zoom in at the highly conserved catalytic center. Metal ion 1 is bound by the three histidines HisM1A,B,C (His54, His56 and His110 in human Glo2). Metal ion 2 is bound
by AspM2 and residues HisM2A,B (Asp58, His59 and His173). Both ions are bridged by AspBri (Asp134). Substrate binding at the back side is indicated by an arrow. (F) Zoom in at
the substrate-binding site. Residues that were demonstrated or suggested to interact with the glycine moiety (1), the γ-glutamyl moiety (2) or the sulfur atom of the substrate
are highlighted. A positively charged residue at position r1 (Lys143), an aromatic amino acid at position r2 (Tyr145), a tyrosine residue at position r3 (Tyr175) and the
glycine-binding residues r4 (Arg249) and r5 (Lys252) are highly conserved. The catalytic center is below the GTSA molecule. The images were generated using Swiss-Pdb viewer
and the structures of human Glo2 and Glo2–5 from A. thaliana (PDB IDs: 1QH5 and 1XM8, respectively [377,387]). See Section 7.3.1 for details.
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of helix α8 described above (Fig. 18B) [378,380] and seem to form the
most important part of the substrate-binding site (Fig. 18F) [417].
Glo2 works via acid–base catalysis (Fig. 19). Owing to the special
kinetics of the enzyme, this property usually seems to be masked
[417]. Of note, the metal ion center was suggested to lower the pKa
value of water by almost ten orders of magnitude to approx. 6
[417]. Thus, the muchmore potent nucleophile OH− can be generated
under physiological conditions (Fig. 19). As soon as the product GSH
from the previous catalytic cycle is replaced by the next thioester
substrate, the nucleophilic attack takes place and a tetrahedral transi-
tion state is formed [417,427]. Metal ion 1 probably stabilizes the
oxyanion of the transition state, whereas metal ion 2 presumably as-
sists the removal of the thiolate leaving group [377,417,427]. The
equilibrium of the hydrolysis is clearly on the product side, and the
loosely associated acid is quickly released as the ﬁrst product. Incontrast, GSH is presumably still associated with metal ion 2 and rath-
er tightly bound via the glycine carboxylate group when the next
water molecule enters the active site at metal ion 1 (Fig. 19) [417].
Product inhibition patterns (obtained for cytosolic Glo2 from
P. falciparum [417] and Glx2-2 from A. thaliana [418]) and viscosity
effects (observed for human Glo2 [428]) support the proposed
“hit-and-run” Theorell-Chance bi-bi mechanism with OH− as the
ﬁrst true substrate and an extremely instable ternary complex
between the enzyme, OH− and the thioester [417]. In addition, rate-
limiting replacement of GSH by the next thioester substrate perfectly
explains not only the pH- and salt-sensitivity of the kcatapp value of Glo2,
but also why the metal-ion composition has a rather moderate effect
on the catalytic efﬁciency as long as the nucleophile is still formed
[417]. In summary, Glo2 exerts a nucleophilic substitution via an addi-
tion–elimination mechanism with metal/base-catalyzed nucleophile
formation and presumably acid-catalyzed GSH formation.
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Whether a ﬂexible quaternary structure is a common property of
different Glo2-isoforms and has an inﬂuence on catalysis remains to
be studied. Depending on the subunit interface, a transient dimerization
of Glo2-isozymes could either directly block the enzyme or regulate the
activity via helixα8 (Fig. 18A–D) [399,400]. Furthermore, the predicted
base accepting the proton from the metal–water complex is so far
unknown (Fig. 19). Residue AspM2 (maybe with the help of HisM2B)
might be a good candidate (Fig. 18E). Regarding the leaving group it is
unclear whether protonation occurs simultaneously with the break-
down of the transition state (Fig. 19), or whether GS− is rather stabi-
lized by metal ion 2. Further questions will presumably arise once the
physiological substrates of insular Glo2 are identiﬁed.7.4. Physiological and medical relevance of Glo catalysis
As reviewed before, traditional and current theories suggest that
glyoxalase catalysis is required for 2-OA detoxiﬁcation and regulatory
processes with (potential) implications for cancer, diabetes, aging
and infectious diseases [23,29–32]. In yeast, none of the three
glyoxalase-encoding genes is essential, and growth phenotypes only
became obvious upon challenge with exogenous MG [382,429]. How-
ever, MG was suggested to modify the regulatory cysteine residues of
Yap1, resulting in a nuclear localization of this transcription factor
and an altered gene expression proﬁle. Accordingly, in the absence
of yeast Glo1, MG levels were elevated and Yap1 was constitutively
activated in the nucleus [430]. The genes encoding Glo1 and Glo2 in
E. coli are also non-essential, and growth phenotypes were inconspic-
uous in the absence of exogenous MG [33,431]. Up-regulation of Glo2,
however, surprisingly decreased the growth rate. This phenotype was
suggested to be caused by the depletion of S-D-lactoylglutathione,
resulting in a decreased KefGB-mediated potassium ion efﬂux [33].
To the best of my knowledge, glyoxalase knock-out studies in ver-
tebrates have not been reported to date. Nevertheless, overexpression
of GLO1 in diabetic rats reduced the levels of hyperglycemia-induced
ROS markers and AGEs (Fig. 2B,D) [432]. In agreement with these
results, overexpression and RNAi studies in C. elegans pointed to a
pro-survival function of Glo1 owing to 2-OA detoxiﬁcation [433]. A
role of Glo1 activity for osteoclastogenesis was revealed for cultured
bone marrow-derived macrophages from mice [434]. Further cell
culture experiments with human MCF7 and RKO cell lines indicated
an up-regulation of GLO2 by the transcription factors p63 and p73,Fig. 19.Model of Glo2 catalysis. The position of the nucleophile-generating metal ion center
GTE, glutathione thioester. See Section 7.3.2 for details.and a protective function for cytosolic Glo2 was detected upon
MG-induced cell death [435].
The cytotoxic effects of exogenous 2-OA on tumors were demon-
strated several times, culminating in the suggestion by Szent-Györgyi
and colleagues to exploit these compounds as cancerostatic agents in
the 1960s [30]. In 1969, Vince and Ward then proposed to directly in-
hibit Glo1 to cause a build-up of endogenous MG in order to kill cancer
cells [436]. This strategy was later adopted for pathogens with high
glycolytic ﬂuxes including malaria parasites [31,399,400,417,423] and
kinetoplastid parasites [390,391,393,394]. Alternatively, inhibition of
Glo1-dependent osteoclastogenesis could have implications for patho-
physiological situations such as osteoporosis or rheumatoid arthritis
[434]. In fact, cell permeable and tight binding inhibitors of mammalian
and parasite glyoxalases were demonstrated to be active in vitro
[30,31,377,380,390,391,399,400,407,434,437]. Some of the anti-tumor
inhibitors also gave ﬁrst promising results in vivo [30,407]. In addition,
a recent study on Leishmania donovani insect stages (promastigotes)
conﬁrmed GLO1 to be essential for parasite survival [438], providing a
genetic proof of principle in contrast to the discouraging results from
the related parasite T. brucei [421] (Section 7.3.1).
In summary, depending on the type of organism, glyoxalases act as a
detoxiﬁcation system and/or were suggested to be involved in 2-OA- or
thioester-dependent regulatory processes and signal transduction.
Moreover, some Glo2-isoforms presumably exert alternative unknown
physiological functions. Although glyoxalases are non-essential in E. coli
and yeast, several studies suggest that Glo1 of human and selected
parasites can be of medical relevance and might be exploited as drug
target. The exact knowledge of glyoxalase properties and catalysis
might therefore be helpful for rational drug development.
8. Glutathione transferases and MAPEG
8.1. Pioneers of GST and MAPEG catalysis
Studies on soluble and microsomal enzymes from thousands of
rodent livers laid the groundwork of modern GST and MAPEG
research. The ﬁrst GST activities were reported in 1961 for soluble
enzyme preparations from rat liver with bromosulfophthalein by
Combes and Stakelum and for chloronitrobenzenes by Booth et al.
[439]. During the following years it became obvious that there are
several GSH-dependent liver enzymes with overlapping conjugation
activities for a variety of substrates. As a consequence, the scientiﬁc
community failed to unambiguously correlate a speciﬁc enzymaticcorresponds to Fig. 18E. Acid–base catalysis is highlighted in red. B, unidentiﬁed base;
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therefore chose in 1974 to assign letters to the rat liver transferases
based upon their order of elution from carboxymethylcellulose
[440]. In 1976, Prohaska and Ganther reported a GSH-dependent
peroxidase activity with organic hydroperoxides for a soluble GST-
isoform [441], and distinct physiological GST-dependent isomerase
or oxidoreductase activities were afterwards identiﬁed or assigned,
i.e. by Benson et al. in 1977 [442] and by Christ-Hazelhof and
Nugteren in 1979 [443].
A GST activity in mitochondria was reported in 1979 [444], and
Kraus puriﬁed the ﬁrst mitochondrial GST from rat liver in 1980
[445]. It took one more decade until Harris et al. unambiguously
showed that a soluble matrix GST exists [446] and ﬁve more years
until the corresponding gene was cloned, and the novel kappa class
was introduced [447]. According to Allocati et al., the ﬁrst evidence
for a GST activity in bacteria was reported for E. coli by Shishido in
1981 [448], but it was not until the late 1980s that soluble bacterial
isoforms were puriﬁed and characterized [449,450]. During the
same time, studies on Schistosoma japonicum GST by Smith and
Johnson lead to a highly versatile tool in modern cell biology: GST-
tagging and afﬁnity puriﬁcation [451]. Around the early 1980s,
Mannervik and colleagues not only established the puriﬁcation of
human pi class GST from different tissues [69], but also demonstrated
that GST-isoforms within the same class exist as homo- and hetero-
dimers, resulting in modular enzyme activities [69,452]. Based
on these ﬁndings, GST-isoforms are nowadays named according to
their class (e.g. GST A for alpha class) and their subunit composition
(e.g. GST A1-2 for a heterodimer between two subunits encoded by
GSTA1 and GSTA2) [439]. In 1991, the Huber lab solved the ﬁrst crystal
structure of a mammalian pi class GST [453], directly followed by the
structures of a mu class GST by Ji et al. [454] and a recombinant alpha
class GST by Sinning et al. [455]. The ﬁrst structure of a kappa class
GST was reported by Armstrong and colleagues in 2004, conﬁrming
previous reports that these enzymes differ signiﬁcantly from the
other soluble GST-isoforms owing to an alternative protein fold
[456]. Today, several hundred GST structures have been deposited
in the protein data bank, indicating that the crystallization of soluble
GST-isoforms is often feasible.
In 1977, Ogino et al. partially puriﬁed the, to my knowledge, ﬁrst
GSH-dependent microsomal protein of the MAPEG superfamily
(Section 2.2.5): labile microsomal prostaglandin-E synthase from
bovine vesicular glands (PTGES1, also termed MPGES1) [457]. A
microsomal GST activity from rat liver was ﬁrst reported two years
earlier for the xenobiotic substrate benzo[a]pyrene-4,5-epoxide
by Nemoto and Gelboin [458]. In 1979 and the following years,
Morgenstern et al. as well as Oesch and colleagues demonstrated
that this enzymatic activity was not caused by soluble contaminants
and puriﬁed the GST from the endoplasmic reticulum [459,460].
The primary sequence of this integral membrane protein, termed mi-
crosomal GST1 (MGST1), was reported in 1985 and revealed no sim-
ilarity with soluble GST-isoforms [461]. In the same year, based on
previous reports by Samuelsson as well as Murphy and colleagues,
Yoshimoto et al. partially puriﬁed and analyzed a GSH-dependent mi-
crosomal leukotriene-C4 synthase (LTC4) [462]. The corresponding
human gene was cloned in 1994 [463,464]. Its sequence revealed a
homology to the integral membrane protein “5-lipoxygenase activat-
ing protein” (FLAP) which was discovered four years earlier by Dixon
et al. [465]. Notably, the activator FLAP on its own seems to neither
have a GSH-dependent nor another enzymatic activity [76]. Based
on the homology of LTC4 and FLAP, Jakobsson et al. discovered two
additional microsomal proteins with GST and peroxidase activities,
MGST2 and MGST3, and introduced in 1999 the term MAPEG for a
novel superfamily consisting of six different human membrane pro-
teins [466]. In the same year, twenty-two years after Ogino's discov-
ery, Jakobsson et al. also cloned human microsomal PTGES1 [467].
The projection structure of MGST1 was solved by Hebert et al. in1997 [468], andMGST1 was also the ﬁrst protein of the MAPEG super-
family for which the detailed structure was published in 2006 [469].
Structures of LTC4 followed one year later [470,471], and, in 2008,
the Hebert lab also reported the structure of human microsomal
PTGES1 [472].
8.2. Structure and function of GST and MAPEG
In the next sections, I will discriminate between three protein
groups: (i) canonical soluble GST, (ii) distantly related soluble
kappa class GST and (iii) hydrophobic MAPEG. Bacterial fosfomycin
resistance proteins with GST activities are members of the superfam-
ily of vicinal oxygen chelate enzymes (Section 7.2.1) [77,395,448] and
will not be discussed. Depending on the organism, canonical soluble
GST are cytosolic proteins, eukaryotic soluble kappa class GST are mi-
tochondrial and/or peroxisomal proteins, and hydrophobic MAPEG
are found in microsomal fractions. Notably, there are exceptions to
these rules, for example, several canonical soluble GST-isoforms
of plants have mitochondrial, chloroplast or peroxisome targeting
sequences and/or were found in these organelles or in the nucleus
[473,474].
8.2.1. Structure of GST and MAPEG
What are the structural differences between GST and MAPEG, and
how conserved are their primary structures throughout evolution?
Based on sequence similarities, Mannervik and colleagues introduced
a nomenclature for canonical soluble GST-isoforms in 1992, resulting
in seven GST classes in mammals (alpha, mu, pi, theta, zeta, omega
and sigma) [439]. In addition, mammals possess a dual-targeted solu-
ble GST-isoform of the kappa class [475] and six proteins of the
non-related hydrophobic MAPEG family [75–77,466].
(i) The combination of alpha, mu and pi class GST is restricted
to vertebrates (single class exceptions are found in parasites,
presumably due to horizontal gene transfer). In contrast, the
zeta and theta classes are conserved among eukaryotes and are
also found in bacteria [77,448,474,476]. Nevertheless, owing to
the similarity-based nomenclature and the variable C-terminal
domain of canonical GST [476], it is not surprising that the classi-
ﬁcation has sometimes a rather limited value with respect
to the mechanism and function. Since the introduction of
the classiﬁcation, numerous additional GST classes have been
found—and are constantly identiﬁed—in non-related organisms
including plants (phi, tau, lambda and DHAR classes) [474],
protists [477,478] and prokaryotes (beta and other classes)
[77,448,479,480]. Of note, slight alterations at the active site
with signiﬁcant functional consequences were even detected
for highly similar members of the same GST class as exempliﬁed
in the following sections.
The N-terminal domain of the canonical soluble GST-isoforms
is rather conserved, whereas the C-terminal α-helical domain
is extremely variable (Fig. 20A) [476]. The glutathione-binding
site, the so-called G-site, is accordingly formed by the conserved
N-terminal thioredoxin fold (Fig. 8C,D and Fig. 20A,B). In
contrast, themodular (hydrophobic) binding site for the electro-
philic substrate, the so-called H-site, highly depends on the
α-helical domain and is located at the domain interface
(Fig. 20A) [71,453–455,481,482]. The GST active site residue is
either a tyrosine residue (Tyra, found in alpha, mu, pi and
sigma classes), a serine (Sera, found in theta, zeta and phi classes)
or a cysteine (Cysa, in beta, omega, lambda and plant DHAR
classes) [448,474,476]. In most cases Tyra adopts the position of
the basic glutathione-binding residue r1 of Grx (Fig. 8A–D),
whereas Sera or Cysa in GST-isoforms corresponds to Cysa of
Grx (see also Section 4.4.2).With respect to thequaternary struc-
ture, members of the soluble GST classes are usually dimeric.
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DHAR classes [473] as well as the canonical P. falciparum GST
which forms tetramers that dissociate upon GSH binding
[71,477].
(ii) In contrast to canonical soluble GST-isoforms, the α-helical
domain in kappa class GST is not fused to the C-terminus
of the thioredoxin fold (Fig. 8C), but is inserted between
helix α2 and strand β3 [456,483]. The architecture of kappa
class GST therefore shares similarities with DsbA in the bacte-
rial periplasm [19]. Moreover, signiﬁcant similarities to bacte-
rial 2-hydroxychromene-2-carboxylate isomerases were found
[77,475,483]. Armstrong and colleagues therefore suggested a
DsbA-like progenitor for this enzyme class [456]. The subcellular
localization in the mitochondrial matrix also supports an endo-
symbiotic/bacterial origin of the GST kappa class in eukaryotes.
Considering the active site, the CPYC-motif of Grx is replaced
by a SPYS-motif in kappa class GST and the ﬁrst residue (Sera)
was shown to be crucial for GS− formation [456].
(iii) The sequence similarities between the six mammalian MAPEG
classes are quite low [77]. Nevertheless, all MAPEG share a sim-
ilar (predicted) trimeric structure with four transmembrane he-
lices for each subunit (Fig. 20C) [76,468,470–472]. (Please note
that the term “membrane-associated” in MAPEG is somehow
misleading because all members are in fact integral membrane
proteins.) Mammalian MAPEG can be roughly subdivided into
the MGST1/PTGES1 group and the MGST2/MGST3/LTC4/FLAP
group [75,77]. Further MAPEG families are found in insects and
bacteria, but not in archaea [75]. Except for FLAP, all mammalian
MAPEG possess conserved glutathione-binding residues: a ﬁrst
arginine residue in helix α1 (r3′), an R-x-Q/N-x-N-x2-E-motif in
helix α2, and a tyrosine residue (r2) in helix α3 (Fig. 20D) [76].
Residues R, Q/N and E in themotif correspond to r1, r5′ and r4, re-
spectively (Fig. 20D). A conserved third arginine residue (Arga)
at the N-terminus of helix α4 seems to generate or stabilize
GS− in LTC4 [470,471,484–486] and in microsomal PTGES1
[472]. Based on the structure of MGST1, this function was also
suggested for a fourth conserved arginine residue in helix α3
[469]. Arga and the fourth arginine indeed sandwich the glutathi-
one sulfur atom in crystallized PTGES1 [472], and the residue in
helixα3was demonstrated to behighly important forMAPEG ca-
talysis [472,487]. Nevertheless, a structural role has been favored
and assigned to it (see also below) [76,487]. Interestingly, as
nicely illustrated by Prage et al. [488], the positions of the
glutathione-binding site in MAPEG as well as the conformation
of the bound substrate differ signiﬁcantly in the crystallized pro-
teins: In MGST1 the GSH-binding site is located in a solvent ex-
posed part of the protein and GSH adopts a C-shaped
conformation [469], whereas in MPEGS1 and LTC4 the active
site is more buried in the membrane area and GSH adopts a
U-shaped conformation [470–472]. The (hydrophobic) sub-
strates of MAPEG were suggested to bind along a cleft that is
formed between helices α1 and α4′ of adjacent subunits facing
the membrane (Fig. 20D) [470–472]. This theory is supported
by MPEGS1 inhibitor studies [488–490], although alternative
binding modes were also suggested for MPEGS1 [491] and
MGST1 [487]. In summary, soluble GST and hydrophobic
MAPEG are non-related proteins. Members of both groups have
highly variable primary structures, whereas variations at the ac-
tive site seem to be rather limited.
8.2.2. Function of GST and MAPEG
Functionally, GST were classiﬁed as RX:glutathione R-transferase
(EC 2.5.1.18). R stands for the electrophilic group, including aliphatic,
aromatic or heterocyclic compounds, and X stands for the leaving
group such as sulfate, nitrile or halide ions (Fig. 3F). Please note that
the former name “glutathione S-transferase” is misleading becausethe glutathionyl-moiety (not a sulfur atom) is transferred [439].
Furthermore, not all GST and MAPEG act as transferases (EC 2), but
(also) add glutathione to epoxides (EC 4) or catalyze disulﬁde and
peroxide reductions (EC 1) and isomerizations (EC 5). Several theta
and zeta class GST were, for example, reported to have very low
activity with CDNB and to weakly bind to glutathione afﬁnity
matrices [476,492]. A conserved physiological function of zeta class
GST is in fact the cis–trans isomerization of 4-maleylacetoacetate to
4-fumarylacetoacetate (EC 5.2.1.2) in the course of phenylalanine/
tyrosine degradation [493]. Some alpha class GST isomerize the
position of a carbon–carbon double bond in selected 3-oxo-Δ5-
steroids yielding 3-oxo-Δ4-steroids (EC 5.3.3.1) [442,494]. The isom-
erases prostaglandin-D2 synthase (EC 5.3.99.2) and prostaglandin-E2
synthases (EC 5.3.99.3) catalyze another intramolecular redox reac-
tion: the cleavage of the endoperoxide in prostaglandin H2 yielding
a hydroxyl and keto group in prostaglandin D2 or E2. Please note
that prostaglandin-D2 synthase is a soluble GSH-dependent sigma
class GST [443,495], whereas prostaglandin-E2 synthases include a
soluble GST, the MAPEG member PTGES1 and the non-related micro-
somal peripheral membrane protein PTGES2 [457,472,496]. The
MAPEG enzyme leukotriene-C4 synthase catalyzes a specialized reverse
lyase reaction: the addition of GSH to the epoxide leukotriene A4 (EC
4.4.1.20) [462–464]. In summary, among all families of glutathione-
dependent enzymes, GST and MAPEG are the most versatile catalysts
converting a plethora of sulfur-, oxygen- or carbon-containing electro-
philic substances.
8.3. The enzymatic mechanism of GST and MAPEG
Owing to the versatility of GST andMAPEG, conjugation, reduction
and isomerization mechanisms will be discussed separately in the
following two sections. Moreover, the mechanisms will be further
categorized based on the aromaticity and the hybridization of the
electrophilic center of the substrate.
8.3.1. The mechanism of GST-catalyzed conjugations and reductions
The traditional model substrate for the spectrophotometric analysis
of a GST conjugation activity is CDNB because of its high reactivity with
many GST-isoforms and high extinction coefﬁcient of 9.8 mM−1 cm−1
at 340 nm [440]. However, numerous other (artiﬁcial) aromatic sub-
strates, as well as non-aromatic substrates such as haloalkanes are
also used [3,440]. As outlined below, the mechanism for aromatic and
non-aromatic substrate moieties has to differ signiﬁcantly. Further-
more, a comparative interpretation of GST steady-state kinetics leading
to a coherent mechanistic model seems almost impossible owing to
controversial data interpretations and the usage of alternative sub-
strates and/or GST classes. Even identical enzymes were analyzed in
numerous different ways, i.e. considering or disregarding (putative)
additional ligand/substrate-binding sites and alternative enzyme
conformations.
For example, a study on rat mu class GST M1-1 in 1974 revealed bi-
phasic kinetics, and Pabst et al. suggested a complex hybrid ping-pong/
sequential mechanism with alternative substrate concentration-
dependent reaction pathways [497]. One part of the mechanism was
in accordance with a previous study suggesting an ordered bi-bi mech-
anism with GSH and the electrophile as the ﬁrst and second substrate,
respectively, and the leaving group and the glutathione conjugate as
the ﬁrst and second product, respectively [497,498]. In contrast, later
experiments on rat mu class GST M1-1 [499,500] and GST M2-2 [501]
as well as alpha class GST A1-1 [502] challenged these models and
were interpreted according to a sequential random mechanism. In a
recent study on mouse GST P1-1, mutations of cysteine residues
unmasked a GSH-dependent positive cooperativity. One of the muta-
tions also switched the patternswith CDNB from sequential to apparent
ping-pong kinetics [503]. (A similar mechanistic switch was observed
for different mutants of the GST-like yeast prion protein Ure2 having a
Fig. 20. Structures of GST and MAPEG. (A) Top view of homodimeric GST along the 2-fold axis. The bound inhibitor S-hexylglutathione (GS-C6) is highlighted at both subunits. The
N-terminal thioredoxin fold and the C-terminal α-helical domain of the subunit on the left side are boxed. The orientation of the subunit on the right side is similar to Fig. 8D. The
active site residue Tyra at the end of strand β1 is labeled. (B) Zoom in at the active site of GST. Residues that were demonstrated or suggested to bind the glycine moiety (1) or the
γ-glutamyl moiety (2) are highlighted. Residue Tyra is involved in deprotonation of the thiol group of GSH and is essential for catalysis. Positively charged residues at position r1
(Lys15) and r4 (Lys49) are conserved in several but not all GST classes, whereas residues interacting with the positively charged amino group of GSH at position r2 (Gln71) and po-
sition r3′ (Asp105′) are highly conserved. The binding site for the electrophilic substrate differs signiﬁcantly between the GST-subclasses as far as the composition, size and acces-
sibility are concerned. In the shown example, the so-called H-site is solvent accessible and hydrophobic owing to residues h1–h3. (C) Top view of homotrimeric leukotriene C4
synthase. The four transmembrane helices are highlighted for one subunit. The three active sites with bound GSH are circled and are partially hidden by a lid from the neighboring
subunit. (D) Zoom in at the active site of leukotriene C4 synthase. Left panel: Residues that were demonstrated or suggested to bind the glycine moiety (1) or the γ-glutamyl moiety
(2) are highlighted. Residue Arga was suggested to deprotonate the thiol group of GSH. The glycine moiety of GSH is bound by residues r1 (Arg51) and r2 (Tyr97). The carboxylate
group of the γ-glutamyl moiety is bound to r3′ (Arg30′) from a neighboring subunit, whereas both subunits interact with the positively charged amino group of GSH via residues r4
(Glu58) and r5′ (Gln53'). The front part of the lid, formed by the second subunit in blue, is omitted for clarity. Right panel: The thiol(ate) group of bound glutathione points through a
narrow window along a hydrophobic cleft that is formed between two subunits. The leukotriene substrate is thought to bind along this cleft. The images were generated using
Swiss-Pdb viewer and the structures of P. falciparum GST and human leukotriene C4 synthase (PDB IDs: 2AAW and 2PNO, respectively [71,470]). See Sections 8.2.1 and 8.3 for
details.
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ple for the molecular evolution of glutathione-dependent enzymes
outlined in Sections 2.3 and 4.2.1.). Since none of the cysteine residues
of GST P1-1 can be found in the proximity of the substrates or in direct
contact with the neighboring subunit in the crystallized enzyme [503],
the mechanisms behind the mutational effects remain to be unraveled.
However, McManus et al. correctly emphasized that not two but three
products are formed in the CDNB reaction—a proton, a chloride anion,
and 1-(S-glutathionyl)-2,4-dinitrobenzene (GSDNB)—and therefore
suggested that the stability of the enzyme–GS− complex and an (ir)re-
versible proton release might be responsible for the kinetic patterns
[503]. In summary, several aspects of the mechanisms in the next para-
graph are rather preliminary and could highly depend on the inves-
tigated system.
(i) Mechanism for aromatic substrate moieties: The SN2 mecha-
nism delineated in Fig. 5 is not possible for aromatic substrates
due to steric hindrance. The negative inductive and mesomeric
effects of the substituents make CDNB an electron deﬁcient ar-
omatic compound (Fig. 21A). Thus, a nucleophilic aromaticsubstitution (SN2Ar) with an addition–elimination mechanism
is very likely (Fig. 21B). After binding of GSH to the G-site, a (po-
tential) network of hydrogen bonds [505], including Tyra/Sera/
Cysa or other residues (Section 8.3.2), lowers the pKa of the
GSH thiol group to a value around 5.2-6.8 [269,501,506–511]. Al-
ternatively, deprotonation might be facilitated upon binding of
the aromatic substrate and formation of the ternary complex
[512]. The order of substrate binding, the deprotonation of GSH,
and a subunit cooperativity might furthermore depend on
whether (the C-terminus of) the protein undergoes signiﬁcant
structural rearrangements [71,137,502,507,512–517]. As soon
as atom C1 of CDNB adopts an orientation that allows the nucle-
ophilic attack of the thiolate, the conjugation occurs. The
sp2-hybridization at the electrophilic center and the aromaticity
are lost, and a negatively charged σ-complex intermediate is
formed (Fig. 21B). This step was suggested to be rate-limiting
for rat GSTM2-2 [501]. Some of the SN2Ar reaction intermediates
(so-called Meisenheimer complexes) are rather stable and can
be characterized [518]. There are even GST crystal structures re-
sembling this state [481,512]. The chloride anion in CDNB is an
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ic system (Fig. 21B). The equilibrium of the elimination is on the
product side. Please note that owing to the different hybridiza-
tion states of the σ complex and GSDNB, either the glutathione
moiety or the aromatic moiety of the product has to alter the po-
sition at the active site upon elimination (Fig. 21B). Crystal struc-
tures support the latter scenario [481]. In the last two steps of the
reaction cycle, the chloride anion and GSDNB leave the active
site. The last step was suggested to be rate-limiting for GST I
from maize [507].
(ii) Mechanism for non-aromatic substrate moieties with sp3-
hybridized electrophilic reaction centers: The conjugation,
thiolysis or reduction of non-aromatic substratemoieties depends
on the GST-isoform and on whether a sp3- or sp2-hybridized
electrophilic reaction center is attacked. Substrates with sp3-
hybridized reaction centers include, for example, haloalkanes, hy-
droperoxides (such as hydrogen peroxide) and disulﬁdes (such as
HEDS). The reactions can, in principle, occur via a SN2 mechanism
with a carbon, oxygen or sulfur atom as the electrophilic center as
outlined in Fig. 5 and Section 2.3.3. Please note that—owing to the
geometry of the transition states—the overall orientation of
GST-bound GS−, the electrophilic substrate and the leaving
group have to be altered as compared to SN2Ar reactions (please
compare panels B and C–E in Fig. 21). Site-directed mutagenesis
studies on GST from P. falciparum—having a tyrosine residue at
the active site—suggested that the GSH-dependent cleavage of
peroxides requires the same residues at the G-site like CDNB turn-
over [71]. Thus, GS− is probably bound in the same orientation for
SN2Ar and SN2 reactions, but the positions of the electrophilic cen-
ter and of the leaving group are signiﬁcantly altered (Fig. 21B–E).
The leaving group of haloalkanes is usually unproblematic
(Fig. 21C), whereas the anionic leaving group of hydroperoxides
requires protonation by an unknown source (Fig. 21D). Moreover,
the turnover of hydrogen peroxide and disulﬁdes requires a sec-
ond SN2 reaction/reduction in contrast to haloalkanes (Fig. 21D,E).
The fate of the glutathione sulfenic acid (GSOH) or of GSSR seems
to be rather ill-deﬁned, and similar questions as for the Grx- and
GPx-catalyzed reactions outlined in Sections 4.4.2 and 5.3.2 arise
(Fig. 21D,E). As an instable sulfenic acid, GSOH might either
a) react while it is still bound to the enzyme, or b) just after it
has left the active site. In the former scenario, a second GSH
molecule would have to enter the (hydrophobic) H-site but
might regenerate the unknown proton donor. In the latter scenar-
io, a soluble base catalyst is required. c) Alternatively, GSOH could
be replaced at the G-site by an incoming GSH molecule ensuring
the efﬁcient formation of the second nucleophile (Fig. 21D). This
mechanism somehow resembles the GST P1-1-dependent reduc-
tion of PrxVI-SOH (Fig. 15C, Section 6.3.2). The situation gets even
more complicated for alkylhydroperoxide substrates such as
tBOOH and cumene hydroperoxide. Which oxygen atom is initial-
ly attacked by GS−? Is GSOH formed for all alkylhydroperoxides
or can sterical constraints and leaving group properties result
in the formation of GSOR (see also Section 8.3.2)? Regarding the
fate of GSSR (Fig. 21E), scenarios a) and c) are much more likely
than scenario b) owing to the inefﬁcient formation of GS- at
physiological pH and the lower reactivity of disulﬁdes as com-
pared to sulfenic acids.
Notably, for cysteine-containing omega, beta, lambda and DHAR
class GST-isoforms the mechanism can be different. While the
SN2Ar reaction with aromatic substrates could follow the pathway
in Fig. 21B, the mechanisms with disulﬁde and hydroperoxide
substrates could be similar to Grx and GPx (Figs. 11 and 13),
including covalently modiﬁed active site cysteine residues that
are subsequently regenerated by GSH. Some GST are therefore
considered to be hybrid forms or evolutionary intermediates
[269,519]. Glutathionylation of the active site cysteine residuewas indeed reported for human omega class GST O1-1 and bacte-
rial beta class GST B1-1 [269,519], and ping-pong kinetics in the
HEDS assay were demonstrated for GST B1-1 [269]. In contrast,
peroxidase assays with GST-like Ure2—which lacks a cysteine res-
idue at the same position [520]—revealed sequential peroxidase
kinetics [521] as expected.
(iii) Mechanism for non-aromatic substrate moieties with sp2-
hybridized electrophilic reaction centers: Two commonly used
substrates are trans-4-hydroxy-2-nonenal, a physiological product
from lipid peroxidation, and the diuretic drug ethacrynic acid [3].
Non-aromatic 4-hydroxy-2-nonenal and aromatic ethacrynic
acid both have an α,β-unsaturated carbonyl moiety in common.
Thus, they are excellent Michael acceptors, and the nucleo-
philic addition of glutathione to these substrates is therefore
a special case of a Michael addition (Fig. 21F). Since the reac-
tion might theoretically follow a variety of pathways, we will
omit the substrate binding steps and directly start with the
ternary complex between GST and the substrates. (One
study suggested a rapid equilibrium random bi-bi mechanism
with ethacrynic acid and GSH [509], but neither speciﬁed the
nature of the second product nor discussed the possibility of
an ordered bi-uni mechanism.)
Depending on the investigated enzyme, either the active site resi-
due Tyr9 in humanGST P1-1 or Tyr9 and proximal Arg15 in human
GST A4-4 were suggested to activate the Michael donor GSH
[509,522,523]. After nucleophilic attack of the thiolate, the ﬁrst
transition state and the enolate intermediate are probably stabi-
lized by Tyr108 (Fig. 21F). This residue is located at the end of the
ﬁrst helix in the α-helical domain and was reported to interact
with the keto group of ethacrynic acid in crystallized GST P1-1
[524]. Accordingly, mutation to phenylalanine signiﬁcantly re-
duced the turnover of ethacrynic acid but not of CDNB [509] (see
also the role of a histidine residue for GST Z1-1, Section 8.3.2). Res-
idue Tyr115 in rat GST M1-1 [482] and residue Tyr212 close to the
C-terminus of GST A4-4 [522] seem to play a similar role for the
turnover of epoxides and 4-hydroxy-2-nonenal. Subsequent pro-
tonation of atom Cα of the substrate could depend on an Arg15-
activated water molecule [522] or on an unidentiﬁed acid
(Fig. 21F). The latter step is stereoselective as revealed by the anal-
ysis of the reverse reaction of another Michael acceptor [525].
Finally, kinetic studies on human GST P1-1 suggested that the re-
lease of the conjugated product is not rate-limiting [509].
In summary, the mechanisms of GST-catalyzed conjugations and
reductions are extremely variable and highly depend on the GST
class and on the substrate. I grouped the mechanisms based on the
aromaticity and the hybridization of the electrophilic center of the
substrate. This classiﬁcation might be helpful to clearly discriminate
between GST-catalyzed SN2Ar, single and double SN2 reactions as
well as nucleophilic (Michael) additions.
8.3.2. The mechanism of GST-catalyzed isomerizations
The following GST-catalyzed isomerase reactions can be grouped
into (i) carbon–carbon double bond shifts, (ii) other intramolecular
redox reactions and (iii) cis–trans isomerizations.
(i) Some mammalian alpha class GST isoforms—such as human GST
A3-3, but not human GST A2-2—possess a signiﬁcant Δ5-Δ4
isomerase activity with selected ketosteroid substrates including
the testosterone and progesterone precursors Δ5-androstene-
3,17-dione and Δ5-pregnene-3,17-dione, respectively (EC
5.3.3.1) [442,494,506]. Even though the Δ5-Δ4 isomerase
activity can be monitored spectrophotometrically at 248 nm
in vitro [442,494,506], there are, to my knowledge, no detailed
reports on the kinetic patterns or on product inhibition studies.
Thus, the presented mechanism is predominantly based on
crystal structures [526,527], activity measurements with wild
Fig. 21.Models of GST-catalyzed conjugations and reductions. (A) Structure and properties of CDNB, the aromatic model substrate for GST catalysis. (B) GST-catalyzed SN2Ar mech-
anism with CDNB. (C) GST-catalyzed single SN2 mechanism with iodomethane. (D) and (E) GST-catalyzed (double) SN2 mechanism with hydrogen peroxide and disulﬁde sub-
strates. (F) GST-catalyzed Michael additions. See Section 8.3.1 for details.
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study [528].
Since the reaction might theoretically follow a variety of
pathways—including a random or an ordered mechanism—we
will directly start with the ternary complex between GST, GSHand Δ5-androstene-3,17-dione and omit the unknown steps
concerning substrate binding and product release (Fig. 22A). Mo-
lecular modeling and co-crystallization experiments of GST A3-3
with GSH and the product Δ4-androstene-3,17-dione showed
that the conserved active site residue Tyr9 and the thiolate
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side of the steroid (the same side where the methyl groups at
C10 and C13 are located) [526,527]. GSH is bound like in other
alpha class GST-isoforms [526,527] with a Km value of approx.
0.1 mM [494]. The steroid is bound via the conserved residue
h1—adopting a different conformation than in Fig. 20B and in
GST A2-2—and additional hydrophobic (aromatic) residues
including Phe222 at the C-terminus [526,527]. The alterations at
the H-site seem to be responsible for the activity, because corre-
sponding modiﬁcations of the H-site of GST A2-2 turned the en-
zyme into an isomerase [510], therefore revealing another
example for the principles outlined in Sections 2.3 and 4.2.1.
In contrast to all reactions described so far, GS− in GST A3-3 was
suggested not to form a covalent bondwith the substrate, but just
to play the role of a Brønsted base removing Hβ from the steroid
(Fig. 22A) [506,527]. (This interpretation is in agreement with
a GST tautomerase activity for 2-hydroxymenthofuran [529].)
The catalytic abstraction of Hβ from atom C4 by the thiolate
and the protonation of C6 by Tyr9 might either occur concerted
or sequential. A sequential reaction would result in a resonance-
stabilized dienolate intermediate. However, human GST A3-3
seems to lack residues for stabilizing such an intermediate after
deprotonation [527], in contrast to the non-related bacterial
ketosteroid isomerases [530]. Thus, the postulated dienolate
[506,526] is presumably not formed during acid–base catalysis,
and the concerted mechanism is favored for GST A3-3 (Fig. 22A)
[527,528]. (As a consequence, the roles of the tyrosine residue at
the active sites of bacterial and human ketosteroid isomerases
are completely different.) The pKa value of the thiol group of
GST-bound GSH was estimated to be 6, supporting its role as a
base [506]. Surprisingly, the pKa value of GSH bound to GST
A3-3 and GST A1-1 was predominantly lowered by Arg15, not
Tyr9 [506,531], exemplifying another mechanistic alteration of
some alpha class GST. Spectrophotometric titrations furthermore
revealed a pKa of 7.9 for the side chain of Tyr9. The value was
reported to increase to approx. 9 in the presence of GSH [506] in
accordancewith a proton transfer fromGSH to Tyr9, regenerating
the acid at the active site of the isomerase (Fig. 22A) [528].
Mutation of Tyr9 in GST A3-3 to phenylalanine did not com-
pletely inactivate the enzyme, and a residual activity was even
observed in the apparent absence of GSH. Johansson and
Mannervik therefore suggested that a hydroxide ion and a
water molecule could replace the thiolate and residue Tyr9, re-
spectively [506]. Notably, the in vitro isomerization of 13-cis-
retinoic acid to all-trans-retinoic acids by human pi class GST
P1-1 was suggested to be even GSH-independent. Inhibition
studies and additional controls clearly revealed that the isomeri-
zation occurs at the classical active site [532]. Thus, either cataly-
tic trace amounts of GSH were “contaminants” in the assay, or
the enzyme works via an alternative isomerization mechanism
using an unidentiﬁed base instead of GS−. To the best of my
knowledge, this question is still unresolved and might have im-
plications not only for GST P1-1 but also for GST A3-3 and
other isomerases: Since GSH is not consumed during the isomer-
ization (and therefore acts as a coenzyme and not as a true sub-
strate), a periodic binding and release of GSH appears to be
unnecessary, and an uni-uni isomerase mechanism cannot be ex-
cluded for selected GST-isoforms.
(ii) The soluble hematopoietic prostaglandin-D2 synthase is a sigma
class GST (GST S1-1) with a versatile repertoire of species-
speciﬁc conjugase and reductase activities [533]. The conserved
GSH-dependent isomerase function for prostaglandin H2 is illus-
trated in Fig. 22B. The H-site of GST S1-1 is extended, resulting
in a unique deep cleft where prostaglandin was suggested to
bind with its peroxide group pointing at the thiolate of glutathi-
one [495]. Residues Tyra and r1 (Fig. 20B) at the G-site of themammalian enzyme were shown to be essential for catalysis
[534]. Residue r1 (Arg14) interacts in mammalian GST S1-1 with
Mg2+ which is bound at the dimer interface [535]. This
ion-binding site is neither found in other GST classes nor in
helminth sigma class GST. Ion binding was demonstrated to
decrease the Kmapp value for GSH, presumably owing to a
reorientation of r1 from the glutathione carboxylate group to-
wards the thiol group [535]. According to a postulated model of
catalysis [495], GS− attacks the peroxide at atom O11 yielding a
GSOR intermediate (Fig. 22B). In this model, the leaving group
(atom O9) of the intermediate was not protonated which seems
rather unlikely. Furthermore, Kanaoka et al. suggested “a GS−
in solution” as a base for subsequent proton abstraction from
atom C11 [495]. However, this scenario is also questionable at
physiological pH, unless there is an activation site for the second
GSH molecule. I therefore suggest a modiﬁed mechanism with a
putative proton donor (Tyr8 or Arg14) and a putative base
(deprotonated Arg14 or Tyr8): The proton donor could ﬁrst stabi-
lize the GSOR intermediate and subsequently generate the base
(Fig. 22B). The base abstracts the proton from atom C11, resulting
in the cleavage of the GSOR intermediate (see also the mecha-
nism for PTGES1 described in Section 8.3.3). In the absence of
biochemical evidence for GSOR formation and reliable kinetic
data, completely different mechanisms are of course possible:
For example, using the isomerization in Fig. 22A as a template
mechanism, GS− could ﬁrst abstract the proton at atom C11
followed by the cleavage of the endoperoxide without GSOR for-
mation. Obviously, more wet lab data is required.
(iii) Evolutionary conserved zeta classGST (e.g.mammalianGST Z1-1)
function as maleylacetoacetate isomerase [493] (Section 8.2.2)
and, in some bacteria, as maleylpyruvate isomerase. The en-
zymes also possess a GSH-dependent peroxidase activity
and a conjugase activity with α-haloacid substrates, but not
with CDNB [448,492,536]. The activity with haloalkanes was
presumably altered and optimized resulting in a bacterial
GST sub-class termed TCHQ-DH (tetrachlorohydroquinone
dehalogenases) [448,537]. The cis–trans isomerase function
of GST Z1-1 is illustrated in Fig. 22C.
Which amino acids of zeta class GST are responsible for the pecu-
liar isomerase activity? The G-site contains an YxRSSC-motif with
the tyrosine at the C-terminus of strand β1, a very short loop, and
the two residues SC at the N-terminus of helix α1 (Fig. 8C). The
ﬁrst serine residue (Sera) was reported to be absolutely essential
for the isomerization activities of humanGSTZ1-1 [536] and abac-
terial zeta class GST [538],whereas a plantmutant had a low resid-
ual activity [539]. The tyrosine, the arginine and the SC-motif are
not strictly conserved in zeta class GST-isoforms. Nevertheless,
mutagenesis studies revealed that the latter residues as well as
an arginine residue in the α-helical domain (Arg175) are also im-
portant for catalysis (i.e. by mediating substrate binding)
[536,538,539]. In a study on bacterial TCHQ-DH, the cysteine resi-
due was even reported to be essential for the isomerase activity
(and the following model might therefore not apply to
TCHQ-DH) [537]. Moreover, a histidine at the end of the ﬁrst
helix of the α-helical domain was suggested to facilitate the de-
protonation of GSH in a subgroup of zeta class GST lacking the cys-
teine residue [540] (this residue appears to be similar to Tyr108 of
GST P1-1, Section 8.3.1). In summary, the catalytic mechanism of
zeta class GST-isoforms is presumably not strictly conserved. The
active site composition of these enzymesmay reﬂect a kind ofmo-
lecular Swiss army knife customized for the catalytic repertoire.
The followingmechanism is based on a pioneer study in 1979 by
Seltzer and Lin (Fig. 22C) [541]: Once GSH is deprotonated and
the maleyl moiety is correctly bound, a nucleophilic addition of
GS- at atom C2 of the substrate takes place. Since the double
bond at C2 is conjugated with the carbonyl group at atom C6,
Fig. 22.Models of GST-catalyzed isomerizations. (A) Δ5-Δ4 steroid isomerization catalyzed by GST A3-3 and selected other GST-isoforms. (B) Intramolecular redox reaction of pros-
taglandin H2 catalyzed by GST S1-1 and other sigma class GST. (C) Evolutionary conserved cis–trans isomerization catalyzed by zeta class GST. See Section 8.3.2 for details.
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Fig. 21F. The resulting dienediol(ate) intermediate can now ro-
tate around the C2\C3 single bond. Assuming rather strong asso-
ciations with glutathione and the consensus maleyl carboxylate
group, and a weaker association with the acetoacetate or pyru-
vate moiety, a loss or alteration of bonds with the latter group
has to be postulated. Accordingly, if the intermediate is protonat-
ed and deprotonated at atom O7, two different residues would
presumably become necessary for acid–base catalysis. Alterna-
tively, a dienediolate intermediate could be stabilized at different
positions by alternative positively charged residues; a plausible
scenario considering several structurally conserved basic resi-
dues at the active site (e.g. Arg13 and Arg175 in human GST
Z1-1). Another possibility is that the keto instead of the enol tau-
tomer is the true substrate of the isomerase. This substrate has a
sp3-hybridized atom C5, resulting in a higher ﬂexibility that
might allow a permanent association of both electrophile car-
boxylate groups. In fact, such a mechanistic model has been pro-
posed by Marsh et al. based on previous studies on TCHQ-DH
[540]. However, the keto tautomer theory is in contrast to the
few available kinetic data [541]. In the last part of the reaction
glutathione is eliminated again, yielding the trans-isomer as a
product.
In summary, alternative mechanisms for three different types of
GST-catalyzed isomerizations have been suggested: one depends on
acid–base catalysis and two depend on a conjugation-elimination
mechanism. Accordingly, GS− could either play a role as a Brønstead
base or form a putative GSOR or a Michael adduct intermediate. The
latter two mechanisms are preliminary and require much more
experimental evidence.8.3.3. The enzymatic mechanism of MAPEG
The activities and mechanisms of MAPEG can be classiﬁed analo-
gously to the GST activities described above: (i) conjugations and re-
ductions on the one hand, and (ii) isomerizations on the other hand.
Although the protein architecture and catalytic residues of MAPEG
are completely different, the principles and limitations described for
GST are also valid for MAPEG. For example, a SN2Ar reaction requires
alternative positions for the substrate, the σ-complex intermediate
and the products during catalysis (Fig. 21B), regardless whether
the electrophile is bound at an H-site in GST or between two of the
three subunits in MAPEG (Fig. 20). Except for (artiﬁcial) SN2Ar reac-
tions, kinetic data on MAPEG catalysis are rather limited which is
not surprising considering the availability, stability and other proper-
ties of the physiological eicosanoid substrates. The corresponding
mechanisms are therefore predominantly based on crystal structures
and activity measurements with wild type and mutant enzymes.
(i) MGST1-3 and presumably other MAPEG catalyze conjugations
and (hydro)peroxide reductions [458–460,466,542,543] that
probably follow SN2Ar or SN2 mechanisms analogous to
Fig. 21B-D (with Arga instead of a tyrosine residue as illustrat-
ed in Fig. 20D). The groups by Morgenstern and Armstrong
revealed that GSH binds very rapidly to free MGST1, whereas
thiolate formation occurs quite slowly. A slow conformational
change resulting in tight glutathione binding and deproton-
ation was therefore suggested to be rate-limiting for the turn-
over of reactive substrates such as CDNB [543,544]. Theories on
structural dynamics of MAPEG including alternative “closed”
and “open” conformations are indeed supported by a variety
of (indirect) results on MGST1 [487,488,490,545] and PTGES1
[472,491,546], and only one of the three MGST1 subunits at a
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[543,545]. In addition to this mechanistic model of extreme neg-
ative subunit cooperativity (one-third-of-the-sites-reactivity),
the enzyme was shown to be activated upon covalent modiﬁca-
tion of the only cysteine residue [542]. This residue is located in a
solvent exposed loop after helix α1 [469] covering the potential
GSH entry site. A preliminary model of MGST1 catalysis can be
summarized as follows: GSH binds with a low afﬁnity to all
three subunits, but a conformational change at only one of the
coupled active sites results in tight GSH binding and deproton-
ation that is presumably mediated by Arga (Arg129) and—based
on site-directed mutagenesis studies [487]—maybe Arg113 (the
fourth conserved arginine at helix α3, Section 8.2.1). A SN2Ar or
SN2 reaction takes place as soon as the nucleophile is formed
and the electrophile is bound in a correct orientation. Product re-
lease—for example of GSDNB for CDNB, or of GSOH and ROH for a
hydroperoxide substrate—is presumably coupled to another con-
formational change [545].
The conversions of lipophilic epoxides—such as benzo[a]
pyrene-4,5-epoxide, catalyzed by MGST1, or leukotriene A4, catalyzed
by LTC4—presumably also occur via a (distorted) SN2 mechanism.
However, the leaving group remains attached and becomes protonat-
ed (Fig. 23A). Please note that these conjugation reactions are not
sensu stricto nucleophilic additions, because the electrophilic center
is sp3- and not sp2-hybridized (like, for example, in Fig. 21F). In con-
trast to the slow activation of GSH in MGST1, the LTC4-catalyzed
thiolate formation is rapid and not rate-limiting [484]. The thiol pKa
value of LTC4-bound GSH is roughly 6, and the thiol proton was
suggested to be directly released into the solvent (contrary to
MGST1) [484]. In agreement with predictions from LTC4 crystal
structures [470,471], residue Arga of LTC4 (Arg104) was shown to
play a central role for thiolate stabilization (Fig. 23A), although mu-
tants still had a residual activity at a higher pH [485,486]. Notably,
the mutation of the conserved fourth arginine residue in helix α3
also signiﬁcantly reduced the activity [486]. Regarding the electro-
philic substrate, LTC4 was reported to have a high speciﬁcity for leu-
kotriene A4 [547]. The responsible structure–function relationships
are unknown. Once the ternary complex is formed and both sub-
strates adopt the correct orientation, the thiolate attacks atom C6
of leukotriene A4, and residue Arg31′ (next to r3′) stabilizes and pre-
sumably protonates the leaving group at C5 (Fig. 23A) [470]. The
stereospeciﬁcity of the reaction—with an inversion of the chirality
resulting in the (R)-conﬁguration of leukotriene C4 at atom C6—is
in accordance with this theory. Moreover, point mutations of
Arg31′ signiﬁcantly reduced the enzymatic activity but had only
minor effects on the Kmapp value for GSH [485,486]. In contrast to
MGST1, each of the three active sites of LTC4 is functional, and a
cooperativity seems to be absent, at least with respect to GS− for-
mation [484].
(ii) The only MAPEG-catalyzed isomerization that has, to my knowl-
edge, been studied in detail, is the PTGES1-dependent intramolec-
ular redox reaction of prostaglandin H2 yielding prostaglandin E2
(Fig. 23B). Similar to MGST1, only one of three PTGES1 reaction
centers was reported to adopt an active conformation in accor-
dance with an extreme negative subunit cooperativity (one-
third-of-the-sites-reactivity) [546]. Furthermore, PTGES1 has a
cysteine residue in the same loop likeMGST1, and covalentmod-
iﬁcation of this residue by 15-deoxy-Δ12,14-prostaglandin J2 was
shown to inhibit the enzyme in vitro [490].
In the presence of S-methylglutathione, PTGES1was shown to be
inactive, supporting the relevance of the GSH thiol group for ca-
talysis [548]. In agreement with the crystal structure of PTGES1
in its closed conformation [472], mutations of Arga (Arg126) andof the conserved arginine residue at helix α3 (Arg110) were
both detrimental for catalysis (Fig. 23B) [472,548]. According to
a preliminary model of PTGES1 catalysis, the thiolate attacks
the endoperoxide at atomO9 once the ternary complex is formed
and the substrates adopt the correct orientation (Fig. 23B). The
reaction is therefore different from the nucleophilic attack at
atom O11 in the mechanistic model for soluble hematopoietic
prostaglandin-D2 synthase (Fig. 22B) [495], even though
GSOR intermediates are suggested in both models (see also
Section 8.3.2). Please note that the cyclopentane rings in the per-
oxide substrate, in the tension-free intermediate and in the
cyclopentanoneproduct have completely different stable confor-
mations which have to be accommodated at the active site. Arga
in PTGES1 was suggested to stabilize and protonate the leaving
group of the SN2 reaction (analogous to Arg31′ in LTC4), and to
abstract the proton from atom C9 resulting in the cleavage of
GSOR (Fig. 23B) [472]. Hence, Arga would act as a base for GSH,
as an acid for O11 and as a base for C9. These are obviously a lot
of functions for a single residue, in particular, considering the
geometric limitations and the range of putative pKa values of
the groups involved. Regarding the role of tyrosines in GST catal-
ysis (Figs. 21 and 22) and the results from site-directedmutagen-
esis for PTGES1 [472,546], the functions of Arg110, Tyr117 and
maybe Tyr130 might have been underestimated so far.
8.3.4. Outlook on GST and MAPEG catalysis and mechanistic questions
Regarding GST- and MAPEG-catalyzed conjugations and reduc-
tions, the following aspects remain to be studied in further detail.
(i) Is there a general order of substrate-binding and product-release
steps depending on the GST or MAPEG class? How are the kinetic
patterns of GST and MAPEG exactly affected by structural para-
meters and how do they determine the rate-limiting step? (ii) A
comprehensive evaluation of the numerous mutational analyses
[71,282,504–507,509–511,517,522,531] could furthermore reveal
how the (potential) hydrogen-bonded network exactly works in the
different GST classes. Moreover, when does the deprotonation of
GSH in GST exactly occur, is the proton transferred to a speciﬁc base
(Fig. 21), and when and how is the proton released? Regarding GS−
formation in MAPEG, I got the impression that Arga and the fourth
conserved arginine residue in helix α3 might both stabilize the
thiolate. The latter residue seems to approach the thiol group only
in the closed enzyme conformation found for crystallized PTGES1
[472]. The additional interaction might explain the more efﬁcient de-
protonation of GSH after a (slow) conformational change in the
MGST1–GSH complex [543,545]. (iii) Another unsolved question is
the fate of GSOH after the GST- or MAPEG-dependent reduction of
peroxides (Fig. 21D). The same holds true for GST disulﬁde substrates
and the fate of GSSR. Whether MAPEG can efﬁciently reduce
disulﬁdes at all has, to my knowledge, not been thoroughly studied.
(iv) Furthermore, MGST1 was reported to have no signiﬁcant activity
with the Michael acceptor ethacrynic acid [542], and it might be
interesting to test whether this is a general feature of MAPEG consid-
ering that the Michael acceptor 15-deoxy-Δ12,14-prostaglandin J2
can act as a suicide inhibitor of PTGES1 and not as a substrate [490].
(v) In the same line of thought, is there a correlation between the
loop connecting helices α1 and α2, the cysteine content in MGST1 and
PTGES1, and the apparently absent negative subunit cooperativity in
LTC4 (having neither the loop nor the cysteine residue)? According to
this hypothesis, MGST2 and MGST3 should also have no one-third-
of-the-sites-reactivity.
There are also several aspects that remain to be addressed with
respect to the GST- and MAPEG-catalyzed isomerizations. (i) The
overall mechanism often seems to be rather unclear. Mutagenesis
and product inhibition experiments would be helpful to address the
substrate-binding and the product-release steps. Most important,
which step is rate-limiting, and does GSH stay as a coenzyme at the
Fig. 23. Preliminary models of MAPEG catalysis. (A) LTC4-catalyzed conjugation of GSH and leukotriene A4. (B) PTGES1-catalyzed intramolecular redox reaction of prostaglandin H2.
See Section 8.3.3 for details.
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catalytic cycles? (ii) What is the nucleophile in GST isomerases that
apparently work without GSH [532]? Which structure–function rela-
tionships and evolutionary scenarios are responsible for this unusual
property? (iii) Are the fates of the protons in the predicted mecha-
nism in Fig. 22A correct [527,528]? Furthermore, the role of Arg15,
which is not conserved among different GST classes, is in my opinion
not fully resolved. Its side chain is located in the proximity of the
thiolate group above ring A of the substrate [526,527] facing the
exit of the substrate tunnel. It might therefore play a role beyond
nucleophile formation/stabilization, for example, by supporting con-
certed acid–base catalysis via hydrogen bonding and/or by lowering
the energy of the transition state. All other presented isomerization
mechanisms are even less clear. Many more kinetic studies are neces-
sary to complement the numerous structures. In summary, GST and
MAPEG have enough tricks up their sleeves to keep a whole new
generation of enzymologists busy.8.4. Physiological and medical relevance of GST and MAPEG catalysis
The physiological relevance of GST and MAPEG catalysis ranges
from ubiquitous catabolism (e.g. zeta class GST), eicosanoid metabo-
lism (MAPEG and sigma class GST) and xenobiotic detoxiﬁcation
(e.g. liver GST and MAPEG) to the susceptibility towards herbicides,
antibiotics or host/pathogen factors (e.g. GST-isoforms from plants,
bacteria and parasites) [3,448,474,477,478]. Obviously, these roles
affect essential aspects of modern life, including agriculture, biotech-
nology and water quality as well as fundamental medical aspects such
as pain, inﬂammation, tumor resistance mechanisms and general
pharmacokinetics. It is nowadays sexy to hype holistic concepts. For
example, “personalized medicine” promises to be the next gold rush
for pharmaceutical industry, and “systems biology” even goes one
step further trying to quantitatively model the whole metabolic
network and its regulation and effects on an organismic level. How-
ever, considering the complexity of GST-isoforms, allelic variants
and overlapping activities on the one hand, and the knowledge (or
complete lack thereof) regarding the enzymatic mechanisms, kinetic
constants and quantitative effects of GST point mutations on the
other hand, I am pretty skeptical about whether such concepts
make sense at all. This brings me to the ﬁnal remarks.9. Concluding remarks
There are at least ﬁve non-related protein folds that have been
optimized for glutathione binding and catalysis in the course of evo-
lution: (i) the fold of a superfamily of ﬂavin-dependent oxidoreduc-
tases in GR, (ii) the thioredoxin fold (sometimes in combination
with other domains), for example, in Grx, PDI, GST, GPx and Prx,
(iii) the βαβββ-motif of vicinal oxygen chelate enzymes in Glo1
and fosfomycin resistance proteins A and B, (iv) the combination of
an α-helical domain with a β-lactamase fold in Glo2, and (v) the
four-helix bundle in MAPEG. I tried to outline and, if possible, to com-
pare the mechanisms of most of these enzyme classes and subclasses.
Furthermore, I emphasized several principles and open questions in
glutathione catalysis regarding nucleophile activation, electrophile
properties, geometric constraints and leaving group properties.
Homologous glutathione-dependent enzymes from different organ-
isms or cellular compartments can obviously exert alternative functions
and/or employ signiﬁcantly different mechanisms. Such functions and
mechanisms often cannot be predicted from in silico analyses. Thus, po-
tential substrates as well as rate constants have to be analyzed in detail
in vitro. This aspect is often neglected or difﬁcult to address, particularly
for complexmulti-component assay systems. In addition,muchmore in
vivo data is required to ﬁgure out whether a predicted function or en-
zyme species is of any physiological relevance. For example, once the ki-
netic parameters are known, it is highly beneﬁcial to also determine the
physiological concentrations of the enzyme and the substrate(s). In
summary, as long as we do not have both—sufﬁcient in vitro and
in vivo data—the physiological function and relevance of many
GSH-dependent enzymes remain nebulous.
Several of the presented mechanistic models and of my comments,
suggestions and criticism will probably turn out to be wrong, however,
my aim is not to divulge imperfect points of view, but to revitalize the
more and more neglected research ﬁeld of enzymology. Although I got
the impression that many colleagues are still deeply interested in the
mechanistic and evolutionary puzzles of glutathione catalysis, funding
agencies and advisory boards nowadays seem to focus on holistic ap-
proaches such as systems biology. I hope this review serves as a moti-
vation not only to connect the numerous ﬁelds of glutathione catalysis,
but also to not forget about the importance and beauty of mechanistic
details. Finally, I want to apologize to those colleagues whose contribu-
tions I might have misquoted or did not cite.
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